Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
EUROPEAN COMMISSION
Consumers, Health, Agriculture and Food Executive Agency
Director
GRANT AGREEMENT
NUMBER — 801553 — InfAct
This ‘Agreement’(‘the Agreement’) is between the following parties:
on the one part,
the Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) ('the Agency'), under
the powers delegated by the European Commission ('the Commission'), represented for the purposes
of signature of this Agreement by Veronique WASBAUER, Director, or his/her duly authorised
representative,
and
on the other part,
1. ‘the coordinator’:
SCIENSANO (Sciensano), established in JULIETTE WYTSMANSTRAAT 14, ELSENE 1050,
Belgium, VAT number: BE0693876830, represented for the purposes of signing the Agreement by
general manager, Myriam SNEYERS
and the following other beneficiaries if they have signed their ‘Accession Form’ (see Annex 3 and
Article 40):
2. GESUNDHEIT ÖSTERREICH GMBH (GÖG), established in STUBENRING 6, WIEN 1010,
Austria, VAT number: ATU62777178,
3. MINISTRY OF CIVIL AFFAIRS (MCA), established in Trg Bosne i Hercegovine 1,
SARAJEVO 71000, Bosnia and Herzegovina,
4. HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO (CIPH), established in ROCKEFELLEROVA
7, ZAGREB 10000, Croatia, VAT number: HR75297532041,
5. Ministry of Health of the Republic of Cyprus (MoHCy), established in 1 Prodromou Street &
17 Chilonos Street 1 & 17, Nicosia 1448, Cyprus,
6. USTAV ZDRAVOTNICKYCH INFORMACI A STATISTIKY CESKE REPUBLIKY
(UZIS), established in PALACKEHO NAMESTI 4, PRAHA 12801, Czech Republic,
7. SOTSIAALMINISTEERIUM (MoSA), established in Suur-Ameerika 1, TALLINN 10122,
Estonia,
1
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
8. TERVEYDEN JA HYVINVOINNIN LAITOS (THL), established in MANNERHEIMINTIE
166, HELSINKI 00271, Finland, VAT number: FI22295006,
9. AGENCE NATIONALE DE SANTE PUBLIQUE (SpFrance), established in 12 RUE DU VAL
D'OSNE, SAINT MAURICE 94415, France, VAT number: FR53130022338,
10. ROBERT KOCH-INSTITUT (RKI), established in Nordufer 20, Berlin 13353, Germany, VAT
number: DE165893430,
11. ETHNIKOS ORGANISMOS PAROCHIS YPIRESION YGIAS (EOPYY), established in
APOSTOLOU PAVLOY 12, ATHENS 15123, Greece, VAT number: EL997478553,
12. DEPARTMENT OF HEALTH (DOH), established in poolbeg St, Hawkins House, Dublin dn
6, Ireland,
13. ISTITUTO SUPERIORE DI SANITA (ISS), established in Viale Regina Elena 299, ROMA
00161, Italy, VAT number: IT03657731000,
14. SLIMIBU PROFILAKSES UN KONTROLES CENTRS (CDPC), established in Duntes 22,
Riga LV1005, Latvia, VAT number: 90009756700,
15. HIGIENOS INSTITUTAS (HI), established in DIDZIOJI STREET 22, VILNIUS LT-01128,
Lithuania,
16. MINISTERE DE LA SANTE (MOHLUX), established in VILLA LOUVIGNY, ALLEE
MARCONI, LUXEMBOURG 2120, Luxembourg,
17. Ministry for Health - Government of Malta (MFH), established in Palazzo Castellania,
Merchants Street 15, Valletta VLT 200, Malta, VAT number: MT12979127,
18. UNIVERSITATEA DE STAT DE MEDICINA SI FARMACIE NICOLAE TESTEMITANU
DIN REPUBLICA MOLDOVA (SMPHU), established in Stefan cel Mare Avenue 165, Chisinau
MD2004, Moldova (Republic of),
19. RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU (RIVM), established
in Antonie Van Leeuwenhoeklaan 9, BILTHOVEN 3721 MA, Netherlands, VAT number:
NL821772302B01,
20. HELSEDIREKTORATE (HD), established in UNIVERSITETSGATA 2, OSLO 0164, Norway,
VAT number: NO983544622,
21. THE MINISTRY OF HEALTH OF THE REPUBLIC OF POLAND (MZ), established in
Miodowa 15, Warsaw 00-952, Poland, VAT number: not applicable,
22. MINISTERIO DA SAUDE - REPUBLICA PORTUGUESA (MS), established in Av. João
Crisóstomo, 9, LISBOA 1049-062, Portugal,
23. INSTITUTUL NATIONAL DE SANATATE PUBLICA (INSP), established in STR DR
LEONTE 1-3 SECTOR 5, BUCURESTI 050463, Romania,
24. INSTITUT ZA ZASTITU ZDRAVLJA SRBIJEDR MILAN JOVANOVIC BATUT (IPHS),
established in DR SUBOTICA STREET 5, BEOGRAD 11000, Serbia, VAT number: RS102000930,
2
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
25. NACIONALNI INSTITUT ZA JAVNO ZDRAVJE (NIJZ), established in TRUBARJEVA
CESTA 2, LJUBLJANA 1000, Slovenia, VAT number: SI44724535,
26. INSTITUTO DE SALUD CARLOS III (ISCIII), established in MONFORTE DE LEMOS 5,
MADRID 28029, Spain, VAT number: ESQ2827015E,
27. FOLKHALSOMYNDIGHETEN (FoHM), established in NOBELS VAG 18, SOLNA 171 82,
Sweden, VAT number: SE202100654501,
28. WELSH ASSEMBLY GOVERNMENT (WG), established in CATHAYS PARK WELSH
ASSEMBLY GOVERNMENT, CARDIFF CF10 3NQ, United Kingdom, VAT number:
GB888835056,
Unless otherwise specified, references to ‘beneficiary’ or ‘beneficiaries’ include the coordinator.
The parties referred to above have agreed to enter into the Agreement under the terms and conditions
below.
By signing the Agreement or the Accession Form, the beneficiaries accept the grant and agree to
implement the action under their own responsibility and in accordance with the Agreement, with all
the obligations and conditions it sets out.
The Grant Agreement is composed of:
Terms and Conditions
Annex 1 Description of the action
Annex 2 Estimated budget for the action
Annex 2a Not applicable
Annex 3 Accession Forms
Annex 4 Model for the financial statements
Annex 5 Model for the certificate on the financial statements
3
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
TERMS AND CONDITIONS
TABLE OF CONTENTS
CHAPTER 1 GENERAL ............................................................................................................................................... 9
ARTICLE 1 — SUBJECT OF THE AGREEMENT.........................................................................................9
CHAPTER 2 ACTION ...................................................................................................................................................9
ARTICLE 2 — ACTION TO BE IMPLEMENTED.........................................................................................9
ARTICLE 3 — DURATION AND STARTING DATE OF THE ACTION......................................................9
ARTICLE 4 — ESTIMATED BUDGET AND BUDGET TRANSFERS........................................................ 9
4.1 Estimated budget..................................................................................................................................... 9
4.2 Budget transfers.......................................................................................................................................9
CHAPTER 3 GRANT .................................................................................................................................................... 9
ARTICLE 5 — GRANT AMOUNT, FORM OF GRANT, REIMBURSEMENT RATE AND FORMS OF
COSTS..............................................................................................................................................9
5.1 Maximum grant amount.......................................................................................................................... 9
5.2 Form of grant, reimbursement rate and forms of costs.......................................................................... 9
5.3 Final grant amount — Calculation....................................................................................................... 10
5.4 Revised final grant amount — Calculation.......................................................................................... 11
ARTICLE 6 — ELIGIBLE AND INELIGIBLE COSTS................................................................................12
6.1 General conditions for costs to be eligible........................................................................................... 12
6.2 Specific conditions for costs to be eligible...........................................................................................12
6.3 Conditions for costs of affiliated entities to be eligible........................................................................15
6.4 Ineligible costs.......................................................................................................................................15
6.5 Consequences of declaration of ineligible costs................................................................................... 16
CHAPTER 4 RIGHTS AND OBLIGATIONS OF THE PARTIES ........................................................................ 16
SECTION 1 RIGHTS AND OBLIGATIONS RELATED TO IMPLEMENTING THE ACTION ................ 16
ARTICLE 7 — GENERAL OBLIGATION TO PROPERLY IMPLEMENT THE ACTION.........................16
7.1 General obligation to properly implement the action........................................................................... 16
7.2 Consequences of non-compliance......................................................................................................... 17
ARTICLE 8 — RESOURCES TO IMPLEMENT THE ACTION — THIRD PARTIES INVOLVED IN THE
ACTION.........................................................................................................................................17
ARTICLE 8A — IMPLEMENTATION OF ACTION TASKS BY BENEFICIARIES NOT RECEIVING EU
FUNDING...................................................................................................................................... 17
ARTICLE 9 — PURCHASE OF GOODS, WORKS OR SERVICES............................................................17
9.1 Rules for purchasing goods, works or services.................................................................................... 17
4
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
9.2 Consequences of non-compliance......................................................................................................... 18
ARTICLE 10 — IMPLEMENTATION OF ACTION TASKS BY SUBCONTRACTORS............................18
10.1 Rules for subcontracting action tasks................................................................................................. 18
10.2 Consequences of non-compliance....................................................................................................... 18
ARTICLE 11 — IMPLEMENTATION OF ACTION TASKS BY AFFILIATED ENTITIES........................19
11.1 Rules for calling upon affiliated entities to implement part of the action...........................................19
11.2 Consequences of non-compliance....................................................................................................... 20
ARTICLE 11A — FINANCIAL SUPPORT TO THIRD PARTIES................................................................20
SECTION 2 RIGHTS AND OBLIGATIONS RELATED TO THE GRANT ADMINISTRATION .............. 20
ARTICLE 12 — GENERAL OBLIGATION TO INFORM............................................................................20
12.1 General obligation to provide information upon request....................................................................20
12.2 Obligation to keep information up to date and to inform about events and circumstances likely to
affect the Agreement........................................................................................................................... 20
12.3 Consequences of non-compliance....................................................................................................... 21
ARTICLE 13 — KEEPING RECORDS — SUPPORTING DOCUMENTATION.........................................21
13.1 Obligation to keep records and other supporting documentation....................................................... 21
13.2 Consequences of non-compliance....................................................................................................... 22
ARTICLE 14 — SUBMISSION OF DELIVERABLES................................................................................. 22
14.1 Obligation to submit deliverables....................................................................................................... 22
14.2 Consequences of non-compliance....................................................................................................... 22
ARTICLE 15 — REPORTING — PAYMENT REQUESTS.......................................................................... 22
15.1 Obligation to submit reports............................................................................................................... 22
15.2 Reporting periods................................................................................................................................ 22
15.2a Request(s) for further pre-financing payment(s).............................................................................. 23
15.3 Periodic reports — Requests for interim payments............................................................................23
15.4 Final report — Request for payment of the balance.......................................................................... 24
15.5 Information on cumulative expenditure incurred................................................................................24
15.6 Currency for financial statements and conversion into euro.............................................................. 25
15.7 Language of reports.............................................................................................................................25
15.8 Consequences of non-compliance....................................................................................................... 25
ARTICLE 16 — PAYMENTS AND PAYMENT ARRANGEMENTS...........................................................25
16.1 Payments to be made.......................................................................................................................... 25
16.2 Pre-financing payment — Amount ....................................................................................................25
16.3 Interim payments — Amount — Calculation.....................................................................................26
16.4 Payment of the balance — Amount — Calculation........................................................................... 26
5
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
16.5 Notification of amounts due................................................................................................................27
16.6 Currency for payments........................................................................................................................ 27
16.7 Payments to the coordinator — Distribution to the beneficiaries.......................................................27
16.8 Bank account for payments.................................................................................................................27
16.9 Costs of payment transfers..................................................................................................................28
16.10 Date of payment................................................................................................................................ 28
16.11 Consequences of non-compliance..................................................................................................... 28
ARTICLE 17 — CHECKS, REVIEWS, AUDITS AND INVESTIGATIONS — EXTENSION OF
FINDINGS..................................................................................................................................... 28
17.1 Checks, reviews and audits by the Agency and the Commission...................................................... 28
17.2 Investigations by the European Anti-Fraud Office (OLAF)...............................................................30
17.3 Checks and audits by the European Court of Auditors (ECA)...........................................................31
17.4 Checks, reviews, audits and investigations for international organisations........................................ 31
17.5 Consequences of findings in checks, reviews, audits and investigations —Extension of
findings.................................................................................................................................................31
17.6 Consequences of non-compliance....................................................................................................... 32
ARTICLE 18 — EVALUATION OF THE IMPACT OF THE ACTION....................................................... 33
18.1 Right to evaluate the impact of the action..........................................................................................33
18.2 Consequences of non-compliance....................................................................................................... 33
SECTION 3 OTHER RIGHTS AND OBLIGATIONS .......................................................................................33
ARTICLE 19 — PRE-EXISTING RIGHTS AND OWNERSHIP OF THE RESULTS (INCLUDING
INTELLECTUAL AND INDUSTRIAL PROPERTY RIGHTS)................................................. 33
19.1 Pre-existing rights and access rights to pre-existing rights................................................................ 33
19.2 Ownership of results and rights of use............................................................................................... 33
19.3 Consequences of non-compliance....................................................................................................... 34
ARTICLE 20 — CONFLICT OF INTERESTS.............................................................................................. 34
20.1 Obligation to avoid a conflict of interests.......................................................................................... 34
20.2 Consequences of non-compliance....................................................................................................... 34
ARTICLE 21 — CONFIDENTIALITY...........................................................................................................34
21.1 General obligation to maintain confidentiality................................................................................... 34
21.2 Consequences of non-compliance....................................................................................................... 34
ARTICLE 22 — PROMOTING THE ACTION — VISIBILITY OF EU FUNDING....................................35
22.1 Communication activities by the beneficiaries................................................................................... 35
22.2 Communication activities by the Agency and the Commission......................................................... 35
22.3 Consequences of non-compliance....................................................................................................... 36
ARTICLE 23 — PROCESSING OF PERSONAL DATA...............................................................................36
6
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
23.1 Processing of personal data by the Agency and the Commission...................................................... 37
23.2 Processing of personal data by the beneficiaries................................................................................ 37
23.3 Consequences of non-compliance....................................................................................................... 37
ARTICLE 24 — ASSIGNMENTS OF CLAIMS FOR PAYMENT AGAINST THE AGENCY ...................37
CHAPTER 5 DIVISION OF BENEFICIARIES’ ROLES AND RESPONSIBILITIES ....................................... 38
ARTICLE 25 — DIVISION OF BENEFICIARIES’ ROLES AND RESPONSIBILITIES............................38
25.1 Roles and responsibilities towards the Agency.................................................................................. 38
25.2 Internal division of roles and responsibilities..................................................................................... 38
25.3 Internal arrangements between beneficiaries — Consortium agreement............................................39
CHAPTER 6 REJECTION OF COSTS — REDUCTION OF THE GRANT — RECOVERY — SANCTIONS
— DAMAGES — SUSPENSION — TERMINATION — FORCE MAJEURE ............................... 39
SECTION 1 REJECTION OF COSTS — REDUCTION OF THE GRANT — RECOVERY —
SANCTIONS .............................................................................................................................................39
ARTICLE 26 — REJECTION OF INELIGIBLE COSTS.............................................................................. 39
26.1 Conditions............................................................................................................................................ 39
26.2 Ineligible costs to be rejected — Calculation — Procedure...............................................................39
26.3 Effects.................................................................................................................................................. 40
ARTICLE 27 — REDUCTION OF THE GRANT......................................................................................... 40
27.1 Conditions............................................................................................................................................ 40
27.2 Amount to be reduced — Calculation — Procedure..........................................................................40
27.3 Effects.................................................................................................................................................. 41
ARTICLE 28 — RECOVERY OF UNDUE AMOUNTS............................................................................... 41
28.1 Amount to be recovered — Calculation — Procedure.......................................................................41
ARTICLE 29 — ADMINISTRATIVE SANCTIONS..................................................................................... 43
SECTION 2 LIABILITY FOR DAMAGES ........................................................................................................ 43
ARTICLE 30 — LIABILITY FOR DAMAGES.............................................................................................43
30.1 Liability of the Agency....................................................................................................................... 43
30.2 Liability of the beneficiaries............................................................................................................... 43
SECTION 3 SUSPENSION AND TERMINATION ............................................................................................44
ARTICLE 31 — SUSPENSION OF PAYMENT DEADLINE ...................................................................... 44
31.1 Conditions............................................................................................................................................ 44
31.2 Procedure............................................................................................................................................. 44
ARTICLE 32 — SUSPENSION OF PAYMENTS.......................................................................................... 44
32.1 Conditions............................................................................................................................................ 44
32.2 Procedure............................................................................................................................................. 45
ARTICLE 33 — SUSPENSION OF THE ACTION IMPLEMENTATION................................................... 45
7
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
33.1 Suspension of the action implementation, by the beneficiaries..........................................................45
33.2 Suspension of the action implementation, by the Agency..................................................................46
ARTICLE 34 — TERMINATION OF THE AGREEMENT OR OF THE PARTICIPATION OF ONE OR
MORE BENEFICIARIES..............................................................................................................47
34.1 Termination of the Agreement, by the beneficiaries...........................................................................47
34.2 Termination of the participation of one or more beneficiaries, by the beneficiaries...........................48
34.3 Termination of the Agreement or of the participation of one or more beneficiaries, by the
Agency................................................................................................................................................. 49
SECTION 4 FORCE MAJEURE ..........................................................................................................................51
ARTICLE 35 — FORCE MAJEURE.............................................................................................................. 51
CHAPTER 7 FINAL PROVISIONS .......................................................................................................................... 52
ARTICLE 36 — COMMUNICATION BETWEEN THE PARTIES...............................................................52
36.1 Form and means of communication....................................................................................................52
36.2 Date of communication....................................................................................................................... 53
36.3 Addresses for communication............................................................................................................. 53
ARTICLE 37 — INTERPRETATION OF THE AGREEMENT.....................................................................53
37.1 Precedence of the Terms and Conditions over the Annexes.............................................................. 53
37.2 Privileges and immunities................................................................................................................... 53
ARTICLE 38 — CALCULATION OF PERIODS, DATES AND DEADLINES........................................... 53
ARTICLE 39 — AMENDMENTS TO THE AGREEMENT......................................................................... 54
39.1 Conditions............................................................................................................................................ 54
39.2 Procedure............................................................................................................................................. 54
ARTICLE 40 — ACCESSION TO THE AGREEMENT............................................................................... 54
40.1 Accession of the beneficiaries mentioned in the preamble................................................................ 55
40.2 Addition of new beneficiaries............................................................................................................. 55
ARTICLE 41 — APPLICABLE LAW AND SETTLEMENT OF DISPUTES.............................................. 55
41.1 Applicable law.....................................................................................................................................55
41.2 Dispute settlement............................................................................................................................... 55
ARTICLE 42 — ENTRY INTO FORCE OF THE AGREEMENT................................................................ 56
8
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
CHAPTER 1 GENERAL
ARTICLE 1 — SUBJECT OF THE AGREEMENT
This Agreement sets out the rights and obligations and the terms and conditions applicable to the grant
awarded to the beneficiaries for implementing the action set out in Chapter 2.
CHAPTER 2 ACTION
ARTICLE 2 — ACTION TO BE IMPLEMENTED
The grant is awarded for the action entitled ‘Information for Action — InfAct’ (‘action’), as
described in Annex 1.
ARTICLE 3 — DURATION AND STARTING DATE OF THE ACTION
The duration of the action will be 36 months as of 01/03/2018 (‘starting date of the action’).
ARTICLE 4 — ESTIMATED BUDGET AND BUDGET TRANSFERS
4.1 Estimated budget
The ‘estimated budget’ for the action is set out in Annex 2.
It contains the estimated eligible costs and the forms of costs, broken down by beneficiary (and
affiliated entity) and budget category (see Articles 5, 6 and 11).
4.2 Budget transfers
The estimated budget breakdown indicated in Annex 2 may be adjusted — without an amendment
(see Article 39) — by transfers of amounts between beneficiaries, budget categories and/or forms of
costs set out in Annex 2, if the action is implemented as described in Annex 1.
However, the beneficiaries may not add costs relating to subcontracts not provided for in Annex 1,
unless such additional subcontracts are approved by an amendment or in accordance with Article 10.
CHAPTER 3 GRANT
ARTICLE 5 — GRANT AMOUNT, FORM OF GRANT, REIMBURSEMENT RATE AND
FORMS OF COSTS
5.1 Maximum grant amount
The ‘maximum grant amount’ is EUR 3,999,191.48 (three million nine hundred and ninety nine
thousand one hundred and ninety one EURO and forty eight eurocents).
5.2 Form of grant, reimbursement rate and forms of costs
9
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
The grant reimburses 80% of the action's eligible costs (see Article 6) (‘reimbursement of eligible
costs grant’) (see Annex 2).
The estimated eligible costs of the action are EUR 4,999,631.35 (four million nine hundred and ninety
nine thousand six hundred and thirty one EURO and thirty five eurocents).
Eligible costs (see Article 6) must be declared under the following forms ('forms of costs' or 'costs
forms'):
(a) for direct personnel costs: as actually incurred costs (actual costs);
(b) for direct costs of subcontracting: as actually incurred costs (actual costs);
(c) for other direct costs: as actually incurred costs (actual costs);
(d) for indirect costs: on the basis of a flat-rate applied as set out in Article 6.2.D (‘flat-rate costs’);
5.3 Final grant amount — Calculation
The ‘final grant amount’ depends on the actual extent to which the action is implemented in
accordance with the Agreement’s terms and conditions.
This amount is calculated by the Agency — when the payment of the balance is made — in the
following steps:
Step 1 – Application of the reimbursement rate to the eligible costs
Step 2 – Limit to the maximum grant amount
Step 3 – Reduction due to the no-profit rule
Step 4 – Reduction due to substantial errors, irregularities or fraud or serious breach of obligations
5.3.1 Step 1 — Application of the reimbursement rate to the eligible costs
The reimbursement rate (see Article 5.2) is applied to the eligible costs (actual costs and flat-rate costs;
see Article 6) declared by the beneficiaries and affiliated entities (see Article 15) and approved by
the Agency (see Article 16).
5.3.2 Step 2 — Limit to the maximum grant amount
If the amount obtained following Step 1 is higher than the maximum grant amount set out in Article
5.1, it will be limited to the latter.
5.3.3 Step 3 — Reduction due to the no-profit rule
The grant must not produce a profit.
‘Profit’ means the surplus of the amount obtained following Steps 1 and 2 plus the action’s total
receipts, over the action’s total eligible costs.
The ‘action’s total eligible costs’ are the consolidated total eligible costs approved by the Agency.
10
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
The ‘action’s total receipts’ are the consolidated total receipts generated during its duration (see
Article 3).
The following are considered receipts:
(a) income generated by the action;
(b) financial contributions given by third parties to the beneficiary or to an affiliated entity
specifically to be used for costs that are eligible under the action.
The following are however not considered receipts:
(a) financial contributions by third parties, if they may be used to cover costs other than the eligible
costs (see Article 6);
(b) financial contributions by third parties with no obligation to repay any amount unused at the
end of the period set out in Article 3.
If there is a profit, it will be deducted in proportion to the final rate of reimbursement of the eligible
actual costs approved by the Agency (as compared to the amount calculated following Steps 1 and 2).
5.3.4 Step 4 — Reduction due to substantial errors, irregularities or fraud or serious breach of
obligations
If the grant is reduced (see Article 27), the Agency will calculate the reduced grant amount by
deducting the amount of the reduction (calculated in proportion to the seriousness of the errors,
irregularities or fraud or breach of obligations, in accordance with Article 27.2) from the maximum
grant amount set out in Article 5.1.
The final grant amount will be the lower of the following two:
- the amount obtained following Steps 1 to 3 or
- the reduced grant amount following Step 4.
5.4 Revised final grant amount — Calculation
If — after the payment of the balance (in particular, after checks, reviews, audits or investigations;
see Article 17) — the Agency rejects costs (see Article 26) or reduces the grant (see Article 27), it
will calculate the ‘revised final grant amount’ for the action or for the beneficiary concerned.
This amount is calculated by the Agency on the basis of the findings, as follows:
- in case of rejection of costs: by applying the reimbursement rate to the revised eligible costs
approved by the Agency for the beneficiary concerned;
- in case of reduction of the grant: by deducting the amount of the reduction (calculated in
proportion to the seriousness of the errors, irregularities or fraud or breach of obligations, in
accordance with Article 27.2) from the maximum grant amount set out in Article 5.1 or from the
maximum EU contribution indicated for the beneficiary in the estimated budget (see Annex 2).
In case of rejection of costs and reduction of the grant, the revised final grant amount will be the
lower of the two amounts above.
11
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
ARTICLE 6 — ELIGIBLE AND INELIGIBLE COSTS
6.1 General conditions for costs to be eligible
‘Eligible costs’ are costs that meet the following criteria:
(a) for actual costs:
(i) they must be actually incurred by the beneficiary;
(ii) they must be incurred in the period set out in Article 3, with the exception of costs relating
to the submission of the periodic report for the last reporting period and the final report
(see Article 15);
(iii) they must be indicated in the estimated budget set out in Annex 2;
(iv) they must be incurred in connection with the action as described in Annex 1 and necessary
for its implementation;
(v) they must be identifiable and verifiable, in particular recorded in the beneficiary’s
accounts in accordance with the accounting standards applicable in the country where the
beneficiary is established and with the beneficiary’s usual cost accounting practices;
(vi) they must comply with the applicable national law on taxes, labour and social security, and
(vii) they must be reasonable, justified and must comply with the principle of sound financial
management, in particular regarding economy and efficiency;
(b) for unit costs: not applicable;
(c) for flat-rate costs:
(i) they must be calculated by applying the flat-rate set out in Annex 2, and
(ii) the costs (actual costs) to which the flat-rate is applied must comply with the conditions
for eligibility set out in this Article.
(d) for lump sum costs: not applicable;
6.2 Specific conditions for costs to be eligible
Costs are eligible if they comply with the general conditions (see above) and the specific conditions
set out below, for each of the following budget categories:
A. direct personnel costs;
B. direct costs of subcontracting;
C. other direct costs;
D. indirect costs;
12
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
‘Direct costs’ are costs that are directly linked to the action implementation and can therefore be
attributed to it directly. They must not include any indirect costs (see Point D below).
‘Indirect costs’ are costs that are not directly linked to the action implementation and therefore cannot
be attributed directly to it.
A. Direct personnel costs
Types of eligible personnel costs
A.1 Personnel costs are eligible if they are related to personnel working for the beneficiary under
an employment contract (or equivalent appointing act) and assigned to the action (‘costs for
employees (or equivalent)’). They must be limited to salaries, social security contributions, taxes
and other costs included in the remuneration, if they arise from national law or the employment
contract (or equivalent appointing act).
They may also include additional remuneration for personnel assigned to the action (including
payments on the basis of supplementary contracts regardless of their nature), if:
(a) it is part of the beneficiary’s usual remuneration practices and is paid in a consistent manner
whenever the same kind of work or expertise is required;
(b) the criteria used to calculate the supplementary payments are objective and generally
applied by the beneficiary, regardless of the source of funding used.
A.2 The costs for natural persons working under a direct contract with the beneficiary other than
an employment contract or seconded by a third party against payment are eligible personnel
costs, if:
(a) the person works under the beneficiary’s instructions and, unless otherwise agreed with
the beneficiary, on the beneficiary’s premises;
(b) the result of the work carried out belongs to the beneficiary, and
(c) the costs are not significantly different from those for personnel performing similar tasks
under an employment contract with the beneficiary.
Calculation
Personnel costs must be calculated by the beneficiaries as follows:
- for persons working exclusively on the action:
{monthly rate for the person
multiplied by
number of actual months worked on the action}.
The months declared for these persons may not be declared for any other EU or Euratom grant.
The ‘monthly rate’ is calculated as follows:
{annual personnel costs for the person
13
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
divided by
12}
using the personnel costs for each full financial year covered by the reporting period concerned.
If a financial year is not closed at the end of the reporting period, the beneficiaries must use the
monthly rate of the last closed financial year available.
- for all other persons:
{daily rate for the person
multiplied by
number of actual days worked on the action (rounded up or down to the nearest half-day)}.
The number of actual days declared for a person must be identifiable and verifiable (see Article
13).
The total number of days declared in EU or Euratom grants, for a person for a year, cannot be
higher than the annual productive days used for the calculations of the daily rate. Therefore,
the maximum number of days that can be declared for the grant are:
{number of annual productive days for the year (see below)
minus
total number of days declared by the beneficiary, for that person for that year, for other EU or Euratom
grants}.
The ‘daily rate’ is calculated as follows:
{annual personnel costs for the person
divided by
number of individual annual productive days}
using the personnel costs and the number of annual productive days for each full financial
year covered by the reporting period concerned. If a financial year is not closed at the end of
the reporting period, the beneficiaries must use the daily rate of the last closed financial year
available.
The ‘number of individual annual productive days’ is the total actual days worked by the person
in the year. It may not include holidays and other absences (such as sick leave, maternity leave,
special leave, etc). However, it may include overtime and time spent in meetings, trainings and
other similar activities.
B. Direct costs of subcontracting (including related duties, taxes and charges, such as non-deductible
value added tax (VAT) paid by beneficiaries that are not public bodies acting as public authority) are
eligible if the conditions in Article 10.1.1 are met.
C. Other direct costs
C.1 Travel costs and related subsistence allowances (including related duties, taxes and charges,
such as non-deductible value added tax (VAT) paid by beneficiaries that are not public bodies
14
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
acting as public authority) are eligible if they are in line with the beneficiary’s usual practices
on travel.
C.2 The depreciation costs of equipment, infrastructure or other assets (new or second-hand)
as recorded in the beneficiary’s accounts are eligible, if they were purchased in accordance
with Article 9.1.1 and written off in accordance with international accounting standards and the
beneficiary’s usual accounting practices.
The costs of renting or leasing equipment, infrastructure or other assets (including related duties,
taxes and charges, such as non-deductible value added tax (VAT) paid by beneficiaries that are not
public bodies acting as public authority) are also eligible, if they do not exceed the depreciation
costs of similar equipment, infrastructure or assets and do not include any financing fees.
The only portion of the costs that will be taken into account is that which corresponds to the
duration of the action and rate of actual use for the purposes of the action.
C.3 Costs of other goods and services (including related duties, taxes and charges, such as non-
deductible value added tax (VAT) paid by beneficiaries that are not public bodies acting as public
authority) are eligible, if they are purchased specifically for the action and in accordance with
Article 9.1.1.
Such goods and services include, for instance, consumables and supplies, dissemination,
protection of results, certificates on the financial statements (if they are required by the
Agreement), translations and publications.
D. Indirect costs
Indirect costs are eligible if they are declared on the basis of the flat-rate of 7% of the eligible direct
costs (see Article 5.2 and Points A to C above).
Beneficiaries receiving an operating grant1 financed by the EU or Euratom budget cannot declare
indirect costs for the period covered by the operating grant.
6.3 Conditions for costs of affiliated entities to be eligible
Costs incurred by affiliated entities are eligible if they fulfil — mutatis mutandis — the general and
specific conditions for eligibility set out in this Article (Article 6.1 and 6.2) and Article 11.1.1.
6.4 Ineligible costs
‘Ineligible costs’ are:
(a) costs that do not comply with the conditions set out above (Article 6.1 to 6.3), in particular:
(i) costs related to return on capital;
1 For the definition, see Article 121(1)(b) of Regulation (EU, Euratom) No 966/2012 of the European Parliament and
of the Council of 25 October 2012 on the financial rules applicable to the general budget of the Union and repealing
Council Regulation (EC, Euratom) No 1605/2002 (OJ L 218, 26.10.2012, p.1) (‘Financial Regulation No 966/2012’):
‘operating grant’ means direct financial contribution, by way of donation, from the budget in order to finance the
functioning of a body which pursues an aim of general EU interest or has an objective forming part of and supporting
an EU policy.
15
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
(ii) debt and debt service charges;
(iii) provisions for future losses or debts;
(iv) interest owed;
(v) doubtful debts;
(vi) currency exchange losses;
(vii) bank costs charged by the beneficiary’s bank for transfers from the Agency;
(viii)excessive or reckless expenditure;
(ix) deductible VAT;
(x) costs incurred during suspension of the implementation of the action (see Article 33);
(xi) in-kind contributions provided by third parties;
(b) costs declared under another EU or Euratom grant (including grants awarded by a Member
State and financed by the EU or Euratom budget and grants awarded by bodies other than the
Agency for the purpose of implementing the EU or Euratom budget); in particular, indirect
costs if the beneficiary is already receiving an operating grant financed by the EU or Euratom
budget in the same period;
(c) costs for staff of a national (or local) administration, for activities that are part of the
administration’s normal activities (i.e. not undertaken only because of the grant);
(d) costs (especially travel and subsistence costs) for staff or representatives of EU institutions,
bodies or agencies.
6.5 Consequences of declaration of ineligible costs
Declared costs that are ineligible will be rejected (see Article 26).
This may also lead to any of the other measures described in Chapter 6.
CHAPTER 4 RIGHTS AND OBLIGATIONS OF THE PARTIES
SECTION 1 RIGHTS AND OBLIGATIONS RELATED TO IMPLEMENTING THE
ACTION
ARTICLE 7 — GENERAL OBLIGATION TO PROPERLY IMPLEMENT THE ACTION
7.1 General obligation to properly implement the action
The beneficiaries must implement the action as described in Annex 1 and in compliance with the
provisions of the Agreement and all legal obligations under applicable EU, international and national
law.
16
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
7.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 8 — RESOURCES TO IMPLEMENT THE ACTION — THIRD PARTIES
INVOLVED IN THE ACTION
The beneficiaries must have the appropriate resources to implement the action.
If it is necessary to implement the action, the beneficiaries may:
- purchase goods, works and services (see Article 9);
- call upon subcontractors to implement action tasks described in Annex 1 (see Article 10);
- call upon affiliated entities to implement action tasks described in Annex 1 (see Article 11).
In these cases, the beneficiaries retain sole responsibility towards the Agency and the other
beneficiaries for implementing the action.
ARTICLE 8A — IMPLEMENTATION OF ACTION TASKS BY BENEFICIARIES NOT
RECEIVING EU FUNDING
Not applicable
ARTICLE 9 — PURCHASE OF GOODS, WORKS OR SERVICES
9.1 Rules for purchasing goods, works or services
9.1.1 If necessary to implement the action, the beneficiaries may purchase goods, works or services.
The beneficiaries must make such purchases ensuring the best value for money or, if appropriate, the
lowest price. In doing so, they must avoid any conflict of interests (see Article 20).
The beneficiaries must ensure that the Agency, the Commission, the European Court of Auditors
(ECA) and the European Anti-fraud Office (OLAF) can exercise their rights under Articles 17 and
18 also towards their contractors.
9.1.2 Beneficiaries that are ‘contracting authorities’ within the meaning of Directive 2004/18/EC2 (or
2014/24/EU3) or ‘contracting entities’ within the meaning of Directive 2004/17/EC4 (or 2014/25/EU5)
must comply with the applicable national law on public procurement.
2 Directive 2004/18/EC of the European Parliament and of the Council of 31 March 2004 on the coordination of
procedures for the award of public work contracts, public supply contracts and public service contracts (OJ L 134,
30.04.2004, p. 114).
3 Directive 2014/24/EU of the European Parliament and of the Council of 26 February 2014 on public procurement and
repealing Directive 2004/18/EC (OJ L 94, 28.3.2014, p. 65).
4 Directive 2004/17/EC of the European Parliament and of the Council of 31 March 2004 coordinating the procurement
procedures of entities operating in the water, energy, transport and postal services sectors (OJ L 134, 30.04.2004, p. 1).
17
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
9.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under Article 9.1.1, the costs related to the contract
concerned will be ineligible (see Article 6) and will be rejected (see Article 26).
If a beneficiary breaches any of its obligations under Article 9.1.2, the grant may be reduced (see
Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 10 — IMPLEMENTATION OF ACTION TASKS BY SUBCONTRACTORS
10.1 Rules for subcontracting action tasks
10.1.1 If necessary to implement the action, the beneficiaries may award subcontracts covering the
implementation of certain action tasks described in Annex 1.
Subcontracting may cover only a limited part of the action.
The beneficiaries must award the subcontracts ensuring the best value for money or, if appropriate,
the lowest price. In doing so, they must avoid any conflict of interests (see Article 20).
The tasks to be implemented and the estimated cost for each subcontract must be set out in Annex
1 and the total estimated costs of subcontracting per beneficiary must be set out in Annex 2. The
Agency may however approve subcontracts not set out in Annex 1 and 2 without amendment (see
Article 39), if:
- they are specifically justified in the periodic technical report and
- they do not entail changes to the Agreement which would call into question the decision
awarding the grant or breach the principle of equal treatment of applicants.
The beneficiaries must ensure that the Agency, the Commission, the European Court of Auditors
(ECA) and the European Anti-Fraud Office (OLAF) can exercise their rights under Articles 17 and
18 also towards their subcontractors.
10.1.2 The beneficiaries must ensure that their obligations under Articles 20, 21, 22 and 30 also apply
to the subcontractors.
Beneficiaries that are ‘contracting authorities’ within the meaning of Directive 2004/18/EC (or
2014/24/EU) or ‘contracting entities’ within the meaning of Directive 2004/17/EC (or 2014/25/EU)
must comply with the applicable national law on public procurement.
10.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under Article 10.1.1, the costs related to the subcontract
concerned will be ineligible (see Article 6) and will be rejected (see Article 26).
5 Directive 2014/25/EU of the European Parliament and of the Council of 26 February 2014 on procurement by entities
operating in the water, energy, transport and postal services sectors and repealing Directive 2004/17/EC (OJ L 94,
28.3.2014, p. 243).
18
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
If a beneficiary breaches any of its obligations under Article 10.1.2, the grant may be reduced (see
Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 11 — IMPLEMENTATION OF ACTION TASKS BY AFFILIATED ENTITIES
11.1 Rules for calling upon affiliated entities to implement part of the action
11.1.1 The following 'affiliated entities' 6 may implement the action tasks attributed to them in
Annex 1:
- TERVISE ARENGU INSTITUUT (NIHD), affiliated or linked to MoSA
- INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM),
affiliated or linked to SpFrance
- GIP INSTITUT DE RECHERCHE ET DOCUMENTATION EN ECONOMIE DE LA SANTE
(IRDES), affiliated or linked to SpFrance
- MINISTERE DES AFFAIRES SOCIALES ET DE LA SANTE (MoH FR), affiliated or linked
to SpFrance
- THE HEALTH RESEARCH BOARD (HRB), affiliated or linked to DOH
- NARODOWY INSTYTUT ZDROWIA PUBLICZNEGO-PANSTWOWY ZAKLAD
HIGIENY (NIPH), affiliated or linked to MZ
- INSTITUTO NACIONAL DE SAUDE DR. RICARDO JORGE (INSA), affiliated or linked to
MS
- UNIVERSIDADE NOVA DE LISBOA (UNL), affiliated or linked to MS
- FUNDACION ESPAÑOLA PARA LA COOPERACION INTERNACIONAL SALUD Y
POLITICA SOCIAL (FCSAI), affiliated or linked to ISCIII
- INSTITUTO ARAGONES DE CIENCIAS DE LA SALUD (IACS), affiliated or linked to ISCIII
- SWANSEA UNIVERSITY (SU), affiliated or linked to WG
- Department of Health (PHE), affiliated or linked to WG
The affiliated entities may declare as eligible the costs they incur for implementing the action tasks
in accordance with Article 6.3.
6 For the definition, see Article 122 of the Financial Regulation (EU, Euratom) No 966/2012: entities affiliated to the
beneficiary are:
(a) entities that form a ‘sole beneficiary’ (i.e. where an entity is formed of several entities that satisfy the criteria for
being awarded a grant, including where the entity is specifically established for the purpose of implementing
an action to be financed by a grant);
(b) entities that satisfy the eligibility criteria and that do not fall within one of the situations referred to in Article
131(4) and that have a link with the beneficiary, in particular a legal or capital link, which is neither limited to
the action nor established for the sole purpose of its implementation.
19
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
The beneficiaries must ensure that the Agency, the Commission, the European Court of Auditors
(ECA) and the European Anti-Fraud Office (OLAF) can exercise their rights under Articles 17 and
18 also towards their affiliated entities.
11.1.2 The beneficiaries must ensure that their obligations under Articles 13, 15, 20, 21 and 22 also
apply to their affiliated entities.
11.2 Consequences of non-compliance
If any obligation under Article 11.1.1 is breached, the costs of the affiliated entity will be ineligible
(see Article 6) and will be rejected (see Article 26).
If any obligation under Article 11.1.2 is breached, the grant may be reduced (see Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 11A — FINANCIAL SUPPORT TO THIRD PARTIES
Not applicable
SECTION 2 RIGHTS AND OBLIGATIONS RELATED TO THE GRANT
ADMINISTRATION
ARTICLE 12 — GENERAL OBLIGATION TO INFORM
12.1 General obligation to provide information upon request
The beneficiaries must provide — during implementation of the action or afterwards and in accordance
with Article 25.2 — any information requested in order to verify eligibility of the costs, proper
implementation of the action and compliance with any other obligation under the Agreement.
12.2 Obligation to keep information up to date and to inform about events and circumstances
likely to affect the Agreement
Each beneficiary must keep information stored in the Participant Portal Beneficiary Register (via
the electronic exchange system; see Article 36) up to date, in particular, its name, address, legal
representatives, legal form and organisation type.
Each beneficiary must immediately inform the coordinator — which must immediately inform the
Agency and the other beneficiaries — of any of the following:
(a) events which are likely to affect significantly or delay the implementation of the action or the
EU’s financial interests, in particular:
(i) changes in its legal, financial, technical, organisational or ownership situation or those
of its affiliated entities and
(ii) changes in the name, address, legal form, organisation type of its affiliated entities;
(b) circumstances affecting:
20
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
(i) the decision to award the grant or
(ii) compliance with requirements under the Agreement.
12.3 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 13 — KEEPING RECORDS — SUPPORTING DOCUMENTATION
13.1 Obligation to keep records and other supporting documentation
The beneficiaries must — for a period of five years after the payment of the balance — keep records
and other supporting documentation, in order to prove the proper implementation of the action and
the costs they declare as eligible.
They must make them available upon request (see Article 12) or in the context of checks, reviews,
audits or investigations (see Article 17).
If there are on-going checks, reviews, audits, investigations, litigation or other pursuits of claims under
the Agreement (including the extension of findings; see Article 17), the beneficiaries must keep the
records and other supporting documentation until the end of these procedures.
The beneficiaries must keep the original documents. Digital and digitalised documents are considered
originals if they are authorised by the applicable national law. The Agency may accept non-original
documents if it considers that they offer a comparable level of assurance.
13.1.1 Records and other supporting documentation on the technical implementation
The beneficiaries must keep records and other supporting documentation on the technical
implementation of the action, in line with the accepted standards in the respective field.
13.1.2 Records and other documentation to support the costs declared
The beneficiaries must keep the records and documentation supporting the costs declared, in particular
the following:
(a) for actual costs: adequate records and other supporting documentation to prove the costs
declared, such as contracts, subcontracts, invoices and accounting records. In addition, the
beneficiaries’ usual cost accounting practices and internal control procedures must enable direct
reconciliation between the amounts declared, the amounts recorded in their accounts and the
amounts stated in the supporting documentation;
(b) for unit costs: not applicable;
(c) for flat-rate costs: adequate records and other supporting documentation to prove the eligibility
of the costs to which the flat-rate is applied. The beneficiaries do not need to identify the costs
21
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
covered or provide supporting documentation (such as accounting statements) to prove the
amount declared at a flat-rate;
(d) for lump sum costs: not applicable;
In addition, for personnel costs (declared as actual costs), the beneficiaries must keep time records
for the number of days declared. The time records must be in writing and approved by the persons
working on the action and their supervisors, at least monthly. In the absence of reliable time records
of the days worked on the action, the Agency may accept alternative evidence supporting the number
of days declared, if it considers that it offers an adequate level of assurance.
As an exception, for persons working exclusively on the action, there is no need to keep time records,
if the beneficiary signs a declaration confirming that the persons concerned have worked exclusively
on the action.
For costs declared by affiliated entities (see Article 11), it is the beneficiary that must keep the originals
of the financial statements and the certificates on the financial statements of its affiliated entities.
13.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, costs insufficiently substantiated
will be ineligible (see Article 6) and will be rejected (see Article 26), and the grant may be reduced
(see Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 14 — SUBMISSION OF DELIVERABLES
14.1 Obligation to submit deliverables
The coordinator must submit the ‘deliverables’ identified in Annex 1, in accordance with the timing
and conditions set out in it.
14.2 Consequences of non-compliance
If the coordinator breaches any of its obligations under this Article, the Agency may apply any of the
measures described in Chapter 6.
ARTICLE 15 — REPORTING — PAYMENT REQUESTS
15.1 Obligation to submit reports
The coordinator must submit to the Agency (see Article 36) the technical and financial report(s) set
out in this Article. These reports include request(s) for payment and must be drawn up using the forms
and templates provided in the electronic exchange system (see Article 36).
15.2 Reporting periods
The action is divided into the following ‘reporting periods’:
- RP1: from month 1 to month 18
22
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
- RP2: from month 19 to month 36
15.2a Request(s) for further pre-financing payment(s)
Not applicable
15.3 Periodic reports — Requests for interim payments
The coordinator must submit a periodic report within 60 days following the end of each reporting
period.
The periodic report must include the following:
(a) a ‘periodic technical report’ containing:
(i) an explanation of the work carried out by the beneficiaries;
(ii) an overview of the progress towards the objectives of the action, including milestones
and deliverables identified in Annex 1.
This report must include explanations justifying the differences between work expected
to be carried out in accordance with Annex 1 and that actually carried out;
(iii) a summary for publication by the Agency;
(iv) the answers to the ‘questionnaire’: covering issues related to the action implementation
and its impact;
(b) a ‘periodic financial report’ containing:
(i) an ‘individual financial statement’ (see Annex 4) from each beneficiary and from each
affiliated entity, for the reporting period concerned.
The individual financial statement must detail the eligible costs (actual costs and flat-rate
costs; see Article 6) for each budget category (see Annex 2).
The beneficiaries and affiliated entities must declare all eligible costs, even if — for
actual costs and flat-rate costs — they exceed the amounts indicated in the estimated
budget (see Annex 2). Amounts which are not declared in the individual financial
statement will not be taken into account by the Agency.
If an individual financial statement is not submitted for a reporting period, it may be
included in the periodic financial report for the next reporting period.
The individual financial statements of the last reporting period must also detail the
receipts of the action (see Article 5.3.3).
Each beneficiary and each affiliated entity must certify that:
- the information provided is full, reliable and true;
- the costs declared are eligible (see Article 6);
23
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
- the costs can be substantiated by adequate records and supporting documentation
(see Article 13) that will be produced upon request (see Article 12) or in the context
of checks, reviews, audits and investigations (see Article 17), and
- for the last reporting period: that all the receipts have been declared (see
Article 5.3.3);
(ii) an explanation of the use of resources and the information on subcontracting (see
Article 10) from each beneficiary and from each affiliated entity, for the reporting period
concerned;
(iii) not applicable;
(iv) a ‘periodic summary financial statement’, created automatically by the electronic
exchange system, consolidating the individual financial statements for the reporting
period concerned and including — except for the last reporting period — the request
for interim payment;
(v) a ‘certificate on the financial statements’ (drawn up in accordance with Annex 5) for
each beneficiary and for each affiliated entity, if:
- the (cumulative) amount of EU contribution it requests as reimbursement of actual
costs (and for which no certificate has yet been submitted) is EUR 325 000 or
more and
- the maximum EU contribution indicated, for that beneficiary or affiliated entity,
in the estimated budget (see Annex 2) as reimbursement of actual costs is
EUR 750 000 or more.
15.4 Final report — Request for payment of the balance
In addition to the periodic report for the last reporting period, the coordinator must submit the final
report within 60 days following the end of the last reporting period.
The final report must include the following:
(a) a ‘final technical report’ with a summary for publication containing:
(i) an overview of the results and their dissemination;
(ii) the conclusions on the action and
(iii) the impact of the action;
(b) a ‘final financial report’ containing a ‘final summary financial statement’, created
automatically by the electronic exchange system, consolidating the individual financial
statements for all reporting periods and including the request for payment of the balance.
15.5 Information on cumulative expenditure incurred
Not applicable
24
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
15.6 Currency for financial statements and conversion into euro
Financial statements must be drafted in euro.
Beneficiaries and affiliated entities with accounting established in a currency other than the euro
must convert the costs recorded in their accounts into euro at the average of the daily exchange
rates published in the C series of the Official Journal of the European Union, calculated over the
corresponding reporting period.
If no daily euro exchange rate is published in the Official Journal of the European Union for the
currency in question, they must be converted at the average of the monthly accounting rates published
on the Commission’s website, calculated over the corresponding reporting period.
Beneficiaries and affiliated entities with accounting established in euro must convert costs incurred
in another currency into euro according to their usual accounting practices.
15.7 Language of reports
All report(s) (including financial statements) must be submitted in the language of the Agreement.
15.8 Consequences of non-compliance
If the report(s) submitted do not comply with this Article, the Agency may suspend the payment
deadline (see Article 31) and apply any of the other measures described in Chapter 6.
If the coordinator breaches its obligation to submit the report(s) and if it fails to comply with this
obligation within 30 days following a written reminder, the Agency may terminate the Agreement
(see Article 34) or apply any of the other measures described in Chapter 6.
ARTICLE 16 — PAYMENTS AND PAYMENT ARRANGEMENTS
16.1 Payments to be made
The following payments will be made to the coordinator:
- a pre-financing payment;
- one or more interim payments, on the basis of the request(s) for interim payment (see
Article 15), and
- one payment of the balance, on the basis of the request for payment of the balance (see
Article 15).
16.2 Pre-financing payment — Amount
The aim of the pre-financing is to provide the beneficiaries with a float.
It remains the property of the EU until the payment of the balance.
The amount of the pre-financing payment will be EUR 1,199,911.52 (one million one hundred and
ninety nine thousand nine hundred and eleven EURO and fifty two eurocents).
The Agency will — except if Article 32 applies — make the pre-financing payment to the coordinator
25
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
within 30 days, either from the entry into force of the Agreement (see Article 42) or from 10 days
before the starting date of the action (see Article 3) , whichever is the latest.
16.3 Interim payments — Amount — Calculation
Interim payments reimburse the eligible costs incurred for the implementation of the action during
the corresponding reporting periods.
The Agency will pay to the coordinator the amount due as interim payment within 60 days from
receiving the periodic report (see Article 15.3), except if Articles 31 or 32 apply.
Payment is subject to the approval of the periodic report. Its approval does not imply recognition of
compliance, authenticity, completeness or correctness of its content.
The amount due as interim payment is calculated by the Agency in the following steps:
Step 1 – Application of the reimbursement rate
Step 2 – Limit to 90% of the maximum grant amount
16.3.1 Step 1 — Application of the reimbursement rate
The reimbursement rate (see Article 5.2) is applied to the eligible costs (actual costs and flat-rate costs;
see Article 6) declared by the beneficiaries and the affiliated entities (see Article 15) and approved by
the Agency (see above) for the concerned reporting period.
16.3.2 Step 2 — Limit to 90% of the maximum grant amount
The total amount of pre-financing and interim payments must not exceed 90% of the maximum grant
amount set out in Article 5.1. The maximum amount for the interim payment will be calculated as
follows:
{90% of the maximum grant amount (see Article 5.1)
minus
{pre-financing and previous interim payments}}.
16.4 Payment of the balance — Amount — Calculation
The payment of the balance reimburses the remaining part of the eligible costs incurred by the
beneficiaries for the implementation of the action.
If the total amount of earlier payments is greater than the final grant amount (see Article 5.3), the
payment of the balance takes the form of a recovery (see Article 28).
If the total amount of earlier payments is lower than the final grant amount, the Agency will pay the
balance within 60 days from receiving the final report (see Article 15.4), except if Articles 31 or 32
apply.
Payment is subject to the approval of the final report. Its approval does not imply recognition of
compliance, authenticity, completeness or correctness of its content.
The amount due as the balance is calculated by the Agency by deducting the total amount of pre-
26
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
financing and interim payments (if any) already made, from the final grant amount determined in
accordance with Article 5.3:
{final grant amount (see Article 5.3)
minus
{pre-financing and interim payments (if any) made}}.
If the balance is positive, it will be paid to the coordinator.
The amount to be paid may however be offset — without the beneficiaries’ consent — against any
other amount owed by a beneficiary to the Agency, the Commission or another executive agency
(under the EU or Euratom budget), up to the maximum EU contribution indicated, for that beneficiary,
in the estimated budget (see Annex 2).
If the balance is negative, it will be recovered from the coordinator (see Article 28).
16.5 Notification of amounts due
When making payments, the Agency will formally notify to the coordinator the amount due,
specifying that it concerns an interim payment or the payment of the balance.
For the payment of the balance, the notification will also specify the final grant amount.
In the case of reduction of the grant or recovery of undue amounts, the notification will be preceded
by the contradictory procedure set out in Articles 27 and 28.
16.6 Currency for payments
The Agency will make all payments in euro.
16.7 Payments to the coordinator — Distribution to the beneficiaries
Payments will be made to the coordinator.
Payments to the coordinator will discharge the Agency from its payment obligation.
The coordinator must distribute the payments between the beneficiaries without unjustified delay.
Pre-financing may however be distributed only:
(a) if 90% of the beneficiaries have acceded to the Agreement (see Article 40) and
(b) to beneficiaries that have acceded to the Agreement (see Article 40).
16.8 Bank account for payments
All payments will be made to the following bank account:
Name of bank: BPOST
Full name of the account holder: SCIENSANO KLANTEN CLIENTS
Full account number (including bank codes):
IBAN code: BE18679000113265
27
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
16.9 Costs of payment transfers
The cost of the payment transfers is borne as follows:
- the Agency bears the cost of transfers charged by its bank;
- the beneficiary bears the cost of transfers charged by its bank;
- the party causing a repetition of a transfer bears all costs of the repeated transfer.
16.10 Date of payment
Payments by the Agency are considered to have been carried out on the date when they are debited
to its account.
16.11 Consequences of non-compliance
16.11.1 If the Agency does not pay within the payment deadlines (see above), the beneficiaries are
entitled to late-payment interest at the rate applied by the European Central Bank (ECB) for its main
refinancing operations in euros (‘reference rate’), plus three and a half points. The reference rate is
the rate in force on the first day of the month in which the payment deadline expires, as published in
the C series of the Official Journal of the European Union.
If the late-payment interest is lower than or equal to EUR 200, it will be paid to the coordinator only
upon request submitted within two months of receiving the late payment.
Late-payment interest is not due if all beneficiaries are EU Member States (including regional and
local government authorities or other public bodies acting on behalf of a Member State for the purpose
of this Agreement).
Suspension of the payment deadline or payments (see Articles 31 and 32) will not be considered as
late payment.
Late-payment interest covers the period running from the day following the due date for payment (see
above), up to and including the date of payment.
Late-payment interest is not considered for the purposes of calculating the final grant amount.
16.11.2 If the coordinator breaches any of its obligations under this Article, the grant may be reduced
(see Article 27) and the Agreement or the participation of the coordinator may be terminated (see
Article 34).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 17 — CHECKS, REVIEWS, AUDITS AND INVESTIGATIONS — EXTENSION
OF FINDINGS
17.1 Checks, reviews and audits by the Agency and the Commission
17.1.1 Right to carry out checks
The Agency or the Commission will — during the implementation of the action or afterwards — check
28
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
the proper implementation of the action and compliance with the obligations under the Agreement,
including assessing deliverables and reports.
For this purpose, the Agency or the Commission may be assisted by external persons or bodies.
The Agency or the Commission may also request additional information in accordance with Article 12.
The Agency or the Commission may request beneficiaries to provide such information to it directly.
Information provided must be accurate, precise and complete and in the format requested, including
electronic format.
17.1.2 Right to carry out reviews
The Agency or the Commission may — during the implementation of the action or afterwards —
carry out reviews on the proper implementation of the action (including assessment of deliverables
and reports) and compliance with the obligations under the Agreement.
Reviews may be started up to five years after the payment of the balance. They will be formally
notified to the coordinator or beneficiary concerned and will be considered to have started on the date
of the formal notification.
If the review is carried out on a third party (see Articles 9 to 11a), the beneficiary concerned must
inform the third party.
The Agency or the Commission may carry out reviews directly (using its own staff) or indirectly (using
external persons or bodies appointed to do so). It will inform the coordinator or beneficiary concerned
of the identity of the external persons or bodies. They have the right to object to the appointment on
grounds of commercial confidentiality.
The coordinator or beneficiary concerned must provide — within the deadline requested — any
information and data in addition to deliverables and reports already submitted (including information
on the use of resources). The Agency or the Commission may request beneficiaries to provide such
information to it directly.
The coordinator or beneficiary concerned may be requested to participate in meetings, including with
external experts.
For on-the-spot reviews, the beneficiaries must allow access to their sites and premises, including to
external persons or bodies, and must ensure that information requested is readily available.
Information provided must be accurate, precise and complete and in the format requested, including
electronic format.
On the basis of the review findings, a ‘review report’ will be drawn up.
The Agency or the Commission will formally notify the review report to the coordinator or beneficiary
concerned, which has 30 days to formally notify observations (‘contradictory review procedure’).
Reviews (including review reports) are in the language of the Agreement.
17.1.3 Right to carry out audits
The Agency or the Commission may — during the implementation of the action or afterwards —
29
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
carry out audits on the proper implementation of the action and compliance with the obligations under
the Agreement.
Audits may be started up to five years after the payment of the balance. They will be formally
notified to the coordinator or beneficiary concerned and will be considered to have started on the date
of the formal notification.
If the audit is carried out on a third party (see Articles 9 to 11a), the beneficiary concerned must inform
the third party.
The Agency or the Commission may carry out audits directly (using its own staff) or indirectly (using
external persons or bodies appointed to do so). It will inform the coordinator or beneficiary concerned
of the identity of the external persons or bodies. They have the right to object to the appointment on
grounds of commercial confidentiality.
The coordinator or beneficiary concerned must provide — within the deadline requested — any
information (including complete accounts, individual salary statements or other personal data) to
verify compliance with the Agreement. The Agency or the Commission may request beneficiaries to
provide such information to it directly.
For on-the-spot audits, the beneficiaries must allow access to their sites and premises, including to
external persons or bodies, and must ensure that information requested is readily available.
Information provided must be accurate, precise and complete and in the format requested, including
electronic format.
On the basis of the audit findings, a ‘draft audit report’ will be drawn up.
The Agency or the Commission will formally notify the draft audit report to the coordinator or
beneficiary concerned, which has 30 days to formally notify observations (‘contradictory audit
procedure’). This period may be extended by the Agency or the Commission in justified cases.
The ‘final audit report’ will take into account observations by the coordinator or beneficiary
concerned. The report will be formally notified to it.
Audits (including audit reports) are in the language of the Agreement.
The Agency or the Commission may also access the beneficiaries’ statutory records for the periodical
assessment of flat-rate amounts.
17.2 Investigations by the European Anti-Fraud Office (OLAF)
Under Regulations No 883/20137 and No 2185/968 (and in accordance with their provisions and
procedures), the European Anti-Fraud Office (OLAF) may — at any moment during implementation
of the action or afterwards — carry out investigations, including on-the-spot checks and inspections,
7 Regulation (EU, Euratom) No 883/2013 of the European Parliament and of the Council of 11 September 2013
concerning investigations conducted by the European Anti-Fraud Office (OLAF) and repealing Regulation (EC)
No 1073/1999 of the European Parliament and of the Council and Council Regulation (Euratom) No 1074/1999 (OJ
L 232, 18.09.2013, p. 1).
8 Council Regulation (Euratom, EC) No 2185/1996 of 11 November 1996 concerning on-the-spot checks and inspections
carried out by the Commission in order to protect the European Communities' financial interests against fraud and other
irregularities (OJ L 292, 15.11.1996, p. 2).
30
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
to establish whether there has been fraud, corruption or any other illegal activity affecting the financial
interests of the EU.
17.3 Checks and audits by the European Court of Auditors (ECA)
Under Article 287 of the Treaty on the Functioning of the European Union (TFEU) and Article 161 of
the Financial Regulation No 966/20129, the European Court of Auditors (ECA) may — at any moment
during implementation of the action or afterwards — carry out audits.
The ECA has the right of access for the purpose of checks and audits.
17.4 Checks, reviews, audits and investigations for international organisations
Not applicable
17.5 Consequences of findings in checks, reviews, audits and investigations —Extension of
findings
17.5.1 Findings in this grant
Findings in checks, reviews, audits or investigations carried out in the context of this grant may lead
to the rejection of ineligible costs (see Article 26), reduction of the grant (see Article 27), recovery of
undue amounts (see Article 28) or to any of the other measures described in Chapter 6.
Rejection of costs or reduction of the grant after the payment of the balance will lead to a revised final
grant amount (see Article 5.4).
Findings in checks, reviews, audits or investigations may lead to a request for amendment for the
modification of Annex 1 (see Article 39).
Checks, reviews, audits or investigations that find systemic or recurrent errors, irregularities, fraud or
breach of obligations may also lead to consequences in other EU or Euratom grants awarded under
similar conditions (‘extension of findings from this grant to other grants’).
Moreover, findings arising from an OLAF investigation may lead to criminal prosecution under
national law.
17.5.2 Findings in other grants
The Agency or the Commission may extend findings from other grants to this grant (‘extension of
findings from other grants to this grant’), if:
(a) the beneficiary concerned is found, in other EU or Euratom grants awarded under similar
conditions, to have committed systemic or recurrent errors, irregularities, fraud or breach of
obligations that have a material impact on this grant and
(b) those findings are formally notified to the beneficiary concerned — together with the list of
9 Regulation (EU, Euratom) No 966/2012 of the European Parliament and of the Council of 25 October 2012 on the
financial rules applicable to the general budget of the Union and repealing Council Regulation (EC, Euratom) No
1605/2002 (OJ L 298, 26.10.2012, p. 1).
31
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
grants affected by the findings — no later than five years after the payment of the balance
of this grant.
The extension of findings may lead to the rejection of costs (see Article 26), reduction of the grant
(see Article 27), recovery of undue amounts (see Article 28), suspension of payments (see Article 32),
suspension of the action implementation (see Article 33) or termination (see Article 34).
17.5.3 Procedure
The Agency or the Commission will formally notify the beneficiary concerned the systemic or
recurrent errors and its intention to extend these audit findings, together with the list of grants affected.
17.5.3.1 If the findings concern eligibility of costs: the formal notification will include:
(a) an invitation to submit observations on the list of grants affected by the findings;
(b) the request to submit revised financial statements for all grants affected;
(c) the correction rate for extrapolation established by the Agency or the Commission on
the basis of the systemic or recurrent errors, to calculate the amounts to be rejected, if the
beneficiary concerned:
(i) considers that the submission of revised financial statements is not possible or
practicable or
(ii) does not submit revised financial statements.
The beneficiary concerned has 90 days from receiving notification to submit observations, revised
financial statements or to propose a duly substantiated alternative correction method. This period
may be extended by the Agency or the Commission in justified cases.
The Agency or the Commission may then start a rejection procedure in accordance with Article 26,
either on the basis of the revised financial statements, the alternative method or the correction rate
announced.
17.5.3.2 If the findings concern substantial errors, irregularities or fraud or serious breach of
obligations: the formal notification will include:
(a) an invitation to submit observations on the list of grants affected by the findings and
(b) the flat-rate the Agency or the Commission intends to apply according to the principle of
proportionality.
The beneficiary concerned has 90 days from receiving notification to submit observations or to
propose a duly substantiated alternative flat-rate.
The Agency or the Commission may then start a reduction procedure in accordance with Article 27,
either on the basis of the alternative flat-rate or the flat-rate announced.
17.6 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, any insufficiently substantiated costs
will be ineligible (see Article 6) and will be rejected (see Article 26).
32
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 18 — EVALUATION OF THE IMPACT OF THE ACTION
18.1 Right to evaluate the impact of the action
The Agency or the Commission may carry out interim and final evaluations of the impact of the action
measured against the objective of the EU programme.
Evaluations may be started during implementation of the action and up to five years after the
payment of the balance. The evaluation is considered to start on the date of the formal notification
to the coordinator or beneficiaries.
The Agency or the Commission may make these evaluations directly (using its own staff) or indirectly
(using external bodies or persons it has authorised to do so).
The coordinator or beneficiaries must provide any information relevant to evaluate the impact of the
action, including information in electronic format.
18.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the Agency may apply the measures
described in Chapter 6.
SECTION 3 OTHER RIGHTS AND OBLIGATIONS
ARTICLE 19 — PRE-EXISTING RIGHTS AND OWNERSHIP OF THE RESULTS
(INCLUDING INTELLECTUAL AND INDUSTRIAL PROPERTY
RIGHTS)
19.1 Pre-existing rights and access rights to pre-existing rights
Where industrial and intellectual property rights (including rights of third parties) exist prior to the
Agreement, the beneficiaries must establish a list of these pre-existing industrial and intellectual
property rights, specifying the owner and any persons that have a right of use.
The coordinator must — before starting the action — submit this list to the Agency.
Each beneficiary must give the other beneficiaries and their affiliated entities access to any pre-existing
industrial and intellectual property rights needed for the implementation of the action and compliance
with the obligations under the Agreement.
19.2 Ownership of results and rights of use
The results of the action (including the reports and other documents relating to it) are owned by the
beneficiaries.
The beneficiaries must give the Agency and the Commission the right to use the results for their
communication activities under Article 22.
33
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
19.3 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 27).
Such a breach may also lead to any of the other measures described in Chapter 6.
ARTICLE 20 — CONFLICT OF INTERESTS
20.1 Obligation to avoid a conflict of interests
The beneficiaries must take all measures to prevent any situation where the impartial and objective
implementation of the action is compromised for reasons involving economic interest, political or
national affinity, family or emotional ties or any other shared interest (‘conflict of interests’).
They must formally notify to the Agency without delay any situation constituting or likely to lead to
a conflict of interests and immediately take all the necessary steps to rectify this situation.
The Agency may verify that the measures taken are appropriate and may require additional measures
to be taken by a specified deadline.
20.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 27) and the Agreement or participation of the beneficiary may be terminated (see Article 34).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 21 — CONFIDENTIALITY
21.1 General obligation to maintain confidentiality
During implementation of the action and for five years after the payment of the balance, the parties
must keep confidential any data, documents or other material (in any form) that is identified as
confidential at the time it is disclosed (‘confidential information’).
They may use confidential information to implement the Agreement.
The confidentiality obligations no longer apply if:
(a) the disclosing party agrees to release the other party;
(b) the information becomes generally and publicly available, without breaching any
confidentiality obligation;
(c) the disclosure of the confidential information is required by EU or national law.
21.2 Consequences of non-compliance
If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 27).
34
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 22 — PROMOTING THE ACTION — VISIBILITY OF EU FUNDING
22.1 Communication activities by the beneficiaries
22.1.1 General obligation to promote the action and its results
The beneficiaries must promote the action and its results.
22.1.2 Information on EU funding — Obligation and right to use the EU emblem
Unless the Agency requests or agrees otherwise, any communication activity related to the action
(including at conferences, seminars, in information material, such as brochures, leaflets, posters,
presentations, etc., in electronic form, via social media, etc.) and any infrastructure, equipment or
major results funded by the grant must:
- display the EU emblem and
- include the following text:
“This [insert appropriate description, e.g. report, publication, conference, infrastructure, equipment, insert
type of result, etc.] was funded by the European Union’s Health Programme (2014-2020).”
When displayed in association with another logo, the EU emblem must have appropriate prominence.
For the purposes of their obligations under this Article, the beneficiaries may use the EU emblem
without first obtaining approval from the Agency.
This does not, however, give them the right to exclusive use.
Moreover, they may not appropriate the EU emblem or any similar trademark or logo, either by
registration or by any other means.
22.1.3 Disclaimer excluding Agency and Commission responsibility
Any communication activity related to the action must indicate the following disclaimer:
"The content of this [insert appropriate description, e.g. report, publication, conference, etc.] represents the
views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the
European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency (CHAFEA)
or any other body of the European Union. The European Commission and the Agency do not accept any
responsibility for use that may be made of the information it contains.”
22.2 Communication activities by the Agency and the Commission
22.2.1 Right to use the beneficiaries’ materials, documents or information
The Agency and the Commission may use information relating to the action, documents notably
summaries for publication and public deliverables as well as any other material, such as pictures or
audio-visual material received from any beneficiary (including in electronic form).
This does not change the confidentiality obligations in Article 21, which still apply.
35
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
The right to use the beneficiary’s materials, documents and information includes:
(a) use for its own purposes (in particular, making them available to persons working for the
Agency, the Commission or any other EU institution, body, office or agency or body or
institutions in EU Member States; and copying or reproducing them in whole or in part, in
unlimited numbers);
(b) distribution to the public (in particular, publication as hard copies and in electronic or digital
format, publication on the internet, as a downloadable or non-downloadable file, broadcasting
by any channel, public display or presentation, communicating through press information
services, or inclusion in widely accessible databases or indexes);
(c) editing or redrafting for communication and publicising activities (including shortening,
summarising, inserting other elements (such as meta-data, legends, other graphic, visual, audio
or text elements), extracting parts (e.g. audio or video files), dividing into parts, use in a
compilation);
(d) translation;
(e) giving access in response to individual requests under Regulation No 1049/200110, without
the right to reproduce or exploit;
(f) storage in paper, electronic or other form;
(g) archiving, in line with applicable document-management rules, and
(h) the right to authorise third parties to act on its behalf or sub-license the modes of use set out
in Points (b), (c), (d) and (f) to third parties if needed for the communication and publicising
activities of the Agency or the Commission.
If the right of use is subject to rights of a third party (including personnel of the beneficiary), the
beneficiary must ensure that it complies with its obligations under this Agreement (in particular, by
obtaining the necessary approval from the third parties concerned).
Where applicable (and if provided by the beneficiaries), the Agency or the Commission will insert
the following information:
“© – [year] – [name of the copyright owner]. All rights reserved. Licensed to the Consumers, Health,
Agriculture and Food Executive Agency (CHAFEA) and the European Union (EU) under conditions.”
22.3 Consequences of non-compliance
If the beneficiary breaches any of its obligations under this Article, the grant may be reduced (see
Article 27).
Such breaches may also lead to any of the other measures described in Chapter 6.
ARTICLE 23 — PROCESSING OF PERSONAL DATA
10 Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access
to European Parliament, Council and Commission documents, OJ L 145, 31.5.2001, p. 43.
36
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
23.1 Processing of personal data by the Agency and the Commission
Any personal data under the Agreement will be processed by the Agency or the Commission under
Regulation No 23/200111 and according to the ‘notifications of the processing operations’ to the Data
Protection Officer (DPO) of the Agency or the Commission (publicly accessible in the DPO register).
Such data will be processed by the ‘data controller’ of the Agency or the Commission, for the
purposes of implementing, managing and monitoring the Agreement or protecting the financial
interests of the EU or Euratom (including checks, reviews, audits and investigations; see Article 17).
The persons whose personal data are processed have the right to access and correct their own personal
data. For this purpose, they must send any queries about the processing of their personal data to the data
controller, via the contact point indicated in the privacy statement(s) on the Agency and Commission
websites.
They also have the right to have recourse at any time to the European Data Protection Supervisor
(EDPS).
23.2 Processing of personal data by the beneficiaries
The beneficiaries must process personal data under the Agreement in compliance with applicable EU
and national law on data protection (including authorisations or notification requirements).
The beneficiaries may grant their personnel access only to data that is strictly necessary for
implementing, managing and monitoring the Agreement.
The beneficiaries must inform the personnel whose personal data are collected and processed by the
Agency or the Commission. For this purpose, they must provide them with the privacy statement(s)
(see above), before transmitting their data to the Agency or the Commission.
23.3 Consequences of non-compliance
If a beneficiary breaches any of its obligations under Article 23.2, the Agency may apply any of the
measures described in Chapter 6.
ARTICLE 24 — ASSIGNMENTS OF CLAIMS FOR PAYMENT AGAINST THE AGENCY
The beneficiaries may not assign any of their claims for payment against the Agency to any third
party, except if approved by the Agency on the basis of a reasoned, written request by the coordinator
(on behalf of the beneficiary concerned).
If the Agency has not accepted the assignment or the terms of it are not observed, the assignment
will have no effect on it.
In no circumstances will an assignment release the beneficiaries from their obligations towards the
Agency.
11 Regulation (EC) No 45/2001 of the European Parliament and of the Council of 18 December 2000 on the protection
of individuals with regard to the processing of personal data by the Community institutions and bodies and on the free
movement of such data (OJ L 8, 12.01.2001, p. 1).
37
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
CHAPTER 5 DIVISION OF BENEFICIARIES’ ROLES AND RESPONSIBILITIES
ARTICLE 25 — DIVISION OF BENEFICIARIES’ ROLES AND RESPONSIBILITIES
25.1 Roles and responsibilities towards the Agency
The beneficiaries have full responsibility for implementing the action and complying with the
Agreement.
The beneficiaries are jointly and severally liable for the technical implementation of the action as
described in Annex 1. If a beneficiary fails to implement its part of the action, the other beneficiaries
become responsible for implementing this part (without being entitled to any additional EU funding
for doing so), unless the Agency expressly relieves them of this obligation.
The financial responsibility of each beneficiary is governed by Articles 28, 29 and 30.
25.2 Internal division of roles and responsibilities
The internal roles and responsibilities of the beneficiaries are divided as follows:
(a) Each beneficiary must:
(i) keep information stored in the Participant Portal Beneficiary Register (via the
electronic exchange system) up to date (see Article 12);
(ii) inform the coordinator immediately of any events or circumstances likely to affect
significantly or delay the implementation of the action (see Article 12);
(iii) submit to the coordinator in good time:
- individual financial statements for itself and its affiliated entities and, if required,
certificates on the financial statements (see Article 15);
- the data needed to draw up the technical reports (see Article 15);
- any other documents or information required by the Agency or the Commission
under the Agreement, unless the Agreement requires the beneficiary to submit
this information directly.
(b) The coordinator must:
(i) monitor that the action is implemented properly (see Article 7);
(ii) act as the intermediary for all communications between the beneficiaries and the
Agency (in particular, providing the Agency with the information described in
Article 12), unless the Agreement specifies otherwise;
(iii) provide a pre-financing guarantee if requested by the Agency (see Article 16.2);
(iv) request and review any documents or information required by the Agency and verify
their completeness and correctness before passing them on to the Agency;
(v) submit the deliverables and reports to the Agency (see Articles 14 and 15);
38
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
(vi) ensure that all payments are made to the other beneficiaries without unjustified delay
(see Article 16).
The coordinator may not subcontract the above-mentioned tasks.
25.3 Internal arrangements between beneficiaries — Consortium agreement
The beneficiaries must have internal arrangements regarding their operation and co-ordination to
ensure that the action is implemented properly. These internal arrangements must be set out in a written
‘consortium agreement’ between the beneficiaries, which may cover:
- internal organisation of the consortium;
- management of access to the electronic exchange system;
- distribution of EU funding;
- additional rules on rights and obligations related to pre-existing rights and results (see Article
19);
- settlement of internal disputes;
- liability, indemnification and confidentiality arrangements between the beneficiaries.
The consortium agreement must not contain any provision contrary to the Agreement.
CHAPTER 6 REJECTION OF COSTS — REDUCTION OF THE GRANT — RECOVERY
— SANCTIONS — DAMAGES — SUSPENSION — TERMINATION —
FORCE MAJEURE
SECTION 1 REJECTION OF COSTS — REDUCTION OF THE GRANT — RECOVERY
— SANCTIONS
ARTICLE 26 — REJECTION OF INELIGIBLE COSTS
26.1 Conditions
The Agency will — at the time of an interim payment, at the payment of the balance or afterwards
— reject any costs which are ineligible (see Article 6), in particular following checks, reviews, audits
or investigations (see Article 17).
The rejection may also be based on the extension of findings from other grants to this grant (see
Article 17.5.2).
26.2 Ineligible costs to be rejected — Calculation — Procedure
Ineligible costs will be rejected in full.
If the rejection of costs does not lead to a recovery (see Article 28), the Agency will formally notify
39
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
the coordinator or beneficiary concerned of the rejection of costs, the amounts and the reasons why
(if applicable, together with the notification of amounts due; see Article 16.5). The coordinator or
beneficiary concerned may — within 30 days of receiving notification — formally notify the Agency
of its disagreement and the reasons why.
If the rejection of costs leads to a recovery, the Agency will follow the contradictory procedure with
pre-information letter set out in Article 28.
26.3 Effects
If the Agency rejects costs at the time of an interim payment or the payment of the balance, it will
deduct them from the total eligible costs declared, for the action, in the periodic or final summary
financial statement (see Article 15.3 and 15.4). It will then calculate the interim payment or payment
of the balance as set out in Article 16.3 or 16.4.
If the Agency — after an interim payment but before the payment of the balance — rejects costs
declared in a periodic summary financial statement, it will deduct them from the costs declared in the
next periodic summary financial statement or final summary financial statement. It will then calculate
the interim payment or payment of the balance as set out in Article 16.3 or 16.4.
If the Agency rejects costs after the payment of the balance, it will deduct the amount rejected from
the total eligible costs declared, by the beneficiary, in the final summary financial statement. It will
then calculate the revised final grant amount as set out in Article 5.4. If the revised final grant amount
is lower than the final grant amount, the Agency will recover the difference (see Article 28).
ARTICLE 27 — REDUCTION OF THE GRANT
27.1 Conditions
The Agency may — at the payment of the balance or afterwards — reduce the grant, if:
(a) a beneficiary (or a natural person who has the power to represent or take decisions on its behalf)
has committed:
(i) substantial errors, irregularities or fraud or
(ii) serious breach of obligations under the Agreement or during the award procedure
(including improper implementation of the action, submission of false information,
failure to provide required information, breach of ethical principles) or
(b) a beneficiary (or a natural person who has the power to represent or take decisions on its behalf)
has committed — in other EU or Euratom grants awarded to it under similar conditions —
systemic or recurrent errors, irregularities, fraud or serious breach of obligations that have a
material impact on this grant (extension of findings from other grants to this grant; see Article
17.5.2).
27.2 Amount to be reduced — Calculation — Procedure
The amount of the reduction will be proportionate to the seriousness of the errors, irregularities or
fraud or breach of obligations.
40
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
Before reduction of the grant, the Agency will formally notify a ‘pre-information letter’ to the
coordinator or beneficiary concerned:
- informing it of its intention to reduce the grant, the amount it intends to reduce and the reasons
why and
- inviting it to submit observations within 30 days of receiving notification.
If the Agency does not receive any observations or decides to pursue reduction despite the observations
it has received, it will formally notify confirmation of the reduction (if applicable, together with the
notification of amounts due; see Article 16).
27.3 Effects
If the Agency reduces the grant at the time of the payment of the balance, it will calculate the
reduced grant amount for the action and then determine the amount due as payment of the balance
(see Article 5.3.4 and 16.4).
If the Agency reduces the grant after the payment of the balance, it will calculate the revised final
grant amount for the action or for the beneficiary concerned (see Article 5.4). If the revised final grant
amount is lower than the final grant amount, the Agency will recover the difference (see Article 28).
ARTICLE 28 — RECOVERY OF UNDUE AMOUNTS
28.1 Amount to be recovered — Calculation — Procedure
The Agency will — at the payment of the balance or afterwards — claim back any amount that
was paid but is not due under the Agreement.
The coordinator is fully liable for repaying debts of the consortium (under the Agreement) even if it
has not been the final recipient of those amounts.
The other beneficiaries’ financial responsibility in case of recovery is limited, for each beneficiary,
to its own debts.
Undue amounts paid by the Agency for costs declared by an affiliated entity will be considered as
amounts unduly paid to the beneficiary.
28.1.1 Recovery at payment of the balance
If the payment of the balance takes the form of a recovery (see Article 16.4), the Agency will formally
notify a ‘pre-information letter’ to the coordinator:
- informing it of its intention to recover, the amount due as the balance and the reasons why and
- inviting the coordinator to submit observations within 30 days of receiving notification.
If no observations are submitted or the Agency decides to pursue recovery despite the observations
it has received, it will confirm the amount to be recovered and formally notify to the coordinator a
debit note with the terms and the date for payment (together with the notification of amounts due;
see Article 16.5).
41
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
If payment is not made by the date specified in the debit note, the Agency or the Commission will
recover the amount:
(a) by ‘offsetting’ it — without the coordinator’s consent — against any amounts owed to the
coordinator by the Agency, Commission or another executive agency (from the EU or Euratom
budget).
In exceptional circumstances, to safeguard the EU’s financial interests, the Agency may offset
before the payment date specified in the debit note;
(b) not applicable;
(c) not applicable;
(d) by taking legal action (see Article 41) or by adopting an enforceable decision under
Article 299 of the Treaty on the Functioning of the EU (TFEU) and Article 79(2) of the
Financial Regulation No 966/2012.
If payment is not made by the date in the debit note, the amount to be recovered (see above) will be
increased by late-payment interest at the rate set out in Article 16.11, from the day following the
payment date in the debit note, up to and including the date the Agency or the Commission receives
full payment of the amount.
Partial payments will be first credited against expenses, charges and late-payment interest and then
against the principal.
Bank charges incurred in the recovery process will be borne by the beneficiary, unless Directive
2007/64/EC applies.
28.1.2 Recovery of amounts after payment of the balance
If — after the payment of the balance — the Agency revised the final grant amount for the action or
for the beneficiary concerned (see Article 5.4), due to a rejection of costs or reduction of the grant, and
the revised final grant amount is lower than the final grant amount (see Article 5.3), the Agency will:
- if the rejection or reduction does not concern a specific beneficiary or its affiliated entities:
claim back the difference from the coordinator (even if it has not been the final recipient of
the amount in question)
or
- otherwise: claim back the difference from the beneficiary concerned.
The Agency will formally notify a pre-information letter to the coordinator or beneficiary concerned:
- informing it of its intention to recover, the amount to be repaid and the reasons why and
- inviting it to submit observations within 30 days of receiving notification.
If no observations are submitted or the Agency decides to pursue recovery despite the observations
it has received, it will confirm the amount to be recovered and formally notify to the coordinator or
beneficiary concerned a debit note. This note will also specify the terms and the date for payment.
42
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
If payment is not made by the date specified in the debit note, the Agency or the Commission will
recover the amount:
(a) by ‘offsetting’ it — without the coordinator’s or beneficiary’s consent — against any amounts
owed to the coordinator or beneficiary by the Agency, Commission or another executive agency
(from the EU or Euratom budget).
In exceptional circumstances, to safeguard the EU’s financial interests, the Agency may offset
before the payment date specified in the debit note;
(b) not applicable;
(c) by taking legal action (see Article 41) or by adopting an enforceable decision under
Article 299 of the Treaty on the Functioning of the EU (TFEU) and Article 79(2) of the
Financial Regulation No 966/2012.
If payment is not made by the date in the debit note, the amount to be recovered (see above) will be
increased by late-payment interest at the rate set out in Article 16.11, from the day following the date
for payment in the debit note, up to and including the date the Agency or the Commission receives
full payment of the amount.
Partial payments will be first credited against expenses, charges and late-payment interest and then
against the principal.
Bank charges incurred in the recovery process will be borne by the beneficiary, unless Directive
2007/64/EC applies.
ARTICLE 29 — ADMINISTRATIVE SANCTIONS
In addition to contractual measures, the Agency or the Commission may also adopt administrative
sanctions under Articles 106 and 131(4) of the Financial Regulation No 966/2012 (i.e. exclusion from
future procurement contracts, grants and expert contracts and/or financial penalties).
SECTION 2 LIABILITY FOR DAMAGES
ARTICLE 30 — LIABILITY FOR DAMAGES
30.1 Liability of the Agency
The Agency cannot be held liable for any damage caused to the beneficiaries or to third parties as a
consequence of implementing the Agreement, including for gross negligence.
The Agency cannot be held liable for any damage caused by any of the beneficiaries or third parties
involved in the action, as a consequence of implementing the Agreement.
30.2 Liability of the beneficiaries
Except in case of force majeure (see Article 35), the beneficiaries must compensate the Agency for
any damage it sustains as a result of the implementation of the action or because the action was not
implemented in full compliance with the Agreement.
43
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
SECTION 3 SUSPENSION AND TERMINATION
ARTICLE 31 — SUSPENSION OF PAYMENT DEADLINE
31.1 Conditions
The Agency may — at any moment — suspend the payment deadline (see Article 16.2 to 16.4) if a
request for payment (see Article 15) cannot be approved because:
(a) it does not comply with the provisions of the Agreement (see Article 15);
(b) the technical or financial report(s) have not been submitted or are not complete or additional
information is needed, or
(c) there is doubt about the eligibility of the costs declared in the financial statements and additional
checks, reviews, audits or investigations are necessary.
31.2 Procedure
The Agency will formally notify the coordinator of the suspension and the reasons why.
The suspension will take effect the day notification is sent by the Agency (see Article 36).
If the conditions for suspending the payment deadline are no longer met, the suspension will be lifted
— and the remaining period will resume.
If the suspension exceeds two months, the coordinator may request the Agency if the suspension will
continue.
If the payment deadline has been suspended due to the non-compliance of the technical or financial
report(s) (see Article 15) and the revised report or statement is not submitted or was submitted but
is also rejected, the Agency may also terminate the Agreement or the participation of the beneficiary
(see Article 34.3.1(i)).
ARTICLE 32 — SUSPENSION OF PAYMENTS
32.1 Conditions
The Agency may — at any moment — suspend payments, in whole or in part for one or more
beneficiaries, if:
(a) a beneficiary (or a natural person who has the power to represent or take decision on its behalf)
has committed or is suspected of having committed:
(i) substantial errors, irregularities or fraud or
(ii) serious breach of obligations under this Agreement or during the award procedure
(including improper implementation of the action, submission of false information,
failure to provide required information, breach of ethical principles) or
(b) a beneficiary (or a natural person who has the power to represent or take decision on its behalf)
has committed — in other EU or Euratom grants awarded to it under similar conditions —
44
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
systemic or recurrent errors, irregularities, fraud or serious breach of obligations that have a
material impact on this grant (extension of findings from other grants to this grant; see
Article 17.5.2).
If payments are suspended for one or more beneficiaries, the Agency will make partial payment(s)
for the part(s) not suspended. If suspension concerns the payment of the balance, the payment (or
recovery) of the amount(s) concerned after suspension is lifted will be considered to be the payment
that closes the action.
32.2 Procedure
Before suspending payments, the Agency will formally notify the coordinator or beneficiary
concerned:
- informing it of its intention to suspend payments and the reasons why and
- inviting it to submit observations within 30 days of receiving notification.
If the Agency does not receive observations or decides to pursue the procedure despite the observations
it has received, it will formally notify confirmation of the suspension. Otherwise, it will formally
notify that the suspension procedure is not continued.
The suspension will take effect the day the confirmation notification is sent by the Agency.
If the conditions for resuming payments are met, the suspension will be lifted. The Agency will
formally notify the coordinator or beneficiary concerned.
During the suspension, the periodic report(s) for all reporting periods except the last one (see Article
15.3) must not contain any individual financial statement(s) from the beneficiary concerned and its
affiliated entities. The coordinator must include them in the next periodic report after the suspension
is lifted or — if suspension is not lifted before the end of the action — in the last periodic report.
The beneficiaries may suspend implementation of the action (see Article 33.1) or terminate the
Agreement or the participation of the beneficiary concerned (see Article 34.1 and 34.2).
ARTICLE 33 — SUSPENSION OF THE ACTION IMPLEMENTATION
33.1 Suspension of the action implementation, by the beneficiaries
33.1.1 Conditions
The beneficiaries may suspend implementation of the action or any part of it, if exceptional
circumstances — in particular force majeure (see Article 35) — make implementation impossible or
excessively difficult.
33.1.2 Procedure
The coordinator must immediately formally notify to the Agency the suspension (see Article 36),
stating:
- the reasons why and
45
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
- the expected date of resumption.
The suspension will take effect the day this notification is received by the Agency.
Once circumstances allow for implementation to resume, the coordinator must immediately formally
notify the Agency and request an amendment of the Agreement, to set the date on which the action
will be resumed, extend the duration of the action and make other changes necessary to adapt the action
to the new situation (see Article 39) — unless the Agreement or the participation of a beneficiary has
been terminated (see Article 34).
The suspension will be lifted with effect from the resumption date set out in the amendment. This
date may be before the date on which the amendment enters into force.
Costs incurred during suspension of the action implementation are not eligible (see Article 6).
33.2 Suspension of the action implementation, by the Agency
33.2.1 Conditions
The Agency may suspend implementation of the action or any part of it, if:
(a) a beneficiary (or a natural person who has the power to represent or take decisions on its behalf)
has committed or is suspected of having committed:
(i) substantial errors, irregularities or fraud or
(ii) serious breach of obligations under this Agreement or during the award procedure
(including improper implementation of the action, submission of false declaration,
failure to provide required information, breach of ethical principles) or
(b) a beneficiary (or a natural person who has the power to represent or take decisions on its behalf)
has committed — in other EU or Euratom grants awarded to it under similar conditions —
systemic or recurrent errors, irregularities, fraud or serious breach of obligations that have a
material impact on this grant (extension of findings from other grants to this grant; see
Article 17.5.2).
33.2.2 Procedure
Before suspending implementation of the action, the Agency will formally notify the coordinator or
beneficiary concerned:
- informing it of its intention to suspend the implementation and the reasons why and
- inviting it to submit observations within 30 days of receiving notification.
If the Agency does not receive observations or decides to pursue the procedure despite the observations
it has received, it will formally notify confirmation of the suspension. Otherwise, it will formally
notify that the procedure is not continued.
The suspension will take effect five days after confirmation notification is received (or on a later date
specified in the notification).
46
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
It will be lifted if the conditions for resuming implementation of the action are met.
The coordinator or beneficiary concerned will be formally notified of the lifting and the Agreement
will be amended, to set the date on which the action will be resumed, extend the duration of the action
and make other changes necessary to adapt the action to the new situation (see Article 39) — unless
the Agreement has already been terminated (see Article 34).
The suspension will be lifted with effect from the resumption date set out in the amendment. This date
may be before the date on which the amendment enters into force.
Costs incurred during suspension are not eligible (see Article 6).
The beneficiaries may not claim damages due to suspension by the Agency (see Article 30).
Suspension of the action implementation does not affect the Agency’s right to terminate the Agreement
or participation of a beneficiary (see Article 34), reduce the grant or recover amounts unduly paid
(see Articles 27 and 28).
ARTICLE 34 — TERMINATION OF THE AGREEMENT OR OF THE PARTICIPATION
OF ONE OR MORE BENEFICIARIES
34.1 Termination of the Agreement, by the beneficiaries
34.1.1 Conditions and procedure
The beneficiaries may terminate the Agreement.
The coordinator must formally notify termination to the Agency (see Article 36), stating:
- the reasons why and
- the date the termination will take effect. This date must be after the notification.
If no reasons are given or if the Agency considers the reasons do not justify termination, the Agreement
will be considered to have been ‘terminated improperly’.
The termination will take effect on the day specified in the notification.
34.1.2 Effects
The coordinator must — within 60 days from when termination takes effect — submit a periodic report
(for the open reporting period until termination; see Article 15.3) and the final report (see Article 15.4).
If the Agency does not receive the report(s) within the deadline (see above), only costs which are
included in an approved periodic report will be taken into account
The Agency will calculate the final grant amount (see Article 5.3) and the balance (see Article 16.4)
on the basis of the report(s) submitted. Only costs incurred until termination are eligible (see Article
6). Costs relating to contracts due for execution only after termination are not eligible.
Improper termination may lead to a reduction of the grant (see Article 27).
47
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
After termination, the beneficiaries’ obligations (in particular, Articles 15, 17, 18, 19, 20, 21, 22, 24,
26, 27 and 28) continue to apply.
34.2 Termination of the participation of one or more beneficiaries, by the beneficiaries
34.2.1 Conditions and procedure
The participation of one or more beneficiaries may be terminated by the coordinator, on request of
the beneficiary concerned or on behalf of the other beneficiaries.
The coordinator must formally notify termination to the Agency (see Article 36) and inform the
beneficiary concerned.
If the coordinator’s participation is terminated without its agreement, the formal notification must be
done by another beneficiary (acting on behalf of the other beneficiaries).
The notification must include:
- the reasons why;
- the opinion of the beneficiary concerned (or proof that this opinion has been requested in
writing);
- the date the termination takes effect. This date must be after the notification, and
- a request for amendment (see Article 39), with a proposal for reallocation of the tasks and the
estimated budget of the beneficiary concerned (see Annexes 1 and 2) and, if necessary, the
addition of one or more new beneficiaries (see Article 40). If termination takes effect after the
period set out in Article 3, no request for amendment must be included, unless the beneficiary
concerned is the coordinator. In this case, the request for amendment must propose a new
coordinator.
If this information is not given or if the Agency considers that the reasons do not justify termination,
the participation will be considered to have been terminated improperly.
The termination will take effect on the day specified in the notification.
34.2.2 Effects
The beneficiary concerned must submit to the coordinator:
(i) a technical report and
(ii) a financial statement covering the period from the end of the last reporting period to the date
when termination takes effect.
This information must be included by the coordinator in the periodic report for the next reporting
period (see Article 15.3)
If the request for amendment is rejected by the Agency (because it calls into question the decision
awarding the grant or breaches the principle of equal treatment of applicants), the Agreement may be
terminated according to Article 34.3.1(c).
48
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
If the request for amendment is accepted by the Agency, the Agreement is amended to introduce the
necessary changes (see Article 39).
Improper termination may lead to a reduction of the grant (see Article 27) or termination of the
Agreement (see Article 34).
After termination, the concerned beneficiary’s obligations (in particular Articles 15, 17, 18, 19, 21,
22, 24, 26, 27 and 28) continue to apply.
34.3 Termination of the Agreement or of the participation of one or more beneficiaries, by the
Agency
34.3.1 Conditions
The Agency may terminate the Agreement or the participation of one or more beneficiaries, if:
(a) one or more beneficiaries do not accede to the Agreement (see Article 40);
(b) a change to their legal, financial, technical, organisational or ownership situation (or those of
its affiliated entities) is likely to substantially affect or delay the implementation of the action
or calls into question the decision to award the grant;
(c) following termination of participation for one or more beneficiaries (see above), the necessary
changes to the Agreement would call into question the decision awarding the grant or breach
the principle of equal treatment of applicants (see Article 39);
(d) implementation of the action is prevented by force majeure (see Article 35) or suspended by
the coordinator (see Article 33.1) and either:
(i) resumption is impossible, or
(ii) the necessary changes to the Agreement would call into question the decision
awarding the grant or breach the principle of equal treatment of applicants;
(e) a beneficiary is declared bankrupt, being wound up, having its affairs administered by the
courts, has entered into an arrangement with creditors, has suspended business activities, or
is subject to any other similar proceedings or procedures under national law;
(f) a beneficiary (or a natural person who has the power to represent or take decisions on its
behalf) has been found guilty of professional misconduct, proven by any means;
(g) a beneficiary does not comply with the applicable national law on taxes and social security;
(h) a beneficiary (or a natural person who has the power to represent or take decisions on its
behalf) has committed fraud, corruption, or is involved in a criminal organisation, money
laundering or any other illegal activity;
(i) a beneficiary (or a natural person who has the power to represent or take decisions on its
behalf) has committed:
(i) substantial errors, irregularities or fraud or
(ii) serious breach of obligations under the Agreement or during the award procedure
49
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
(including improper implementation of the action, submission of false information,
failure to provide required information, breach of ethical principles);
(j) a beneficiary (or a natural person who has the power to represent or take decisions on its
behalf) has committed — in other EU or Euratom grants awarded to it under similar conditions
— systemic or recurrent errors, irregularities, fraud or serious breach of obligations that have
a material impact on this grant (extension of findings from other grants to this grant; see
Article 17.5.2);
(k) despite a specific request by the Agency, a beneficiary does not request — through the
coordinator — an amendment to the Agreement to end the participation of one of its affiliated
entities that is in one of the situations under points (e), (f), (g), (h), (i) or (j) and to reallocate
its tasks
34.3.2 Procedure
Before terminating the Agreement or participation of one or more beneficiaries, the Agency will
formally notify the coordinator or beneficiary concerned:
- informing it of its intention to terminate and the reasons why and
- inviting it, within 30 days of receiving notification, to submit observations and — in case of
Point (i.ii) above — to inform the Agency of the measures to ensure compliance with the
obligations under the Agreement.
If the Agency does not receive observations or decides to pursue the procedure despite the observations
it has received, it will formally notify to the coordinator or beneficiary concerned confirmation of
the termination and the date it will take effect. Otherwise, it will formally notify that the procedure
is not continued.
The termination will take effect:
- for terminations under Points (b), (c), (e), (g), (i.ii) and (k) above: on the day specified in the
notification of the confirmation (see above);
- for terminations under Points (a), (d), (f), (h), (i.i) and (j) above: on the day after the notification
of the confirmation is received.
34.3.3 Effects
(a) for termination of the Agreement:
The coordinator must — within 60 days from when termination takes effect — submit a periodic
report (for the last open reporting period until termination; see Article 15.3) and a final report
(see Article 15.4).
If the Agreement is terminated for breach of the obligation to submit reports (see Articles 15.8
and 34.3.1(i)), the coordinator may not submit any reports after termination.
If the Agency does not receive the report(s) within the deadline (see above), only costs which
are included in an approved periodic report will be taken into account.
50
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
The Agency will calculate the final grant amount (see Article 5.3) and the balance (see
Article 16.4) on the basis of the report(s) submitted. Only costs incurred until termination
takes effect are eligible (see Article 6). Costs relating to contracts due for execution only after
termination are not eligible.
This does not affect the Agency’s right to reduce the grant (see Article 27) or to impose
administrative sanctions (Article 29).
The beneficiaries may not claim damages due to termination by the Agency (see Article 30).
After termination, the beneficiaries’ obligations (in particular Articles 15, 17, 18, 19, 21, 22,
24, 26, 27 and 28) continue to apply.
(b) for termination of the participation of one or more beneficiaries:
The coordinator must — within 60 days from when termination takes effect — submit a request
for amendment (see Article 39), with a proposal for reallocation of the tasks and estimated
budget of the beneficiary concerned (see Annexes 1 and 2) and, if necessary, the addition of
one or more new beneficiaries (see Article 40). If termination is notified after the period set out
in Article 3, no request for amendment must be submitted unless the beneficiary concerned is
the coordinator. In this case the request for amendment must propose a new coordinator.
The beneficiary concerned must submit to the coordinator:
(i) a technical report and
(ii) a financial statement covering the period from the end of the last reporting period to
the date when termination takes effect.
This information must be included by the coordinator in periodic report for the next reporting
period (see Article 15.3).
If the request for amendment is rejected by the Agency (because it calls into question the
decision awarding the grant or breaches the principle of equal treatment of applicants), the
Agreement may be terminated according to Article 34.3.1(c).
If the request for amendment is accepted by the Agency, the Agreement is amended to
introduce the necessary changes (see Article 39).
After termination, the concerned beneficiary’s obligations (in particular Articles 15, 17, 18, 19,
20, 21, 22, 24, 26, 27 and 28) continue to apply.
SECTION 4 FORCE MAJEURE
ARTICLE 35 — FORCE MAJEURE
‘Force majeure’ means any situation or event that:
- prevents either party from fulfilling their obligations under the Agreement,
- was unforeseeable, exceptional situation and beyond the parties’ control,
51
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
- was not due to error or negligence on their part (or on the part of third parties involved in the
action), and
- proves to be inevitable in spite of exercising all due diligence.
The following cannot be invoked as force majeure:
- any default of a service, defect in equipment or material or delays in making them available,
unless they stem directly from a relevant case of force majeure,
- labour disputes or strikes, or
- financial difficulties.
Any situation constituting force majeure must be formally notified to the other party without delay,
stating the nature, likely duration and foreseeable effects.
The parties must immediately take all the necessary steps to limit any damage due to force majeure
and do their best to resume implementation of the action as soon as possible.
The party prevented by force majeure from fulfilling its obligations under the Agreement cannot be
considered in breach of them.
CHAPTER 7 FINAL PROVISIONS
ARTICLE 36 — COMMUNICATION BETWEEN THE PARTIES
36.1 Form and means of communication
Communication under the Agreement (information, requests, submissions, 'formal notifications', etc.)
must:
- be made in writing and
- bear the number of the Agreement.
Until the payment of the balance: all communication must be made through the electronic exchange
system and using the forms and templates provided there.
After the payment of the balance: formal notifications must be made by registered post with proof
of delivery (‘formal notification on paper’).
Communications in the electronic exchange system must be made by persons authorised according to
the Participant Portal Terms & Conditions. For naming the authorised persons, each beneficiary must
have designated — before the signature of this Agreement — a ‘legal entity appointed representative
(LEAR)’. The role and tasks of the LEAR are stipulated in his/her appointment letter (see Participant
Portal Terms & Conditions).
If the electronic exchange system is temporarily unavailable, instructions will be given on the Agency
and Commission websites.
52
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
36.2 Date of communication
Communications are considered to have been made when they are sent by the sending party (i.e. on
the date and time they are sent through the electronic exchange system).
Formal notifications through the electronic exchange system are considered to have been made when
they are received by the receiving party (i.e. on the date and time of acceptance by the receiving party,
as indicated by the time stamp). A formal notification that has not been accepted within 10 days after
sending is considered to have been accepted.
Formal notifications on paper sent by registered post with proof of delivery (only after the payment
of the balance) are considered to have been made on either:
- the delivery date registered by the postal service or
- the deadline for collection at the post office.
If the electronic exchange system is temporarily unavailable, the sending party cannot be considered
in breach of its obligation to send a communication within a specified deadline.
36.3 Addresses for communication
The electronic exchange system must be accessed via the following URL:
https://ec.europa.eu/research/participants/portal/desktop/en/projects/
The Agency will formally notify the coordinator and beneficiaries in advance any changes to this URL.
Formal notifications on paper (only after the payment of the balance) addressed to the Agency must
be sent to the following address:
Consumers, Health, Agriculture and Food Executive Agency (CHAFEA)
Health and Food Safety Unit Health and Food Safety Unit
Drosbach Building
L-2920 Luxembourg
Formal notifications on paper (only after the payment of the balance) addressed to the beneficiaries
must be sent to their legal address as specified in the Participant Portal Beneficiary Register.
ARTICLE 37 — INTERPRETATION OF THE AGREEMENT
37.1 Precedence of the Terms and Conditions over the Annexes
The provisions in the Terms and Conditions of the Agreement take precedence over its Annexes.
Annex 2 takes precedence over Annex 1.
37.2 Privileges and immunities
Not applicable
ARTICLE 38 — CALCULATION OF PERIODS, DATES AND DEADLINES
53
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
In accordance with Regulation No 1182/7112, periods expressed in days, months or years are calculated
from the moment the triggering event occurs.
The day during which that event occurs is not considered as falling within the period.
ARTICLE 39 — AMENDMENTS TO THE AGREEMENT
39.1 Conditions
The Agreement may be amended, unless the amendment entails changes to the Agreement which
would call into question the decision awarding the grant or breach the principle of equal treatment
of applicants.
Amendments may be requested by any of the parties.
39.2 Procedure
The party requesting an amendment must submit a request for amendment signed in the electronic
exchange system (see Article 36).
The coordinator submits and receives requests for amendment on behalf of the beneficiaries (see
Annex 3).
If a change of coordinator is requested without its agreement, the submission must be done by another
beneficiary (acting on behalf of the other beneficiaries).
The request for amendment must include:
- the reasons why;
- the appropriate supporting documents, and
- for a change of coordinator without its agreement: the opinion of the coordinator (or proof that
this opinion has been requested in writing).
The Agency may request additional information.
If the party receiving the request agrees, it must sign the amendment in the electronic exchange system
within 45 days of receiving notification (or any additional information the Agency has requested). If
it does not agree, it must formally notify its disagreement within the same deadline. The deadline may
be extended, if necessary for the assessment of the request. If no notification is received within the
deadline, the request is considered to have been rejected.
An amendment enters into force on the day of the signature of the receiving party.
An amendment takes effect on the date agreed by the parties or, in the absence of such an agreement,
on the date on which the amendment enters into force.
ARTICLE 40 — ACCESSION TO THE AGREEMENT
12 Regulation (EEC, Euratom) No 1182/71 of the Council of 3 June 1971 determining the rules applicable to periods, dates
and time-limits (OJ L 124, 8/6/1971, p. 1).
54
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
40.1 Accession of the beneficiaries mentioned in the preamble
The other beneficiaries must accede to the Agreement by signing the Accession Form (see Annex 3) in
the electronic exchange system (see Article 36) within 30 days after its entry into force (see Article 42).
They will assume the rights and obligations under the Agreement with effect from the date of its entry
into force (see Article 42).
If a beneficiary does not accede to the Agreement within the above deadline, the coordinator must
— within 30 days — request an amendment to make any changes necessary to ensure proper
implementation of the action. This does not affect the Agency's right to terminate the Agreement (see
Article 34).
40.2 Addition of new beneficiaries
In justified cases, the beneficiaries may request the addition of a new beneficiary.
For this purpose, the coordinator must submit a request for amendment in accordance with Article 39.
It must include an Accession Form (see Annex 3) signed by the new beneficiary in the electronic
exchange system (see Article 36).
New beneficiaries must assume the rights and obligations under the Agreement with effect from the
date of their accession specified in the Accession Form (see Annex 3).
ARTICLE 41 — APPLICABLE LAW AND SETTLEMENT OF DISPUTES
41.1 Applicable law
The Agreement is governed by the applicable EU law, supplemented if necessary by the law of
Belgium.
41.2 Dispute settlement
If a dispute concerning the interpretation, application or validity of the Agreement cannot be settled
amicably, the General Court — or, on appeal, the Court of Justice of the European Union — has sole
jurisdiction. Such actions must be brought under Article 272 of the Treaty on the Functioning of the
EU (TFEU).
As an exception, if such a dispute is between the Agency and ‘MINISTRY OF CIVIL AFFAIRS’,
‘UNIVERSITATEA DE STAT DE MEDICINA SI FARMACIE NICOLAE TESTEMITANU DIN
REPUBLICA MOLDOVA’, ‘HELSEDIREKTORATE’, ‘INSTITUT ZA ZASTITU ZDRAVLJA
SRBIJEDR MILAN JOVANOVIC BATUT’, the competent Belgian courts have sole jurisdiction.
If a dispute concerns administrative sanctions, offsetting or an enforceable decision under Article
79(2) of the Financial Regulation No 966/2012 and Article 299 TFEU (see Articles 28, 29 and 30),
the beneficiaries must bring action before the General Court — or, on appeal, the Court of Justice
of the European Union — under Article 263 TFEU. Actions against enforceable decisions must be
brought against the Commission (not against the Agency).
55
Grant Agreement number: 801553 — InfAct — HP-JA-2017
Associated with documentCHAFEA MGA — Multi:-v2.0
Ref. Ares(2018)3121156 13/06/2018
ARTICLE 42 — ENTRY INTO FORCE OF THE AGREEMENT
The Agreement will enter into force on the day of signature by the Agency or the coordinator,
depending on which is later.
SIGNATURES
For the coordinator For the Agency
[--TGSMark#signature-906160809_75_210--] [--TGSMark#signature-service_75_210--]
56
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
EUROPEAN COMMISSION
Consumers, Health, Agriculture and Food Executive Agency
Health and Food Safety Unit
ANNEX 1 (part A)
Project
NUMBER — 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Table of Contents
1.1. The project summary................................................................................................................................. 3
1.2. The list of beneficiaries..............................................................................................................................4
1.3. Workplan Tables - Detailed implementation..............................................................................................6
1.3.1. WT1 List of work packages........................................................................................................... 6
1.3.2. WT2 List of deliverables................................................................................................................ 7
1.3.3. WT3 Work package descriptions................................................................................................. 10
Work package 1......................................................................................................................... 10
Work package 2......................................................................................................................... 14
Work package 3......................................................................................................................... 17
Work package 4......................................................................................................................... 19
Work package 5......................................................................................................................... 23
Work package 6......................................................................................................................... 27
Work package 7......................................................................................................................... 31
Work package 8......................................................................................................................... 35
Work package 9......................................................................................................................... 39
Work package 10....................................................................................................................... 44
1.3.4. WT4 List of milestones................................................................................................................ 48
1.3.5. WT5 Critical Implementation risks and mitigation actions........................................................... 51
1.3.6 WT6 Summary of project effort in person-months........................................................................53
1.3.7. WT7 Tentative schedule of project reviews.................................................................................55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
1.1. The project summary
Project Number 1 801553 Project Acronym 2 InfAct
One form per project
General information
Project title 3
Information for Action
Starting date 4 01/03/2018
Duration in months 5 36
Call (part) identifier 6 HP-JA-2017
HP-JA-06-2017
Topic Joint Action on Health Information towards a sustainable EU health information system
that supports country knowledge, health research and policy-making.
Fixed EC Keywords
Health Information, Health, Public Health, Population Health, Health Information
Free keywords
System, Health System Performance, Health Inequality, ERIC
Abstract 7
InfAct (Information for Action) is a JA on health information (HI). HI is essential to build up country specific and
cross-country knowledge. HI is the basis to inform national health policies, to steer population health investment
decisions, to assess the effectiveness of different approaches to enhance population health through promotion,
prevention, treatments and care. Timely, up-to-date HI is also vital in framing EU wide programs and policies.
The major outcome expected of the JA is a sustainable solid infrastructure on EU HI through improving the
availability of comparable, robust and policy-relevant health status data and health system performance information.
Through country collaboration, the JA streamlines HI activities, reduces the data collection burden and works for a
sustainable and robust data collection in Europe that facilitates and supports country knowledge, health research and
policy making.
The JA gives attention to:
• develop the business case and roadmap for implementation of the European Research Infrastructure Consortium on
Health Information for Research and Evidence-based Policy
o governance structures,
o national HI consortia and domain specific HI research networks
• assess HI systems (HIS) in MS and regions
• develop a roadmap for training in HI with the objective to tackle HI inequality through Europe
• standardize HI instruments, tools and methods
• strengthen the HI efficiency for public health policy through new ways of using health and non-health data sources
• enhance the introduction of the interoperability of health data sources
• enhance the translation of HI into public policy
The JA watches for the sustainability of all actions taken by the JA. Coordination, dialogue and interaction with
the Commission Expert Groups on HI and on HSPA, Eurostat, DG Research and other relevant DGs, international
organization (WHO, OECD) reinforce further the sustainability of the JAs’ work and outcomes.
Page 3 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
1.2. List of Beneficiaries
Project Number 1 801553 Project Acronym 2 InfAct
List of Beneficiaries
Project Project
No Name Short name Country entry exit
month8 month
1 SCIENSANO Sciensano Belgium 1 36
2 GESUNDHEIT ÖSTERREICH GMBH GÖG Austria 1 36
Bosnia and
3 MINISTRY OF CIVIL AFFAIRS MCA 1 36
Herzegovina
HRVATSKI ZAVOD ZA JAVNO
4 CIPH Croatia 1 36
ZDRAVSTVO
5 Ministry of Health of the Republic of Cyprus MoHCy Cyprus 1 36
USTAV ZDRAVOTNICKYCH INFORMACI
6 UZIS Czech Republic 1 36
A STATISTIKY CESKE REPUBLIKY
7 SOTSIAALMINISTEERIUM MoSA Estonia 1 36
TERVEYDEN JA HYVINVOINNIN
8 THL Finland 1 36
LAITOS
AGENCE NATIONALE DE SANTE
9 SpFrance France 1 36
PUBLIQUE
10 ROBERT KOCH-INSTITUT RKI Germany 1 36
ETHNIKOS ORGANISMOS PAROCHIS
11 EOPYY Greece 1 36
YPIRESION YGIAS
12 DEPARTMENT OF HEALTH DOH Ireland 1 36
13 ISTITUTO SUPERIORE DI SANITA ISS Italy 1 36
SLIMIBU PROFILAKSES UN
14 CDPC Latvia 1 36
KONTROLES CENTRS
15 HIGIENOS INSTITUTAS HI Lithuania 1 36
16 MINISTERE DE LA SANTE MOHLUX Luxembourg 1 36
17 Ministry for Health - Government of Malta MFH Malta 1 36
UNIVERSITATEA DE STAT DE
MEDICINA SI FARMACIE NICOLAE Moldova
18 SMPHU 1 36
TESTEMITANU DIN REPUBLICA (Republic of)
MOLDOVA
RIJKSINSTITUUT VOOR
19 RIVM Netherlands 1 36
VOLKSGEZONDHEID EN MILIEU
20 HELSEDIREKTORATE HD Norway 1 36
THE MINISTRY OF HEALTH OF THE
21 MZ Poland 1 36
REPUBLIC OF POLAND
MINISTERIO DA SAUDE - REPUBLICA
22 MS Portugal 1 36
PORTUGUESA
INSTITUTUL NATIONAL DE SANATATE
23 INSP Romania 1 36
PUBLICA
Page 4 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
1.2. List of Beneficiaries
Project Project
No Name Short name Country entry exit
month8 month
INSTITUT ZA ZASTITU ZDRAVLJA
24 IPHS Serbia 1 36
SRBIJEDR MILAN JOVANOVIC BATUT
NACIONALNI INSTITUT ZA JAVNO
25 NIJZ Slovenia 1 36
ZDRAVJE
26 INSTITUTO DE SALUD CARLOS III ISCIII Spain 1 36
27 FOLKHALSOMYNDIGHETEN FoHM Sweden 1 36
28 WELSH ASSEMBLY GOVERNMENT WG United Kingdom 1 36
Page 5 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
1.3. Workplan Tables - Detailed implementation
1.3.1. WT1 List of work packages
WP Person- Start End
WP Title Lead beneficiary10
Number9 months11 month12 month13
WP1 Coordination of the action 1 - Sciensano 63.83 1 36
WP2 Dissemination 1 - Sciensano 16.50 1 36
WP3 Evaluation of the action 15 - HI 14.40 1 36
Integration national policies and
WP4 26 - ISCIII 92.40 1 36
sustainability
Status of health information systems
WP5 10 - RKI 116.10 1 36
in MSs and regions
Strengthen EU countries’ health
WP6 22 - MS 115.75 1 36
information capacity
Proof of concept of sustainable
WP7 1 - Sciensano 100.20 1 36
structure on health information
Tools and methods for health
WP8 13 - ISS 138.30 1 36
information support
Innovation in health information for
WP9 9 - SpFrance 137.10 1 36
public health policy development
Assessing and piloting
WP10 interoperability for public health 4 - CIPH 139.15 1 36
policy
Total 933.73
Page 6 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
1.3.2. WT2 list of deliverables
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type 15 Date (in
Number14 number9 level16
months)17
Conceptual framework
D1.1 WP1 1 - Sciensano Report Public 3
and vision
Risk management and
D1.2 WP1 1 - Sciensano Report Public 3
contingency plan
D1.3 Interim report WP1 1 - Sciensano Report Public 18
D1.4 Final report WP1 1 - Sciensano Report Public 36
Websites,
Leaflet and Website
D2.1 WP2 1 - Sciensano patents Public 3
(MD1 & MD3)
filling, etc.
Websites,
D2.2 Promotional video WP2 4 - CIPH patents Public 18
filling, etc.
Layman version of final
D2.3 WP2 15 - HI Report Public 36
report (MD2)
Conference and
D2.4 WP2 1 - Sciensano Report Public 36
workshops
Interim & final report
D3.1 of “External Evaluation WP3 26 - ISCIII Report Public 36
Committee”
Terms of Reference and
D4.1 Operating Procedure of WP4 26 - ISCIII Report Public 6
the AoM
Reports on AoM
D4.2 WP4 26 - ISCIII Report Public 36
assessments
D4.3 Fact sheets WP4 26 - ISCIII Report Public 29
Reports on key holders
and relevant EU-
D4.4 WP4 26 - ISCIII Report Public 31
international partners
meeting
Sustainability Plan:
follow-up of integrated
D4.5 proposals and long- WP4 26 - ISCIII Report Public 31
term reporting scenarios
(MD4)
Pilot HI system peer
D5.1 assessment and review WP5 17 - MFH Report Public 32
of experience
Cataloguing health
information networks,
D5.2 WP5 19 - RIVM Report Public 32
projects and indicator
sets
Page 7 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type15 Date (in
Number14 number9 level16
months)17
Prioritisation in HI
D5.3 development and WP5 10 - RKI Report Public 32
recommendations
Mapping needs,
capacities and training
D6.1 WP6 22 - MS Report Public 18
programmes in health
information
A flagship training
programme to improve
MS capacities in
D6.2 population health WP6 22 - MS Report Public 24
and health system
performance analysis
and monitoring
Training Piloting and
D6.3 Flagship Training WP6 22 - MS Report Public 30
Programme Evaluation
Road map for capacity
D6.4 WP6 22 - MS Report Public 36
building programme
A sustainable network
D7.1 WP7 1 - Sciensano Report Public 24
of networks
HIREP-ERIC: Business
D7.2 case and road map for WP7 19 - RIVM Report Public 30
implementation
Governance structures
D7.3 of a sustainable health WP7 1 - Sciensano Report Public 18
information system
Websites,
Health Information web
D7.4 WP7 1 - Sciensano patents Public 24
platform
filling, etc.
Health Information
System development:
data collection and
D8.1 WP8 13 - ISS Report Public 28
quality assurance
for a common health
information system
Sustainable ECHI
process from technical,
D8.2 WP8 19 - RIVM Report Public 32
content and user
perspective
Guidelines for
accessibility and
D8.3 WP8 13 - ISS Report Public 32
availability of health
information
Guidelines for MSs
D8.4 and regions for health WP8 10 - RKI Report Public 32
reports
Page 8 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Due
Deliverable WP Dissemination
Deliverable Title Lead beneficiary Type15 Date (in
Number14 number9 level16
months)17
Road map and case
D9.1 WP9 9 - SpFrance Report Public 24
study report
Guidelines, case study
D9.2 WP9 9 - SpFrance Report Public 30
and best practices
Report series on the
D9.3 application of the best WP9 9 - SpFrance Report Public 32
practices
Tool kit to produce
D9.4 WP9 28 - WG Demonstrator Public 33
better health indicators
Road map for uptake
of indicators –
D9.5 WP9 9 - SpFrance Report Public 34
opportunities and
obstacles
Report: interoperability
D10.1 WP10 4 - CIPH Report Public 30
landscape in Europe
Technical report:
D10.2 interoperability WP10 26 - ISCIII Report Public 36
implementation
Page 9 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
1.3.3. WT3 Work package descriptions
Work package number 9 WP1 Lead beneficiary 10 1 - Sciensano
Work package title Coordination of the action
Start month 1 End month 36
Objectives
The aim of this work package is to manage the Joint Action and to systematically monitor its activities. This includes
the day-to-day follow-up of the scientific, administrative and financial aspects. WP1 will ensure that the contractual
obligations are fulfilled and ensure the expected results are delivered as planned.
The objectives are:
1. To effectively monitor the JA and its scientific, administrative and financial aspects.
2. To guarantee the adherence to the work plan, to the overall project aim and to the timing; to guarantee available
resources and the signature of the contractual agreements (consortium and grand agreement).
3. To secure timely submission of interim progress reports and cost statements.
4. To facilitate and ensure convergence between WPs to work together towards a sustainable EU health information
system and with other Joint Actions, e.g. eHealth.
5. To coordinate actions of WPs that request active participation of MSs, EU DGs and institutions and international
organisations. Examples of such actions are surveys or mapping exercises.
Description of work and role of partners
WP1 - Coordination of the action [Months: 1-36]
Sciensano, GÖG, MCA, CIPH, MoHCy, UZIS, MoSA, THL, SpFrance, RKI, EOPYY, DOH, ISS, CDPC, HI,
MOHLUX, MFH, SMPHU, RIVM, HD, MZ, MS , INSP, IPHS, NIJZ, ISCIII, FoHM, WG
Task 1.1. Coordination of the Joint Action (Lead: Sciensano)
Sciensano performs the overall coordination ensuring a smooth running of the JA: (1) timely delivery of reports; (2)
organisation of the JA meetings; (3) establishment of the JA information and communication flow and feedbacks
to all competent authorities (CAs). Coordination includes regular assessment, planning future work and reporting
to the relevant bodies (including CHAFEA, Expert Groups on Health Information (EGHI) and on Health System
Performance Assessment (HSPA)) on progress, possible deviations, proposed modifications and negotiation of
subsequent amendments. It further includes the implementation of actions, as stipulated in the consortium agreement
such as conflict resolution. Coordination is achieved through regular (seven 6-monthly) Steering Committee (SCM)
and 3 General Assembly (GA) meetings. Teleconferences are organised between face-to-face SCMs. In these meetings
coherence between the WPs will be fostered and interlinkage between the WPs will be a major agenda point for
discussion. Especially during the kick-off meeting attention will be given to this topic. Additionally, at the start of the
project a survey will be sent out to the BRIDGE Health partners and potentially other networks in health information
to reduce the risk on redundancy and waste of resources and to ensure that the JA builds further on existing knowledge
and experiences. This survey will also be used by WP7. Each CA is responsible for the coordination of its affiliated
entities, subcontractors and collaborating stakeholders. WP1 will also propose a meeting with the coordinators of the
other Joint Actions to ensure proper liaison.
Task 1.2. Administrative and financial Project Management (Lead: Sciensano)
This includes (1) with respect to meetings: preparation, organisation, reporting and chairing; (2) the preparation and
distribution of the status reports; (3) the preparation and distribution of the financial reports; (4) solving conflicts and (5)
organisation of hands-on supervision: revision of deliverables; and monitoring of progress of the milestones. Next, the
Sciensano will monitor the budget and the compliance with the contract and consortium agreement; respond to audits
requested by CHAFEA by providing the requested documents; and assure the overall quality of the JA.
Task 1.3. Risk Management (Lead: Sciensano)
A risk management and contingency plan will be developed based on identified potential risks that could impede the
execution of certain phases of the JA. Problems will be dealt with proactively if possible, or as soon as they emerge,
using this plan.
Page 10 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Participation per Partner
Partner number and short name WP1 effort
1 - Sciensano 36.00
2 - GÖG 1.46
3 - MCA 0.50
4 - CIPH 1.50
5 - MoHCy 0.50
6 - UZIS 0.50
7 - MoSA 0.00
NIHD 0.50
8 - THL 1.50
9 - SpFrance 0.50
INSERM 0.50
IRDES 0.50
MoH FR 0.50
10 - RKI 1.50
11 - EOPYY 0.47
12 - DOH 0.50
13 - ISS 1.50
14 - CDPC 0.50
15 - HI 1.50
16 - MOHLUX 0.50
17 - MFH 1.45
18 - SMPHU 0.50
19 - RIVM 1.50
20 - HD 0.50
21 - MZ 0.00
NIPH 0.50
22 - MS 0.50
INSA 0.50
UNL 0.50
23 - INSP 0.50
24 - IPHS 0.50
25 - NIJZ 1.45
26 - ISCIII 1.50
IACS 1.50
27 - FoHM 0.50
Page 11 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Partner number and short name WP1 effort
28 - WG 0.50
SU 0.50
Total 63.83
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in
Number14
months)17
Conceptual framework
D1.1 1 - Sciensano Report Public 3
and vision
Risk management and
D1.2 1 - Sciensano Report Public 3
contingency plan
D1.3 Interim report 1 - Sciensano Report Public 18
D1.4 Final report 1 - Sciensano Report Public 36
Description of deliverables
D1.1 Conceptual framework and vision: The conceptual framework and vision of InfAct will be developed.
D1.2 Risk management and contingency plan: A plan that identifies critical risk events which could have an adverse
impact on the action, the likelihood of their occurrence, their impact and consequences, and also measures to avoid or
minimise the risks.
D1.3 Interim report: The interim report describes the activities of the JA and the status of the milestones and
deliverables submitted by month 18. It also includes the interim financial reporting.
D1.4 Final report: The final report describes the activities of the JA and the status of the milestones and deliverables
submitted by month 36. It also includes the final financial reporting.
D1.1 : Conceptual framework and vision [3]
The conceptual framework and vision of InfAct will be developed.
D1.2 : Risk management and contingency plan [3]
A plan that identifies critical risk events processes which could have an adverse impact on the action, the likelihood
of their occurrence, their impact and consequences, and also measures to avoid or minimise the risks.
D1.3 : Interim report [18]
The Interim report describes the activities of the JA and the status of the milestones and deliverables submitted by
month 18. It also includes the interim financial reporting.
D1.4 : Final report [36]
The final report describes in the activities of the JA and the status of the milestones and deliverables submitted by
month 36. It also includes the final financial reporting.
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
MS1 Kick-off meeting 1 - Sciensano 1 Report of the kick-off
Page 12 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Coordination meetings with
the WP leaders and co- Minutes of meetings: M1, 6,
MS2 1 - Sciensano 36
leaders (Steering Committee 12, 18, 24, 30, 36
meetings)
Interim report and final
MS3 Mid-term and final review 1 - Sciensano 36
delivered at month 18, 36
MS4 Mid-term Assembly 1 - Sciensano 18 Report of the meeting
MS5 Final Conference 1 - Sciensano 36 Report
Page 13 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Work package number 9 WP2 Lead beneficiary 10 1 - Sciensano
Work package title Dissemination
Start month 1 End month 36
Objectives
To ensure that
1. the results of the JA are available to the target audience;
2. the communication is most optimal to ensure the continuation of the JA in a sustainable structure is enacted;
3. the widest possible scale of implementation is reached after the end of the project and thus maximise the impact of
the project.
Description of work and role of partners
WP2 - Dissemination [Months: 1-36]
Sciensano, GÖG, CIPH, HI, ISCIII
Task 2.1. Coordination of internal and external communication (Lead: Sciensano)
A communication strategy and dissemination plan is developed and regularly updated, ensuring information is available
to Competent Authorities in the JA, stakeholders in the Member States, the EU and international organisation, and the
general public. The dissemination plan safeguards the coordination and harmonisation of the communication. A web
platform, leaflets, flyers, newsletters, conference/workshop proceedings, press releases, social media (e.g. Twitter) and
scientific papers are main tools for timely communication and keeping contact details, results, work documents and
event calendar up to date. When, during the JA, input of third parties is requested, e.g. through surveys, the dissemination
plan ensures the coherence and a minimal burden of these requests. The dissemination plan warrants user-friendliness,
readability and understandability of the communication. The dissemination plan ensures the dynamic promotion of
activities which need active involvement of stakeholders and/or MS. In collaboration with WP7 the National Consortia
will be stimulated to disseminate the fact sheets and to provide information on InfAct on their national website. The
translation of these factsheets into national languages will be promoted.
Task 2.2. Visual identity (Lead: Sciensano)
The dissemination work starts by developing a strong and appealing visual identity to reach as large an audience as
possible, keeping in mind that the JA should grow an interest from the scientific/health community in Europe and
especially its policymakers in- and outside the health arena. The more the outcomes of the JA are known, the larger the
support will be for a continued investment in a sustainable and standardised health information management approach,
not only during the JA, but also beyond with the setup of a European Research Infrastructure Consortium on Health
Information for Research and Evidence-based Policy. Visual identity includes the development of the project logo, a
layout/colour scheme for presentations, publications such as project information leaflets and posters, a website and a
banner. A template for project reports is developed following the general visual identity of the project.
Task 2.3. Audiovisual communication (Lead: Sciensano)
A collaborative online platform to share documents with all partners will be set up. We will define the structure of this
platform and manage authorisation of partners. We will develop a website detailing among others the project’s aim,
methods, partners, outcomes (reports, articles), event calendar. A twitter account will be set up and available through
the website.
Task 2.4. Promotional video of a sustainable structure (Lead: Sciensano)
To enhance visibility of the European Research Infrastructure Consortium on Health Information for Research and
Evidence-based Policy and to attract attention of MS, policymakers and the scientific/health community a promotional
video or digital animation is commissioned. The WP defines the content of the video and contributes to the script
development.
Task 2.5. JA on tour (Lead: Sciensano)
JA beneficiaries will participate in the annual European Public Health conference, reaching over 1000 people working
in public health. WP2 partners will prepare contributions and invite others to contribute. One or more workshops will
be proposed per year. The WP2 will seek collaboration with EUPHA section on Health Information and collaborative
Page 14 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
stakeholders such as WHO, OECD, the European Observatory on Health Systems and Policies, and DG Sante to organise
at least one 1-day EPH pre-conference. In 2018, focus will be on methodology. This will shift to results and perspectives
for the future in 2019 and 2020. WP2 partners will also participate actively (by organising sessions) in conferences
with high political visibility such as European Health Forum Gastein (one meeting) and in other international meetings
related to health information.
Task 2.6. Publications (Lead: Sciensano)
WP2 will coordinate the writing, edition and publication of:
- an information leaflet (for stakeholders and people interested in public health and information management)
- a Fact Sheet (disseminating highlights of the JA, for distribution to a wider audience, including policy briefs prepared
by WP4)
- peer-reviewed scientific articles
- the Technical and Scientific Description of the European Research Infrastructure Consortium on Health Information
for Research and Evidence-based Policy and its statutes (see WP7)
- layman version of the final report
Participation per Partner
Partner number and short name WP2 effort
1 - Sciensano 6.00
2 - GÖG 4.50
4 - CIPH 1.00
15 - HI 3.00
26 - ISCIII 2.00
Total 16.50
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in
Number14
months)17
Websites,
Leaflet and Website
D2.1 1 - Sciensano patents Public 3
(MD1 & MD3)
filling, etc.
Websites,
D2.2 Promotional video 4 - CIPH patents Public 18
filling, etc.
Layman version of final
D2.3 15 - HI Report Public 36
report (MD2)
Conference and
D2.4 1 - Sciensano Report Public 36
workshops
Description of deliverables
D2.1. Leaflet and Website: A leaflet to promote the project must be produced at the beginning of the JA. Each
JA must have a dedicated website. The website has a public part and another restricted part accessible only to the
applicants.
D2.2. Promotional video: A promotional video will be produced to promote the ERIC on health information as
sustainable structure favouring the maximal participation of MS.
Page 15 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
D2.3. Layman version of final report: Layman version of final technical report. This is a short (max. 10 pages)
version of the final report, written for the interested public as a target group.
D2.4. Conference and workshops: Reports of workshops (at least one) on health information systems at major
European scientific/policy conferences in the field of health, (co-)organised, facilitated and held by the JA.
D2.1 : Leaflet and Website (MD1 & MD3) [3]
A leaflet to promote the project must be produced at the beginning of the JA. Each JA must have a dedicated website.
The website has a public part and another restricted part accessible only to the applicants.
D2.2 : Promotional video [18]
A promotional video will be produced to promote the ERIC on health information as sustainable structure favouring
the maximal participation of MS.
D2.3 : Layman version of final report (MD2) [36]
Layman version of final technical report. This is a short (max. 10 pages) version of the final report, written for the
interested public as a target group.
D2.4 : Conference and workshops [36]
Reports of workshops (at least one) on health information systems at major European scientific/policy conferences in
the field of health, (co-)organised, facilitated and held by the JA
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
MS6 Dissemination plan 1 - Sciensano 3 Dissemination plan
MS7 Update dissemination plan 1 - Sciensano 24 Updated dissemination plan
Scientific/policy conference
MS8 1 - Sciensano 36 Conference report (abstracts)
EPH 2018-2019-2020
MS9 European Health Forum 2019 2 - GÖG 36 Conference report (abstracts)
Page 16 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Work package number 9 WP3 Lead beneficiary 10 15 - HI
Work package title Evaluation of the action
Start month 1 End month 36
Objectives
The mandatory WP3 combines both an internal and external evaluation including an impact assessment. The internal
evaluation seeks to analyse and provide feedback on the specific achievements of the WPs and ensures that InfAct
is making progress in its activities towards policy-actionable outcomes and to identify anchors for sustainability. The
internal evaluation is based on the dialogue between WP leaders. It is discussed in the SC and GA, and has the EHGI and
EGHSPA as sounding board. The external evaluation focuses on the overarching InfAct outcomes (main deliverables)
and their impact. The external evaluation is based on the expert advice of different stakeholders representing the potential
InfAct target audiences. External stakeholders with expertise in EU-wide action in the domain of public health with
focus on health information (health status and health systems) and research will be involved including administrators in
research and public health, but especially EUPHA and ASPHER. The external evaluation will produce critical reviews
of the outcomes, track the progress of the project and provide strategic recommendations for the project.
Description of work and role of partners
WP3 - Evaluation of the action [Months: 1-36]
HI, Sciensano, INSP, ISCIII
Task 3.1. Internal evaluation (Lead: HI)
The internal evaluation should be practical and consists of a periodic (M 1, 12, 24, 35) evaluation with the WP leaders
through a focused questionnaire: a) the alignment of the tasks with the overall InfAct timeline, b) the feasibility of
the specific actions to get to the milestones; c) the formulation of actionable outcomes; d) the potential risks in the
achievement of the specified goals; and e) possible contributions towards sustainability. The results of the surveys are
summarised for discussion in the SC, GA and EGHI & EGHSPA and added to the JA interim report. In addition, the
internal evaluation will organise a peer-review of the deliverables. The WP leaders will have deliverables assigned to
them that they need to evaluate, review critically and provide feedback on using a predefined template.
Task 3.2. External evaluation (Lead: INSP and IACS)
Using the JA documents and other results, including the reports under task 3.1, an external evaluation occurs at 3 time
points during the JA (M 13, 25, 35). Members of the External evaluation are EUPHA (1), EUPHA section on Public
Health Monitoring and Reporting (1), and Health Services Research (1), ASPHER (2), EGHI (1), EGHSPA (1), Ministry
of Research (1), Ministry of Health (1), Coordinators of other JAs (1), Advocacy group (1). The external evaluation
committee appoints a meeting chair among its members.
The missions of the Committee are:
a) to discuss and validate the activity report of the project for the previous period (achievement of the objectives and
impact on the target groups) using the list of milestones and deliverables and the internal evaluation report;
b) to discuss and validate the work plan for the following period including links with other existing projects, how to
boost complementarity across deliverables within InfAct and strategic advice;
c) to discuss and critically review the outcomes in function of actionability for policy, sustainability and success and/
or pitfalls towards a sustainable structure.
Task 3.3. Impact Assessment (Lead: Sciensano)
An impact assessment will be carried out measuring the perception of a sustainable structure at the start and at the end
of InfAct through a survey. Additionally, each of the major meetings and workshops will be assessed. An evaluation
sheet will be distributed at the end of the meeting or workshop in order to evaluate its impact. Finally, Google analytics
will be used to evaluate the outreach of InfAct through the website.
Participation per Partner
Page 17 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Partner number and short name WP3 effort
1 - Sciensano 5.40
15 - HI 5.00
23 - INSP 2.50
26 - ISCIII 0.00
IACS 1.50
Total 14.40
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in
Number14
months)17
Interim & final report
D3.1 of “External Evaluation 26 - ISCIII Report Public 36
Committee”
Description of deliverables
D3.1. Interim & final report of “External Evaluation Committee”: It will document the minutes of the meetings (M
13, 25, 35) of the External Evaluation Committee. The document will include the detailed information of the JA
evaluations as described in Task 3.2, the updated work plans from the minutes of the SC and updated dissemination
plans (WP2)
D3.1 : Interim & final report of “External Evaluation Committee” [36]
It will document the minutes of the meetings (M 13, 25, 35) of the External Evaluation Committee. The document
will include the detailed information of the JA evaluations as described in Task 3.2, the updated work plans from the
minutes of the SC and updated dissemination plans (WP2)
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
MS10 Agreement with subcontracts 26 - ISCIII 10 Subcontracts are signed
First interim internal and Report is distributed to
MS11 15 - HI 13
external evaluation report partners
Second interim internal and Report is distributed to
MS12 15 - HI 25
external evaluation report partners
Final interim internal and Report is published including
MS13 15 - HI 36
external evaluation report both interim reports
Page 18 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Work package number 9 WP4 Lead beneficiary 10 26 - ISCIII
Work package title Integration national policies and sustainability
Start month 1 End month 36
Objectives
To develop a sustainability plan and a follow-up method supporting the InfAct outcomes, activities and best practices
to be integrated in regional, national and EU-international policies. WP 4 will closely work together with all other WPs
and foster coherence by finding common pathways for sustainability. The tasks of WP4 are essential to reach specific
objectives SO1 and SO2, especially in relation to the MoU (WP7) and the use of the different WPs for translating results
into policy.
Specific objectives:
1. To involve MSs and EU departments and international institutions (WHO/OECD) in development and progress of
the JA (goals/main outcomes);
2. To support MSs to integrate main activities and deliverables of this JA into national/regional policies;
3. To propose a sustainability plan for a HI system and the findings of InfAct;
4. To support with MSs and international institutions the potential adoption of new identified best practices in line with
the Health Evidence Network (HEN) in current health management/decision-making;
5. To provide MSs key elements to discuss infrastructures to assess long-term sustainability of this JA (close
collaboration with WP7).
Description of work and role of partners
WP4 - Integration national policies and sustainability [Months: 1-36]
ISCIII, Sciensano, GÖG, SpFrance, ISS, RIVM, WG
Development of a sustainability plan based on the following pillars:
a) MS involvement through health and research authorities in interaction with international institutions;
b) integration of the JA outcomes into policies at regional, national and European level;
c) strengthen national health information consortia involving health and research authorities.
Task 4.1. Support sustainability and integration of JA health information activities in MS/AC through an Assembly of
Members (AoM) (Lead: ISCIII)
Two AoM meetings will be organised with high governmental representatives (M18 and M32)
a) Targeted audience: Ministries of Health (MH) and Ministries of Research (MR) of all MSs participating in JA.
Relevant European Commission services (e.g. DG SANTE, EUROSTAT) and international organisations (e.g. WHO-
Europe, OECD and IANPHI)
b) Aim: The AoM will meet to discuss JA progress, outcomes, analyse structural alternatives for long-term activities,
legal/data protection context, evidence-based policy recommendations and the Sustainability Plan. AoM national
representatives will act as liaison with their research, national health system and national Public Health authorities.
c) Objectives: To agree on Operational Procedures and to create a consensus around the MoU (WP7). To give feedback/
policy guidance to the JA counterparts. To foster dialogues/proposals for long-term projection of JA activities and
identifying national nodes (close collaboration with WP7). To assess structural alternatives for long-term JA activities.
d) Outcomes: Reports on AoM (M21, M34). Nomination of AoM members (M3). Operating Procedure (M6).
Task 4.2. Policy dialogues (4 meetings and 3 workshops) (Lead: ISCIII)
a) Aim: Awareness and acceptance in decision-makers on innovative actions to improve EU HI systems.
b) Targeted audience: heads of National Consortia (developed in WP7), WP leaders and EU-international partners.
c) Organisation: meetings will be organised over 2 days to minimise travel budget
a. Two half-day meetings between National Consortia (M18, M30);
b. Two half-day meetings between National Consortia and EU-international organisations (M18 and 30);
c. Two half-day workshops with National Consortia and WP-leaders (M18, M30);
d. One workshop on how to integrate evidence into HI systems with all participants mentioned in a-c, together with
the HEN network (M18).
d) Expected outcomes for sustainability: translating JA results and innovative outcomes into policies and decision-
making at MS/regional and international EU-level (WHO-OECD). These activities will be performed in line with the
HEN Network, the EVIPNET network, the e-Health network, EU-EGHI, HSPA, and the “Action plan to strengthen
Page 19 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
the use of evidence, information and research for policymaking in the WHO European Region” presented in the 66th
session of the WHO Regional Committee for Europe in September 2016”. Additionally, fact sheets will be developed
and used in these meetings, reporting on the main outcomes of the JA (collaboration with WP2, 5-10).
Task 4.3. Sustainability Plan (Lead: ISCIII)
WP4 will provide a sustainability plan to integrate the findings of InfAct in EU/MS protocols. It will translate JA results/
innovative outcomes into MS Health Information systems, with the insight and consensus provided in the meetings
and workshops with WP leaders, ministries of Health and Research representatives, national consortium, and EU-
international partners (Tasks 4.1 and 4.2). It will include a follow-up system that is regularly updated in order to identify
and quantify MSs incorporating JA outcomes, innovative best practices, evidence-based policy recommendations and
national and EU-Entities involved. It will also be based on other WP activities/expected deliverables that will be
mapped/monitored (national/regional/local levels) and assessed for their sustainability/contribution to sustainability.
WPs involved:
a) WP5: Peer review assessment, health information networks/projects/indicators, prioritisation in health information
b) WP6: Training programme and road map
c) WP7: Setup of national consortia, criteria required for domain specific networks, business case and road map for
HIREP-ERIC, HI web platform and MoU for HIREP-ERIC
d) WP8: Sustainable ECHI process and guidelines for accessibility and harmonisation of data
e) WP9: Road map for new data sources, guidelines for development/testing new indicators including composite
indicators. WP4 will contribute with other WPs to innovative and policy-relevant data for health system performance
f) WP10: Getting interoperability implemented
Participation per Partner
Partner number and short name WP4 effort
1 - Sciensano 7.00
2 - GÖG 2.00
9 - SpFrance 0.95
MoH FR 6.05
13 - ISS 2.00
19 - RIVM 0.40
26 - ISCIII 72.00
28 - WG 0.00
SU 2.00
Total 92.40
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
Terms of Reference and
D4.1 Operating Procedure of 26 - ISCIII Report Public 6
the AoM
Reports on AoM
D4.2 26 - ISCIII Report Public 36
assessments
D4.3 Fact sheets 26 - ISCIII Report Public 29
Page 20 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
Reports on key holders
and relevant EU-
D4.4 26 - ISCIII Report Public 31
international partners
meeting
Sustainability Plan:
follow-up of integrated
D4.5 proposals and long- 26 - ISCIII Report Public 31
term reporting scenarios
(MD4)
Description of deliverables
D4.1. Terms of Reference and Operating Procedure of the AoM: These include identification of members,
constitution, governance, mission, terms of reference and rules.
D4.2. Reports on AoM assessments: Reports based on meetings of AoM, including procedures and activities
regarding the sustainability plan on months 21 and 34.
D4.3. Fact sheets: These fact sheets can be used as a road map for the Policy dialogues to raise awareness and
acceptance in decision-makers on innovative actions to improve EU HI systems that will be held on months 18 and
30 for key players, international organisations and leaders of WP5, WP6, WP7, WP8, WP9, WP10. Contribution with
deliverables and tasks from WP9,WP7 and WP5.
D4.4. Reports on key holders and relevant EU-international partners meeting Workshop or pre-conference in EPH
D4.5. Sustainability Plan - follow-up of integrated proposals and long-term reporting scenarios: The plan focuses
on the integration of JA findings in MS HI Systems and their projections in the future, following reasonable
probabilities. It will translate JA results and innovative outcomes into EU-national HI systems, with the insight
and consensus provided in the meetings and workshops with WP leaders, AoM, national consortium, and EU-
international partners. It will include systematic EU-wide information and results on integration of policy brief,
identifying new approaches incorporated in national, regional and international systems, and their long-term
perspectives.
D4.1 : Terms of Reference and Operating Procedure of the AoM [6]
These include identification of members, constitution, governance, mission, terms of reference and rules.
D4.2 : Reports on AoM assessments [36]
Reports based on meetings of AoM, including procedures and activities regarding the sustainability plan on months
21 and 34.
D4.3 : Fact sheets [29]
These fact sheets can be used as a road map for the Policy dialogues to raise awareness and acceptance in decision-
makers on innovative actions to improve EU HI systems that will be held on months 18 and 30 for key players,
international organisations and leaders of WP5, WP6, WP7, WP8, WP9, WP10. Contribution with deliverables and
tasks from WP9,WP7 and WP5.
D4.4 : Reports on key holders and relevant EU-international partners meeting [31]
Workshop or pre-conference in EPH
D4.5 : Sustainability Plan: follow-up of integrated proposals and long-term reporting scenarios (MD4) [31]
The plan focuses on the integration of JA findings in MS HI Systems and their projections in the future, following
reasonable probabilities. It will translate JA results and innovative outcomes into EU-national HI systems, with
the insight and consensus provided in the meetings and workshops with WP leaders, AoM, national consortium,
and EU-international partners. It will include systematic EU-wide information and results on integration of policy
Page 21 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
brief, identifying new approaches incorporated in national, regional and international systems, and their long-term
perspectives.
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Strategic Board National
MS14 Assembly of Members 26 - ISCIII 3
representatives are appointed
Review and analysis of
MS15 implementation from other 26 - ISCIII 32 Meeting reports
WPs by AoM
Policy dialogues with key
Reports of 2 AoMs and 3
MS16 stakeholders at the national 26 - ISCIII 30
workshops
and international level
MS17 Sustainability Plan 26 - ISCIII 32 Approval by AoM
Page 22 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Work package number 9 WP5 Lead beneficiary 10 10 - RKI
Work package title Status of health information systems in MSs and regions
Start month 1 End month 36
Objectives
The objectives of the work package are:
1. To map and assess health information systems in Europe (WHO toolkit);
2. To create the information database to underlie a sustainable one-stop shop where stakeholders can find and contact
international expert networks, projects and indicator collecting bodies relating to comparable health data on public
health issues or health system performance;
3. To engage in the prioritisation of health information developments, also with a view to tackling health information
inequalities in Europe.
WP5 will closely work together with other WPs as it is an essential part of SO1 and SO2. The results of WP5 will
be exchanged with and have an impact on the works and deliverables of WP4, WP7, WP6 WP8 and WP9 through
the indicator development, identification and sharing of best practices, drawing on previous HI projects, consolidating
networks, creating a HI platform to be used by multiple WPs and translating results into policy.
Description of work and role of partners
WP5 - Status of health information systems in MSs and regions [Months: 1-36]
RKI, Sciensano, GÖG, CIPH, MoHCy, MoSA, THL, ISS, CDPC, HI, MFH, SMPHU, RIVM, HD, INSP, IPHS,
ISCIII, WG
Task 5.1. Mapping and assessment of health information systems (WHO toolkit) (Lead: MFH)
This proposal aims to address health information inequalities between countries by training and through peer-review.
This process supports the participating MSs in identifying action points for direct and long-term improvement and
strengthening of their HI systems and all MSs through the presentation of the process as good practice example. MSs
with less advanced health information systems are triggered towards active involvement in this task.
A health information (HI) system assessment tool has been developed by WHO Europe through the European Health
Information Initiative (EHII), which is currently being revised. The assessment is done in close collaboration with WHO:
- Training of reviewers and peer reviewers;
- Piloting peer review aiming for 9 countries: 3 pilots on sets of 3 MSs: MSs B & C would assess any background
material and conduct an assessment on site in MS A. This is repeated till the HI system is assessed in all 3 countries.
The task lead and co-lead may participate in the assessment as observers;
- The review of the pilot focuses on MS’ experience, possibly including a SWOT and cost-utility analysis;
- The results of the review will guide the methodology in other MSs.
Task 5.2. Cataloguing international health information collection networks, projects and indicator/data sets (Lead:
RIVM)
This task consists of mapping, based on in- and exclusion criteria, supported by experts:
1. active international health data collection networks on a) population health-oriented topics and b) health system/
health services-oriented topics, supported by PH and HSP experts;
2. previous and ongoing indicator generating projects and related health indicator projects with EU coverage;
3. existing indicator sets and currently produced indicators in Europe; making an inventory of issues most relevant
for reducing the reporting burden in the EU (e.g. definitions, data sources, policy priorities, data production costs);
collaborating with WHO, OECD, Eurostat and EC to further the indicator mapping exercise initiated by EHII and
addressing concrete possibilities to reduce reporting burden.
In order to upload the information in a web platform of the JA (WP7), this task defines the structure, variables, metadata
and functions.
Task 5.3. Prioritisation in health information developments / Tackle health information inequalities (Lead: RKI)
This task aims to draw up a framework to structure and facilitate the prioritisation of health information and, with
it, the selection of indicators. Prioritisation in health information development is needed to ensure that the available
indicators provide appropriate information for public health policy action (agenda-keeping) and point to emerging public
health issues (agenda-setting). The task will build upon work done in the BRIDGE Health project. Information on
Page 23 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
nationally applied priority setting methods will be compiled and reviewed with a view to European health information
prioritisation. Appropriate methods may include (Delphi) surveys. The process and the criteria of the process will be
proposed to the AoM (WP4) and translated into a work plan (road map) for the coming 5 years (WP7). The process
will take place at the level of the Member States, coordinated by the national nodes. With regard to 5.3, all MSs will
be contacted to participate in a survey on priority-setting; however, only a smaller number of MSs will contribute to
method development and data analysis. These MSs assigned PM for their collaboration.
Participation per Partner
Partner number and short name WP5 effort
1 - Sciensano 13.00
2 - GÖG 3.50
4 - CIPH 0.50
5 - MoHCy 2.00
7 - MoSA 0.00
NIHD 2.20
8 - THL 1.00
10 - RKI 30.90
13 - ISS 2.00
14 - CDPC 6.00
15 - HI 18.80
17 - MFH 3.00
18 - SMPHU 4.00
19 - RIVM 11.20
20 - HD 5.00
23 - INSP 4.00
24 - IPHS 2.00
26 - ISCIII 4.00
28 - WG 0.00
SU 3.00
Total 116.10
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
Pilot HI system peer
D5.1 assessment and review of 17 - MFH Report Public 32
experience
Cataloguing health
D5.2 19 - RIVM Report Public 32
information networks,
Page 24 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
projects and indicator
sets
Prioritisation in HI
D5.3 development and 10 - RKI Report Public 32
recommendations
Description of deliverables
D5.1. Pilot HI system peer assessment and review of experience: Pilot HI system assessment reports, for each of the
MSs participating in the pilot and review of pilot experience and proposed methodology for HI system assessment
through peer review.
1. Report on experience of MSs
2. Scientific publication(s) reporting on the experience of HI system peer assessment
3. Manual for implementation of HI system peer assessment in other MSs
D5.2. Cataloguing health information networks, projects and indicator sets: Catalogue of networks, including
two (draft) articles: 1) analysis of the presence of EU countries in a selection of networks that have a relatively
high MS participation providing a view on information inequalities within the EU (NL) and 2) overview of the
scientific publications from (subsets of) the identified networks containing international comparisons (NL); catalogue
of relevant public health projects (Participant, summary report/present on website); recommendations to reduce
reporting burden and establishment of a way forward (e.g. a working group with OECD and WHO) (NO, report);
manual for the web transfer of catalogues and sustainable process to update the information (ALL, report)
D5.3. Prioritisation in HI development and recommendations: Report on prioritisation strategies in surveyed countries
and recommendations for a draft framework for health information prioritisation in Europe.
D5.1 : Pilot HI system peer assessment and review of experience [32]
Pilot HI system assessment reports, for each of the MSs participating in the pilot and review of pilot experience and
proposed methodology for HI system assessment through peer review. 1. Report on experience of MSs 2. Scientific
publication(s) reporting on the experience of HI system peer assessment 3. Manual for implementation of HI system
peer assessment in other MSs
D5.2 : Cataloguing health information networks, projects and indicator sets [32]
Catalogue of networks, including two (draft) articles: 1) analysis of the presence of EU countries in a selection of
networks that have a relatively high MS participation providing a view on information inequalities within the EU
(NL) and 2) overview of the scientific publications from (subsets of) the identified networks containing international
comparisons (NL); catalogue of relevant public health projects (Participant, summary report/present on website);
recommendations to reduce reporting burden and establishment of a way forward (e.g. a working group with OECD
and WHO) (NO, report); manual for the web transfer of catalogues and sustainable process to update the information
(ALL, report)
D5.3 : Prioritisation in HI development and recommendations [32]
Report on prioritisation strategies in surveyed countries and recommendations for a draft framework for health
information prioritisation in Europe.
Page 25 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Report circulated only to
HI system peer assessment
MS18 17 - MFH 28 concerned MSs and CHAFEA
country reports
project officer
Review of pilot HI system
peer assessment experience
MS19 including scientific 17 - MFH 32 Report presented on website
publication and manual for
peer assessment
Method development for
MS20 10 - RKI 12 Report presented on website
prioritisation
Page 26 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Work package number 9 WP6 Lead beneficiary 10 22 - MS
Work package title Strengthen EU countries’ health information capacity
Start month 1 End month 36
Objectives
This work package aims to reduce HI system inequality between and within MSs at developing a capacity strengthening
baseline programme at EU level to support critical areas of health information use and management. Setting a European
framework for the MSs’ information capacity and their contribution to the overall level.
The WP will identify, map and summarise current programmes in “population health and health system performance
analysis and monitoring” in the MSs including issues related to training, research and policymaking. A needs assessment
in this area will also be performed.
A sustainable flagship training programme will be defined aiming at reducing HI inequalities within and between MS.
This programme must result as practical approach, with focus on enhancing capacity of the national health information
consortia and including field training and insights for its sustainability. Document on how-to-do this programme and
a proposal for the flagship programme will be produced. Two institutions will perform a pilot of key elements of this
flagship programme. The programme proposal will be evaluated. Final output will be a road map for capacity building
programme for EU MSs. WP6 will interact with the other WPs by engaging the experts in the different WPs for the
training programme.
Description of work and role of partners
WP6 - Strengthen EU countries’ health information capacity [Months: 1-36]
MS , Sciensano, CIPH, THL, EOPYY, DOH, ISS, CDPC, RIVM, INSP, IPHS, NIJZ, ISCIII
Task 6.1. Mapping needs, capacities and education/training programmes in health information across MSs (Lead: MS)
Health information is a comprehensive area, including indicator development, data collection, data analysis and
inference, information management and translational research. Health information is often taught in different courses
or as modules of information systems or as part of epidemiology courses, but most of the courses are vertical with focus
on one or only some topics.
The WP will identify:
- Map and summarise MSs’ health information needs (technical resources, tools and training) and current existing
programmes in “population health and health system performance analysis and monitoring” in the MS, including issues
related to training, research and policymaking
- Data will be collected from MS representatives and an expert panel, but will consider also relevant EU and WHO-Euro
projects, key informers, published literature search and a scoping search of internet sources, complemented with case
studies to deepen understanding. Further MS needs on health information will be surveyed and assessed, in collaboration
with the mapping of the HI systems in WP5.
Links with ECDC (infectious diseases epidemiological and microbiological data and information system), European
Observatory (health indicators on health systems), and the ECDC fellowship programme, OECD and WHO information
educational programmes will be promoted.
Task 6.2. Design of a flagship training programme to improve MS capacities in population health and health system
performance analysis and monitoring (Lead: MS)
Based on the results of Task 6.1, a flagship programme will be defined. The capacity building programme will cover
different components such as health status monitoring (longitudinal studies, surveys, population-based registries, …),
health care performance and health care outcomes, health system performance and policy translation (linking health
indicators and health objectives). The objectives are to increase knowledge on availability and use of standardised
methods, common practices, etc. within MSs. The capacity building programme will strongly build on e-learning tools
but also face-to-face activities such as workshops, seminars etc. are needed. The capacity building programme is oriented
towards professionals working in public institutions. Some components of the capacity building programme will be
piloted (in Task 6.3). The selection of the components will be done based on results of Task 6.1 in addition to the already
planned trainings in WP5 (evaluation of HI systems) and WP9 (complex composite health indicators DALY).
Task 6.3. Evaluating training programme (Lead: MS)
Page 27 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
The proposal of the flagship capacity programme will be evaluated for its feasibility, coverage of required components,
cost, target audience etc. using the knowledge and expertise of the experts of the consortium. The programme will
subsequently be adjusted leading to the final objective.
Task 6.4. Road map for capacity building programme for EU MS (Lead: MS)
A business case and road map for sustainable capacity building programme for EU MS will be prepared. This road
map will include:
- Description of already existing capacity building actions and how those should be maintained and further developed;
- Description and comparisons of training programme structures aiming at reducing health information inequality
including exchange programmes, on-site trainings, group trainings to ensure a sustainable instrument for capacity
building in MSs;
- Areas of health information for which adequate capacity building activities are missing and how to start developing
those;
- How to get MSs better informed about already existing and new capacity building opportunities;
- Financial plan: Ways to obtain future funding for development and maintenance of a health information capacity
building programme.
Participation per Partner
Partner number and short name WP6 effort
1 - Sciensano 2.00
4 - CIPH 7.00
8 - THL 19.03
11 - EOPYY 1.00
12 - DOH 0.00
HRB 1.00
13 - ISS 3.50
14 - CDPC 3.00
19 - RIVM 0.80
22 - MS 20.00
INSA 10.00
UNL 30.00
23 - INSP 8.42
24 - IPHS 4.00
25 - NIJZ 3.00
26 - ISCIII 3.00
Total 115.75
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
Mapping needs,
D6.1 22 - MS Report Public 18
capacities and training
Page 28 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
programmes in health
information
A flagship training
programme to improve
MS capacities in
D6.2 population health 22 - MS Report Public 24
and health system
performance analysis and
monitoring
Training Piloting and
D6.3 Flagship Training 22 - MS Report Public 30
Programme Evaluation
Road map for capacity
D6.4 22 - MS Report Public 36
building programme
Description of deliverables
D6.1. Mapping needs, capacities and training programmes in health information: A report summarising the existing
health information programmes and their contents and other relevant pedagogic details. Identification of the most
significant and relevant health information inequalities among MSs. A detailed knowledge of existing health
information systems and their capacity to respond to community requirements.
D6.2. A flagship training programme to improve MS capacities in population health and health system performance
analysis and monitoring: Flagship Capacity Building Programme for “population health and health system
performance analysis and monitoring” proposal document
D6.3. Training Piloting and Flagship Training Programme Evaluation: Piloting Training of modular key issues and
Flagship Capacity Building Proposal Evaluation – three outcomes:
1. One report will provide information about the experience of 2-3 key issues piloted in two groups of people from
several MSs
2. A second report on the evaluation of the Flagship Capacity Building Programme proposal, resulting from
formal evaluation, web meetings and a face-to-face meeting. This shall include improvements, guidelines and
recommendations
3. Improved version of the Flagship Capacity Building Programme
D6.4. Road map for capacity building programme: Road map for capacity building programme on health information
in Europe: Implementation Guidelines for MSs, including recommendations reducing information inequalities among
MSs and recommendations for sustainability
D6.1 : Mapping needs, capacities and training programmes in health information [18]
A report summarising the existing health information programmes and their contents and other relevant pedagogic
details. Identification of the most significant and relevant health information inequalities among MSs. A detailed
knowledge of existing health information systems and their capacity to respond to community requirements.
D6.2 : A flagship training programme to improve MS capacities in population health and health system performance
analysis and monitoring [24]
Flagship Capacity Building Programme for “population health and health system performance analysis and
monitoring” proposal document
D6.3 : Training Piloting and Flagship Training Programme Evaluation [30]
Piloting Training of modular key issues and Flagship Capacity Building Proposal Evaluation – three outcomes: 1.
One report will provide information about the experience of 2-3 key issues piloted in two groups of people from
several MSs 2. A second report on the evaluation of the Flagship Capacity Building Programme proposal, resulting
Page 29 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
from formal evaluation, web meetings and a face-to-face meeting. This shall include improvements, guidelines and
recommendations 3. Improved version of the Flagship Capacity Building Programme
D6.4 : Road map for capacity building programme [36]
Road map for capacity building programme on health information in Europe: Implementation Guidelines for MSs,
including recommendations reducing information inequalities among MSs and recommendations for sustainability
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Mapping of Health
Information education/
MS21 22 - MS 18 Task 6.1 completed
training programmes and
needs
Flagship capacity build
MS22 22 - MS 24 Tasks 6.2 completed
programme
Page 30 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Work package number 9 WP7 Lead beneficiary 10 1 - Sciensano
Work package title Proof of concept of sustainable structure on health information
Start month 1 End month 36
Objectives
The objective of this work package is to develop and carry out a proof of concept of a sustainable organisational
structure that supports EU-centred research activities in the area of health data and information to support population
health monitoring and health system performance assessment with the aim to foster evidence-based (health) policy. This
involves refining the concept of a European Research Infrastructure Consortium on Health Information for Research
and Evidence-based Policy (HIREP-ERIC) as depicted by the BRIDGE Health project. The HIREP-ERIC’s business
case will be developed and a road map is to be presented. The corner stones of the HIREP-ERIC will be laid down,
some of them tested and a better understanding of the HIREP-ERIC’s potential services will be fostered throughout the
EU and its Member States and associated countries. Long-term financing mechanisms for the HIREP-ERIC to ensure
sustainability will be evaluated. WP7 will work closely with other WPs and integrate their findings in the HIREP-ERIC.
The Steering Committee will be able to provide extensive feedback on the developments in this WP, bringing together
all WP leaders. WP4 will also closely interact with WP7 as the findings of WP7 will be distributed and presented in
the Assembly of Members.
Description of work and role of partners
WP7 - Proof of concept of sustainable structure on health information [Months: 1-36]
Sciensano, CIPH, UZIS, THL, SpFrance, RKI, EOPYY, ISS, CDPC, HI, MFH, RIVM, MZ, IPHS, ISCIII, FoHM,
WG
Task 7.1. A sustainable networks of networks: research and health information networks are the foundations of the
HIREP-ERIC (Lead: Sciensano)
National consortia (NC) bring together the key players in health information in MSs and domain specific nodes (DSN)
bring together experts in a specific HI field. Best practices to establish NCs in MSs are identified. WP7 assists in setting
up NCs and in identifying the consortium lead. It develops guidelines and recommendations for the functioning and
tasks of NCs and determines minimal requirements and prerequisites for effective functioning. WP7 will stimulate the
NCs to spread the information about InfAct in their countries. Criteria and procedures for the inclusion and selection of
DSNs are developed and an evaluation process including the requirements for sustainability for DSNs are developed.
The DSNs are to be the reference in health information in a specific domain within the EU. The governance structure
of HIREP-ERIC includes a Network Committee. The composition and tasks of the Network Committee are developed
and its functioning will be piloted with focus on the process of finding sustainable financial support for pilot DSNs.
Task 7.2. Business case and road map for implementation (Lead: RIVM)
The business case is based on BRIDGE Health results and includes:
- Mission and vision of the HIREP-ERIC;
- Short-term and long-term sustainable strategy;
- Analysis of the information needs of current health policies in MSs and the EU;
- Development of the final management structure;
- Identification of users and criteria for development of service definition;
- A scoping study to select and specify services with highest utility;
- A short-term and long-term time planning and cost estimation, including high and low estimates for the tasks to be
executed and personnel involved;
- Added value of the HIREP-ERIC for its financers;
- Market space of HIREP-ERIC in the EU health information landscape. Based on the experiences, pilots of the JA,
the business case is translated into a 5-year operational HIREP-ERIC road map with a detailed work plan including
specific objectives, outcome and deliverables.
Task 7.3. Development of the governance structures of a sustainable health information system (Lead: Sciensano)
1. Development of the Technical and Scientific description of HIREP-ERIC and defining statutes of HIREP-ERIC. This
is done in direct interaction with the specific task force within EGHI (DG Sante). This includes
a. The governance structure including the terms of reference of the different committees such as
- Governance board
Page 31 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
- Scientific committee
- Ethical and privacy committee
- Consultation platform
- Network Committee
b. The development of the memorandum of understanding (MoU) of MSs regarding the setup of the HIREP-ERIC. The
MoU is supported by a consensus on a policy paper on the HIREP-ERIC, prepared and submitted for decision-making
to the MSs to join the ERIC-HIREP. The AoM (see 4.1), the Expert Group on Health Information and on Health System
Performance analysis will be involved in commenting and improving the draft version of this document. The task is
also linked to WP2 (promotion video) and the Technical and Scientific Description, Statutes (see above)
2. Promotion of the HIREP-ERIC through presentation of the business plan and road map of the HIREP-ERIC directly
in the MSs through country visits with bilateral meeting with Ministries of Health and of Research representatives and
through the setup of meetings mimicking the Assembly of Members
3. Mapping membership for upload in the web platform
4. Submission of ERIC and ESFRI road map
Task 7.4. Health information web platform (Lead: Sciensano)
Functional design and development of a website providing the support platform for the HIREP-ERIC. The site
contains repository functions for technical reports and scientific articles, methods and tools, health information projects,
indicators/data sets, information on NCs, DSNs, training programmes, financial source information collected in the JA.
WP7 standardises and harmonises the business requirement prepared by the different WPs (5-10) to develop the web
platform using previous projects, national and international experiences. The website includes various search options,
upload and reporting (summaries, tables, (geographical) tools as standard functionalities for community actions and
discussion forums. The development makes use of standards as given by Inspire and the FAIR principles (Findable,
Accessible, Interoperable, and Reusable). The development ensures that each network is responsible for its own update,
but in return that the application can be used within its own web tools. For sustainability, possible automation using
a scraping tool is evaluated.
Participation per Partner
Partner number and short name WP7 effort
1 - Sciensano 50.00
4 - CIPH 1.00
6 - UZIS 1.00
8 - THL 3.10
9 - SpFrance 1.05
INSERM 5.45
MoH FR 1.50
10 - RKI 6.00
11 - EOPYY 1.50
13 - ISS 3.00
14 - CDPC 4.00
15 - HI 1.00
17 - MFH 1.00
19 - RIVM 10.00
21 - MZ 0.00
NIPH 1.00
24 - IPHS 1.00
Page 32 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Partner number and short name WP7 effort
26 - ISCIII 3.00
IACS 3.00
27 - FoHM 0.60
28 - WG 1.40
SU 0.60
Total 100.20
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type15 Dissemination level16 Date (in
Number14
months)17
A sustainable network of
D7.1 1 - Sciensano Report Public 24
networks
HIREP-ERIC: Business
D7.2 case and road map for 19 - RIVM Report Public 30
implementation
Governance structures
D7.3 of a sustainable health 1 - Sciensano Report Public 18
information system
Websites,
Health Information web
D7.4 1 - Sciensano patents Public 24
platform
filling, etc.
Description of deliverables
D7.1. A sustainable network of networks : The deliverable (1) provides guidelines on setting up NCs based on good
practices and experiences in this process by MS during the JA, (2) provides criteria for in- and exclusion of DSNs and
(3) defines the terms of reference for the functioning of the Network Committee of the HIREP-ERIC
D7.2. HIREP-ERIC: Business case and road map for implementation: The target population of this report are
countries’ Ministries of Health and Ministries of Research. The report describes the Business case and a 5-year road
map for implementation with a detailed work plan including specific objectives, outcome, deliverables and KPI for
monitoring
D7.3. Governance structures of a sustainable health information system: The deliverable contains the Technical and
Scientific description of HIREP-ERIC and defining statutes of HIREP-ERIC and the list of MSs who have signed the
memorandum of understanding
D7.4. Health Information web platform: Web platform containing information on past / current health information-
related projects, indicators; networks of national consortia, of domain specific nodes, of training experts, of financial
resources; on data sources and methods
D7.1 : A sustainable network of networks [24]
The deliverable (1) provides guidelines on setting up NCs based on good practices and experiences in this process by
MS during the JA, (2) provides criteria for in- and exclusion of DSNs and (3) defines the terms of reference for the
functioning of the Network Committee of the HIREP-ERIC
D7.2 : HIREP-ERIC: Business case and road map for implementation [30]
The target population of this report are countries’ Ministries of Health and Ministries of Research. The report
describes the Business case and a 5-year road map for implementation with a detailed work plan including specific
objectives, outcome, deliverables and KPI for monitoring
Page 33 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
D7.3 : Governance structures of a sustainable health information system [18]
The deliverable contains the Technical and Scientific description of HIREP-ERIC and defining statutes of HIREP-
ERIC and the list of MSs who have signed the memorandum of understanding
D7.4 : Health Information web platform [24]
Web platform containing information on past / current health information-related projects, indicators; networks of
national consortia, of domain specific nodes, of training experts, of financial resources; on data sources and methods
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Guidelines for national
Guidelines and criteria are
MS23 consortia and domain-specific 1 - Sciensano 18
described
nodes
Operational plan with
5-year operational plan
MS24 1 - Sciensano 30 workplan, timeline, and
HIREP-ERIC
means
Memorandum of
MS25 1 - Sciensano 18 Number of MSs have signed
understanding HIREP-ERIC
Specifications (content,
Business structure web structure, functions,
MS26 1 - Sciensano 18
platform reporting) of web platform are
defined
Page 34 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Work package number 9 WP8 Lead beneficiary 10 13 - ISS
Work package title Tools and methods for health information support
Start month 1 End month 36
Objectives
Main objectives are to:
1. provide guidance at EU level to improve use of multi-source health and non-health (WP9) information to support
public health decision-making, policy creation, research
2. summarise existing experience in EU on health data and health indicators by reviewing and identifying existing
standardised data collection methods and common procedures
3. maintain and develop identified standardised data collection methods and related quality assurance procedures
4. contribute to improved and sustainable use and usability of ECHI, according to technical and content updates and
links to policy (priorities)
5. elaborate common procedures and guidelines for accessibility and availability of health information both for
individual-based data and health indicators
6. elaborate guidelines for preparing comparable standard reports
7. coordinate a network of national/regional health information experts involved in Domain-Specific Nodes, in
agreement with WP7
8. contribute to provide contents to the web-based platform according to FAIR principles
Description of work and role of partners
WP8 - Tools and methods for health information support [Months: 1-36]
ISS, Sciensano, MoHCy, UZIS, MoSA, THL, SpFrance, RKI, EOPYY, DOH, CDPC, MFH, RIVM, HD, MZ, IPHS,
NIJZ, ISCIII, FoHM, WG
Task 8.1. Generating knowledge on data collection methods, and availability and accessibility of health information
(Lead: ISS)
This task implies
1. summarizing existing knowledge and definition of data, indicators, standardised data collection methods, common
procedures, availability and accessibility procedures (including best practices and case studies) covering different data
sources (population-based registries, surveys, longitudinal studies, health system performance, other administrative
sources, data collected through e-health solutions) for health status determinants; starting from data collection methods
adopted in MSs, a stepwise approach suggesting alternatives to a ‘gold standard’ will be provided. Activities of the task
are interlinked with the review of health information systems in MSs and regions conducted by WP5 in order to identify
and select health data and indicators to be taken into account. A link with WP9 will be established to avoid possible
overlaps in evaluating data and indicators: Task 8.1 will focus on established health indicators and quality methods,
whereas Task 9.2 will be specific for emerging and new health indicators;
2. maintaining and developing data collection standards (in relation to EUROSTAT/Inspire standards, International
standards) and related quality assurance procedures (e.g. periodical revisions of collection methods or web scraping
tools will be considered and evaluated);
3. contributing to a web-based platform implementation providing an inventory of collected methods as a support for
the European Health Information System. Activities of the task will be interlinked with WP7 that will be in charge of
the development of the web-based platform (Task 7.4).
Task 8.2. This task investigates the sustainable use(ability) of the ECHI-shortlist and its future implementation and
alteration process (Lead: RIVM)
This includes the need for technical updates, actionable content, flexible format/structure and aligning with other
international organisations. The task builds on WP5 and other WPs of the BRIDGE Health project and on previous EC-
commanded evaluation studies of ECHI. Discussion partners are a.o. EUROSTAT, WHO, OECD, DG SANTE and DG
EMPL, with the EGHI and EG-HSPA groups as sounding boards. The work will be technically supported by a small
expert group. Activities are:
- Compiling ECHI-relevant historical and technical background information;
- Improving and implementing a sustainable ECHI update process;
- Reviewing the ECHI format/structure and content including more links to policy (priorities);
Page 35 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
- Preparing dissemination on the JA website, using the FAIR principles, and preparing a sustainable procedure for
updating the information.
Task 8.3. Guidelines for accessibility, availability and reporting of health information including quality of data/indicators
and quality of reporting (Lead: ISS)
1. Based on the reviews conducted in Task 8.1, including best practices and case studies, guidelines on accessibility
and availability of data and indicators will be elaborated. Activities of the task will be interlinked with WP6 in order
to provide specific material to be included in the training programme to improve MS capacities in Population Health
and HSPM analysis (Task 6.2);
2. Starting from evidence, best practices and case studies on health reporting, quality assurance guidelines on health
reporting from MSs, common guidelines and recommendations will be developed. Recommendations for a draft concept
for European health reporting, including potential formats and target groups will be provided. Interactions/overlapping
with JAF-Health and European Observatory on Health Systems and Policies will be avoided.
Task 8.4. Coordinating networks of experts involved in all WP activities within the entire JA; contribution to web-based
platform (Lead: NIJZ)
In close collaboration with WP7, the task will provide a standard approach and common rules for selecting and involving
health experts in all WPs including researchers, health professionals, regulators, stakeholders, and patient organisations.
The activity of coordination of all networks established in the different WPs will also be executed. Best practices in
establishing and maintaining such groups will be reviewed, e.g. Member States Platform in JA CANCON (WP5). The
contribution to contents for the web-based platform will be provided in synergy with other WPs.
Participation per Partner
Partner number and short name WP8 effort
1 - Sciensano 2.00
5 - MoHCy 1.90
6 - UZIS 4.50
7 - MoSA 0.00
NIHD 0.50
8 - THL 10.50
9 - SpFrance 0.00
INSERM 3.50
10 - RKI 9.40
11 - EOPYY 1.50
12 - DOH 2.20
13 - ISS 60.00
14 - CDPC 8.00
17 - MFH 0.80
19 - RIVM 11.20
20 - HD 4.00
21 - MZ 0.00
NIPH 3.50
24 - IPHS 1.50
25 - NIJZ 6.00
Page 36 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Partner number and short name WP8 effort
26 - ISCIII 1.50
27 - FoHM 0.60
28 - WG 0.00
SU 5.20
Total 138.30
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
Health Information
System development:
data collection and
D8.1 13 - ISS Report Public 28
quality assurance
for a common health
information system
Sustainable ECHI
process from technical,
D8.2 19 - RIVM Report Public 32
content and user
perspective
Guidelines for
accessibility and
D8.3 13 - ISS Report Public 32
availability of health
information
Guidelines for MSs and
D8.4 10 - RKI Report Public 32
regions for health reports
Description of deliverables
D8.1. Health Information System development: data collection and quality assurance for a common health
information system: A report summarising standardised data collection methods and quality methods by source of
information and chronic disease for the Health Information System.
D8.2. Sustainable ECHI process from technical, content and user perspective: Practical input for the improved
and sustainable use and usability of ECHI: A report summarising up-to-date opportunities, challenges and EU-
wide agreed recommendations for 1) an ECHI format that is supportive of both health descriptive purposes and
(prioritised) policy planning, 2) a sustainable data update procedure and 3) sustainable web dissemination of ECHI
documentation, all including (small) pilots
D8.3. Guidelines for accessibility and availability of health information: Guidelines (including road maps and
recommendations) on accessibility and availability of health information at European level and at participating MS
level
D8.4. Guidelines for MSs and regions for health reports: Guidelines (including recommendations) for participating
MSs and regions providing standardised and comparable reports
D8.1 : Health Information System development: data collection and quality assurance for a common health
information system [28]
A report summarising standardised data collection methods and quality methods by source of information and chronic
disease for the Health Information System.
D8.2 : Sustainable ECHI process from technical, content and user perspective [32]
Page 37 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Practical input for the improved and sustainable use and usability of ECHI: A report summarising up-to-date
opportunities, challenges and EU-wide agreed recommendations for 1) an ECHI format that is supportive of
both health descriptive purposes and (prioritised) policy planning, 2) a sustainable data update procedure and 3)
sustainable web dissemination of ECHI documentation, all including (small) pilots
D8.3 : Guidelines for accessibility and availability of health information [32]
Guidelines (including road maps and recommendations) on accessibility and availability of health information at
European level and at participating MS level
D8.4 : Guidelines for MSs and regions for health reports [32]
Guidelines (including recommendations) for participating MSs and regions providing standardised and comparable
reports
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Questionnaires for MSs
MS27 regarding data collection 13 - ISS 10 Report on survey results
methods and procedures
Research/desk work on Research/desk work on
MS28 review of data collection 13 - ISS 24 review of data collection
methods and procedures methods and procedures
Research / desk work on Publication of report on
MS29 10 - RKI 24
health reporting in MSs website
ECHI documentation, format, Present on website; report +
MS30 19 - RIVM 32
technical and content update expert meeting
Page 38 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Work package number 9 WP9 Lead beneficiary 10 9 - SpFrance
Work package title Innovation in health information for public health policy development
Start month 1 End month 36
Objectives
The specific objectives are:
1. Identify and share inspiring examples from MSs with regards to emerging indicators and data sources potentially
useful to target priority public health actions and healthcare strategies, including providing evidence on what is possible
within MSs;
2. Develop and disseminate best practices/guidelines and methodologies;
3. Deliver new and policy-relevant data in certain specific areas of high interest (chronic diseases, elderly care, secondary
patient characteristics including co-morbidity, polypharmacy), in addition to data from registries, death certificates and
health surveys (EHIS, SILC, HES…);
4. Enlarge the set of morbidity indicators available across the EU at different geographical levels and in a timelier way
(beyond ECHI and what is currently provided by Eurostat) and inform the development of future regulations.
Description of work and role of partners
WP9 - Innovation in health information for public health policy development [Months: 1-36]
SpFrance, Sciensano, GÖG, CIPH, UZIS, RKI, DOH, ISS, CDPC, HI, MFH, RIVM, HD, MS , INSP, NIJZ, ISCIII,
FoHM, WG
The cost of collected data such as Health Information Systems and HES remains high while the availability of generated
data from a variety of sectors is increasing. This WP will assess the potential use of these new data sets for public
health policy purposes and will consider new ways of using existing data using linkage, modelling and other techniques
to enhance their value. It aims also at producing timely and valid population health indicators at different territorial
levels for better decision. More efficient ways of generating comparable health information across Europe by using data
collected for other purposes are required.
WP9 will work in collaboration with WP4 (in particular Task 4.3), with WP5 (in particular Task 5.2), with WP8 as
indicated in Task 9.5. WP9 can be useful to identify new training needs for professionals that will be useful for WP6
(Task 6.1 and Task 6.2). Opportunities for training and short visits could be identified based on the inspiring examples
and experiences of WP9 participants in working with new sources and new indicators.
Task 9.1. Identifying and sharing inspiring examples from MSs with regards to emerging indicators and promising data
sources for public health and healthcare strategies (Lead: SpFrance)
1. Identify emerging indicators on health and its determinants, different from those already compiled in existing health
information databases (OECD, WHO, Eurostat…)
2. Identify emerging and promising sources of data to develop relevant indicators on health and data, at different
geographical scale, with special attention to the utilisation of data from different sources (primary care, drug prescription,
healthcare reimbursement and hospital discharge). Investigate the potential of modelling techniques to enhance the
scope of existing indicators by extending to areas where data are sparse
3. Share experience on the use of these emerging indicators, promising sources and modelling techniques to enhance
the relevance of the information for policymaking at different levels (national and subnational) to increase the capacity
to support policies
Task 9.2. Develop and propose generic and shared methods, best practices and standards to define, construct, validate,
and disseminate relevant and reliable emerging indicators from new data sources in addition to health data from
registries, death certificates and surveys (EHIS, SILC, HES…) (Lead: SpFrance)
1. Health monitoring: develop and propose generic and shared methods, best practices and standards to define, construct,
validate, and disseminate relevant and reliable emerging indicators from new data sources and assess their public health
value in relation to more classic sources of data, such as morbidity registries, mortality data and surveys.
2. HSPA: building on the previous European research, guidelines for developing and testing specific new indicators
to assess performance of integrated healthcare systems will be provided. Methods for linking different sources of data
will also be included. One workshop will be organised with health system performance experts (BRIDGE Health,
EuroReach, OECD, European Observatory, WHO Europe). This meeting aims to (1) identify data needs and gaps for
Page 39 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
monitoring health system performance (HSP) and (2) define a road map for improving health system performance
comparisons in member states (indicators, methods and communication platform).
Expected outcomes:
1. a validated framework for collecting and comparing data and information on HSP;
2. a platform (or action plan) for facilitating research on HSP;
3. understanding and support of stakeholders for the JA goals.
Task 9.3. Apply best practices (Lead: SpFrance)
Apply these best practices to health indicators for a limited number of priority public health targets that are of interest
to demonstrate the value of the infrastructure for MSs and potential users of the HI infrastructure (such as different DGs
from the EC, OCDE, WHO…) for indicators for public health/prevention/health systems governance purposes at multi-
country level. This would allow having multi-country results and trends at different geographical levels. The priority
targets will be defined at the early stage of the implementation of WP9.
Two meetings will be organised on perinatal health and healthy life years.
EuroPeristat meeting
This meeting has two aims:
1. Development and validation of emerging indicators on maternal and newborn morbidity using hospital and
administrative data (tasks 9.1, 9.2, 9.3); and
2. Definition of mechanisms and an action plan for the uptake of indicators into the regular EU data collection system
(task 9.3 and 9.5, WP 7, task 7.1 on functional networks).
Members from the 31 countries participating in the Euro-Peristat project, plus key stakeholders for both aims (SpFrance
France, Eurostat, OECD, EU user and professional groups) from which about one-third of participants (50 estimated
in total) can be self-financed.
Outcomes:
1. A validated protocol for indicator collection and validation;
2. A consensual action plan for uptake of indicators;
3. Understanding and support of stakeholders for the JA goals.
EHLEIS meeting
Aim: discussion on the trends of HLY in Europe and discussion on the country reports and new developments with
HLY experts from MSs.
Outcomes: better understanding of healthy ageing within Europe and key developments on the gap between the evolution
of HLY and the EU targets.
Task 9.4. Development of composite indicators to a) monitor the burden of disease at population level and b) monitor
the health system performance (Lead: ISCIII)
1. Propose further development of composite health indicators, including Health Expectancies in collaboration with
EHLEIS, Burden of Diseases (BoD) metrics (Disability Adjusted Life Years) in collaboration with IHME (Institute for
Health Metrics and Evaluation) and WHO EURO BoD network, population attributable fractions due to potentially
preventable risk factors (behavioural, metabolic and environmental…), mortality amenable to healthcare, preventable
death (articulation with ESTAT project) based on morbidity indicators, and indicator sets that track the SDGs. Less
advanced countries will be supported in their capacity development in this field by participating in the workshops
organised in discussion groups. 3 workshops will be organised:
1. Towards harmonizing Global, European and National Burden of Disease (BoD) methodologies: Expert Consultation
Workshop, Berlin, August 2018. Aim: the workshop aims to adapt and further develop the IHME BoD concept and
methodologies with a view to making them transferable and applicable to European and national BoD. This effort will
contribute to harmonising BoD methodologies at national and EU regional levels, thereby increasing comparability
and facilitating knowledge exchange on BoD bilaterally and multilaterally in the European Union. The workshop will
further explore how a European BoD can be embedded in a sustainable European Health Information System (EU-HIS).
Outcomes: development of an option of how to integrate the BoD concept into national accounts.
2. Methodological workshop to conduct and use BoD studies to influence policy and practice, Paris. Aim: the workshop
will explore options for implementing harmonised national BoD approaches. It will furthermore identify ways and
means of analysing and transforming national BoD data into information which is relevant, comprehensible and
actionable for health and other policies. Outcomes: draft recommendations describing which criteria should be fulfilled
by BoD studies and respective data analysis/reporting so that these instruments will serve the objective of advising
political action at national, regional and international levels.
3. Training for a comprehensive and harmonised BoD approach at national, regional and international level. Aim: foster
and deepen expert exchanges about implementing a comprehensive BoD concept with a view to harmonising national,
Page 40 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
regional and international BoD approaches which span diseases, disease groups and public health fields. Outcomes:
expand the number of health information specialists trained to implement BoD approaches at the international, national
and regional level. Development of expertise and capability to undertake country studies and collectively to undertake
a Europe wide BoD analysis in support of the EHII (European Health Information Initiative) and to promote a cross-
Europe approach to identify and address causes of ill health.
2. Assess the feasibility of merging mortality and morbidity information (from hospital discharge records, primary care
electronic records and vital statistics reports) among different geographical regions in different MSs. Regional or local
differences may then be used to explore both the quality of health information systems and inequalities in access to
healthcare.
Task 9.5. Explore mechanisms for the uptake of indicators into the regular EU data collection system (Eurostat
regulations), WHO and OECD– Link with WP 1, WP 2 and WP4, 8 (Lead: SpFrance)
On longer term, the production of indicators with robust shared methodologies from these emerging and/or new data
sources will contribute to the evaluation/assessment of prevention measures and public health interventions. Candidate
domains are perinatal health and injury data. At least one test case will be developed based on perinatal health data.
Participation per Partner
Partner number and short name WP9 effort
1 - Sciensano 4.00
2 - GÖG 3.00
4 - CIPH 1.00
6 - UZIS 2.00
9 - SpFrance 43.15
INSERM 9.55
IRDES 7.75
MoH FR 0.95
10 - RKI 1.00
12 - DOH 1.30
13 - ISS 5.00
14 - CDPC 8.00
15 - HI 12.00
17 - MFH 1.00
19 - RIVM 2.00
20 - HD 4.00
22 - MS 0.35
INSA 1.50
23 - INSP 2.00
25 - NIJZ 5.00
26 - ISCIII 6.00
27 - FoHM 1.55
28 - WG 0.00
SU 7.50
Page 41 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Partner number and short name WP9 effort
PHE 7.50
Total 137.10
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
Road map and case study
D9.1 9 - SpFrance Report Public 24
report
Guidelines, case study
D9.2 9 - SpFrance Report Public 30
and best practices
Report series on the
D9.3 application of the best 9 - SpFrance Report Public 32
practices
Tool kit to produce better
D9.4 28 - WG Demonstrator Public 33
health indicators
Road map for uptake of
D9.5 indicators – opportunities 9 - SpFrance Report Public 34
and obstacles
Description of deliverables
D9.1. Road map and case study report: Case studies related to emerging indicators developed / used at regional
and country level, data sources used for their calculation; indicators performance assessment strengths, limits and
complementarity with more classic indicators and to suitable data sources potentially useful for a more relevant,
reliable and complete description of the population health status for different geographical level of information.
Prospective road map for further development of the European health information system, in terms of new data
sources to investigate and include in the future
D9.2. Guidelines, case study and best practices: Report on guidelines for development and testing of specific new
indicators to assess the performance of integrated care systems, including methods for linking different sources of
data and for assessing availability of new indicators at European level. Methods / criteria that NPHIs carried out
(or plan to carry out) to validate health indicators from HCU data (Healthcare utilisation), through a few case study
reports. Best practices to be shared by MSs to define, validate and implement new health indicators
D9.3. Report series on the application of the best practices: Report series on the application of the best practices with
topic-specific reports on themes, as described in Task 9.4, providing data and public health messages targeted to key
stakeholders
D9.4. Tool kit to produce better health indicators: Tool kit to produce BoD estimates and other composite indicator
outcomes at national and subnational level and overview report of available Burden of Disease estimates for EU
countries
D9.5. Road map for uptake of indicators – opportunities and obstacles: Road map for uptake of indicators in EU and
international data collections – opportunities and obstacles, in particular for perinatal health
D9.1 : Road map and case study report [24]
Case studies related to emerging indicators developed / used at regional and country level, data sources used for their
calculation; indicators performance assessment strengths, limits and complementarity with more classic indicators
and to suitable data sources potentially useful for a more relevant, reliable and complete description of the population
health status for different geographical level of information. Prospective road map for further development of the
European health information system, in terms of new data sources to investigate and include in the future
Page 42 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
D9.2 : Guidelines, case study and best practices [30]
Report on guidelines for development and testing of specific new indicators to assess the performance of integrated
care systems, including methods for linking different sources of data and for assessing availability of new indicators
at European level. Methods / criteria that NPHIs carried out (or plan to carry out) to validate health indicators from
HCU data (Healthcare utilisation), through a few case study reports. Best practices to be shared by MSs to define,
validate and implement new health indicators
D9.3 : Report series on the application of the best practices [32]
Report series on the application of the best practices with topic-specific reports on themes, as described in Task 9.4,
providing data and public health messages targeted to key stakeholders
D9.4 : Tool kit to produce better health indicators [33]
Tool kit to produce BoD estimates and other composite indicator outcomes at national and subnational level and
overview report of available Burden of Disease estimates for EU countries
D9.5 : Road map for uptake of indicators – opportunities and obstacles [34]
Road map for uptake of indicators in EU and international data collections – opportunities and obstacles, in particular
for perinatal health
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
MS31 3 workshops on BoD 28 - WG 15 Workshop reports
MS32 EuroPeristat Meeting 9 - SpFrance 6 Meeting report
Health system performance
MS33 9 - SpFrance 6 Meeting report
expert workshop
MS34 EHLEIS meeting 1 - Sciensano 30 Meeting report
Page 43 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Work package number 9 WP10 Lead beneficiary 10 4 - CIPH
Work package title Assessing and piloting interoperability for public health policy
Start month 1 End month 36
Objectives
Motivated by the need to establish a holistic European model and data infrastructure able to translate data, information
and knowledge into support for policymaking using services based on data linkage, data sharing, data management and
knowledge development, and stemming from a number of case studies, WP10 will pilot the methods and techniques
required to reach this goal.
For that purpose, WP10 will develop upon the building blocks defined in the European Interoperability Framework,
and get inspiration from the EIF for e-Health. EIF documents describe four “vertical” interoperability layers – legal,
organisational, semantic and technical as well as a “background” layer – interoperability governance. WP10 tasks have
been set up according to these layers.
This WP will specifically:
1. Map and analyse national and international inspirational case studies with the focus on public health surveillance and/
or research, where interoperability, data linkage, data sharing and data management, data security and privacy issues
play an important role;
2. Develop empirical work on interoperability, data linkage, data sharing and data management, using a number of case
study pilots on a range of topics, applying a variety of data sources from different countries. Pilots aim to address a
number of case studies able to cover two dimensions, using a distributed system:
- Dimension 1: Domain including health status, health determinants or health system performance
- Dimension 2: Goal including public health monitoring/surveillance or public health effectiveness and efficiency (i.e.
impact research).
Description of work and role of partners
WP10 - Assessing and piloting interoperability for public health policy [Months: 1-36]
CIPH, Sciensano, SpFrance, ISS, CDPC, HD, MS , NIJZ, ISCIII, WG
The main objective is a thorough description of the methods and techniques used to get sound knowledge out of data
linkage, sharing and management (i.e. semantic harmonisation, quality assurance) and reporting.
WP10 will liaise with eHealth JA in adopting and utilising standardisation and harmonisation methodologies to address
issues of semantic interoperability where such standards exist. Some inspirational examples may use datasets and
variables where such standards do not yet exist and will contribute to the development of such standards. WP10 will
also pay special attention to cooperation and communication with the upcoming Joint Action on e-Health, especially
their proposed work packages on innovative use of health data (WP5, WP9), enhancing continuity of care (WP6) and
implementation challenges (WP7).
WP10 will also contribute to tasks:
a) in WP4: adding insight to the technical and scientific description of a European Research Infrastructure Consortium
(ERIC) on Health Information;
b) in WP5: providing the EIF perspective to the mapping exercise on health information systems across Europe;
c) in WP6: providing insight on specific learning needs that should be present in an eventual capacity building
programme;
d) in WP7: contributing to the business case and implementation road map of an ERIC
e) in WP8: WP10 contents should feed WP8’s knowledge base.
f) Conversely, WP10 should be getting insight from WP9 with regard to the validation of indicators carried out as part
of WP9’s tasks.
Task 10.1. Mapping exercise: identification of inspirational experiences (Lead: CIPH)
The specific objective is to identify a number of ‘best practices’ in the MS participant countries. Inspirational (best
practice) experiences will be included according to the following criteria; the experience:
1. addresses the study of health status, health determinants, and/or health systems performance;
2. provides insight into surveillance and/or impact or effectiveness research;
Page 44 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
3. includes a variety of data sources (e.g. patient registries, population-based registries, surveys, electronic health or
medical records, administrative data) from different countries;
4. addresses data linkage, sharing, and management (quality assurance) activities;
5. produces outcomes reported to public health stakeholders, particularly policymakers.
Method: WP10 partners and contributors will be invited to identify experiences in their corresponding countries. Task
leaders will interview the person in charge of the experience to double-check whether or not the experience fits the
selection criteria. If this is the case, the contact person will respond to a self-administered survey meant to thoroughly
describe the experience.
Task 10.2. Mapping exercise: legal and organisational interoperability (Lead: CIPH)
For each experience that fits the criteria, we will analyse how legal and organisational interoperability was or is being
addressed. The exercise will also include the analysis of enablers and barriers linked to these two EIF domains. Outcomes
will be reported to public health stakeholders, particularly policymakers.
Method: Experiences’ leaders will respond to a survey that will be the basis for a semi-structured interview with the task
team. The results of this process will be debated with a focus group of international experts on legal and organisational
interoperability.
Task 10.3. Mapping exercise: semantic and technical interoperability (Lead: CIPH)
Each experience will be analysed to see how semantic and technical interoperability was or is being addressed. The
exercise will also include the analysis of enablers and barriers affecting these two EIF domains. Solutions that have
been successfully implemented in other infrastructures like research infrastructures, will be analysed.
Method: Experience leaders will respond to a survey that will be the basis for a semi-structured interview with the task
team. The results of this process will be debated with a focus group of international experts on semantic and technical
interoperability. A set of interoperable infrastructures in the domain of health and public health will be identified. The
solutions they have developed to address interoperability issues and deliver FAIR data while ensuring security and data
privacy will be analysed.
Task 10.4. Empirical case studies (Lead: IACS)
Contributors in WP10 will carry out empirical work on interoperability, data linkage, data sharing and data management
in a number of topics of interest for public health policymaking in Europe. The different case studies should provide
insight into the methods and techniques used to get sound and relevant outputs from different data sources in different
countries. Case studies will also provide insight into the enablers and barriers that influence interoperability achievement
and focus on identification of key issues in the application of the upcoming European General Data Protection
Regulation.
Method: Case study partners have ensured availability and access to a set of individual linkable data from heterogeneous
sources (e.g. electronic health records, hospital administrative data, health surveys, longitudinal cohort studies,
population-based disease registries); the linkage of such data by means of protocol-driven approaches (e.g. extracting
relevant fields, selecting records according to predefined inclusion or exclusion criteria); the implementation of
statistical codes developed elsewhere, and the transfer of intermediate outputs to a central node for outcomes reporting.
Participation per Partner
Partner number and short name WP10 effort
1 - Sciensano 3.00
4 - CIPH 61.00
9 - SpFrance 0.00
INSERM 9.00
13 - ISS 8.50
14 - CDPC 5.50
20 - HD 5.00
Page 45 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Partner number and short name WP10 effort
22 - MS 0.35
UNL 0.50
25 - NIJZ 2.80
26 - ISCIII 0.00
IACS 34.50
28 - WG 0.00
SU 9.00
Total 139.15
List of deliverables
Due
Deliverable
Deliverable Title Lead beneficiary Type 15
Dissemination level 16 Date (in
Number14
months)17
Report: interoperability
D10.1 4 - CIPH Report Public 30
landscape in Europe
Technical report:
D10.2 interoperability 26 - ISCIII Report Public 36
implementation
Description of deliverables
D10.1. Report: interoperability landscape in Europe: The report will contain a description of the experiences as well
as the enablers and barriers, recommendations on good regulatory and organisational practices, identification of
key issues in the application of the upcoming European General Data Protection Regulation, inventory of technical
solutions and recommendations on federated data sharing and analysis.
D10.2. Technical report: interoperability implementation: This report aims at providing insight to WP4 and WP7 with
focus on “getting interoperability sustainably implemented” in an eventual sustainable European structure on Health
Information.
D10.1 : Report: interoperability landscape in Europe [30]
The report will contain a description of the experiences as well as the enablers and barriers, recommendations on
good regulatory and organisational practices, identification of key issues in the application of the upcoming European
General Data Protection Regulation, inventory of technical solutions and recommendations on federated data sharing
and analysis.
D10.2 : Technical report: interoperability implementation [36]
This report aims at providing insight to WP4 and WP7 with focus on “getting interoperability sustainably
implemented” in an eventual sustainable European structure on Health Information.
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Report on mapping exercise:
MS35 identification of inspirational 4 - CIPH 12 Report
experiences
Page 46 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Schedule of relevant Milestones
Due
Milestone
Milestone title Lead beneficiary Date (in Means of verification
number18
months)
Report on mapping exercise:
MS36 legal and organisational 4 - CIPH 18 Report
interoperability
Report on mapping exercise:
MS37 semantic and technical 4 - CIPH 18 Report
interoperability
MS38 Empirical case studies 26 - ISCIII 36 Report
Page 47 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
1.3.4. WT4 List of milestones
Due
Milestone WP
Milestone title Lead beneficiary Date (in Means of verification
number18 number9
months)17
MS1 Kick-off meeting WP1 1 - Sciensano 1 Report of the kick-off
Coordination meetings
with the WP leaders
Minutes of meetings: M1, 6,
MS2 and co-leaders WP1 1 - Sciensano 36
12, 18, 24, 30, 36
(Steering Committee
meetings)
Mid-term and final Interim report and final
MS3 WP1 1 - Sciensano 36
review delivered at month 18, 36
MS4 Mid-term Assembly WP1 1 - Sciensano 18 Report of the meeting
MS5 Final Conference WP1 1 - Sciensano 36 Report
MS6 Dissemination plan WP2 1 - Sciensano 3 Dissemination plan
Update dissemination
MS7 WP2 1 - Sciensano 24 Updated dissemination plan
plan
Scientific/policy
MS8 conference EPH WP2 1 - Sciensano 36 Conference report (abstracts)
2018-2019-2020
European Health
MS9 WP2 2 - GÖG 36 Conference report (abstracts)
Forum 2019
Agreement with
MS10 WP3 26 - ISCIII 10 Subcontracts are signed
subcontracts
First interim internal
Report is distributed to
MS11 and external evaluation WP3 15 - HI 13
partners
report
Second interim internal
Report is distributed to
MS12 and external evaluation WP3 15 - HI 25
partners
report
Final interim internal
Report is published including
MS13 and external evaluation WP3 15 - HI 36
both interim reports
report
Strategic Board National
MS14 Assembly of Members WP4 26 - ISCIII 3
representatives are appointed
Review and analysis of
MS15 implementation from WP4 26 - ISCIII 32 Meeting reports
other WPs by AoM
Policy dialogues with
key stakeholders Reports of 2 AoMs and 3
MS16 WP4 26 - ISCIII 30
at the national and workshops
international level
MS17 Sustainability Plan WP4 26 - ISCIII 32 Approval by AoM
HI system peer Report circulated only to
MS18 assessment country WP5 17 - MFH 28 concerned MSs and CHAFEA
reports project officer
Page 48 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Due
Milestone WP
Milestone title Lead beneficiary Date (in Means of verification
number18 number9
months)17
Review of pilot HI
system peer assessment
experience including
MS19 WP5 17 - MFH 32 Report presented on website
scientific publication
and manual for peer
assessment
Method development
MS20 WP5 10 - RKI 12 Report presented on website
for prioritisation
Mapping of Health
Information education/
MS21 WP6 22 - MS 18 Task 6.1 completed
training programmes
and needs
Flagship capacity build
MS22 WP6 22 - MS 24 Tasks 6.2 completed
programme
Guidelines for national
Guidelines and criteria are
MS23 consortia and domain- WP7 1 - Sciensano 18
described
specific nodes
Operational plan with
5-year operational plan
MS24 WP7 1 - Sciensano 30 workplan, timeline, and
HIREP-ERIC
means
Memorandum of
MS25 understanding HIREP- WP7 1 - Sciensano 18 Number of MSs have signed
ERIC
Specifications (content,
Business structure web structure, functions,
MS26 WP7 1 - Sciensano 18
platform reporting) of web platform are
defined
Questionnaires for
MSs regarding data
MS27 WP8 13 - ISS 10 Report on survey results
collection methods and
procedures
Research/desk work
Research/desk work on
on review of data
MS28 WP8 13 - ISS 24 review of data collection
collection methods and
methods and procedures
procedures
Research / desk work
Publication of report on
MS29 on health reporting in WP8 10 - RKI 24
website
MSs
ECHI documentation,
Present on website; report +
MS30 format, technical and WP8 19 - RIVM 32
expert meeting
content update
MS31 3 workshops on BoD WP9 28 - WG 15 Workshop reports
MS32 EuroPeristat Meeting WP9 9 - SpFrance 6 Meeting report
Health system
MS33 performance expert WP9 9 - SpFrance 6 Meeting report
workshop
Page 49 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Due
Milestone WP
Milestone title Lead beneficiary Date (in Means of verification
number18 number9
months)17
MS34 EHLEIS meeting WP9 1 - Sciensano 30 Meeting report
Report on mapping
exercise: identification
MS35 WP10 4 - CIPH 12 Report
of inspirational
experiences
Report on mapping
exercise: legal
MS36 WP10 4 - CIPH 18 Report
and organisational
interoperability
Report on mapping
exercise: semantic
MS37 WP10 4 - CIPH 18 Report
and technical
interoperability
MS38 Empirical case studies WP10 26 - ISCIII 36 Report
Page 50 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
1.3.5. WT5 Critical Implementation risks and mitigation actions
Risk
Description of risk WP Number Proposed risk-mitigation measures
number
The lead organisation has to provide qualified
Departure of key staff in the substitutes. The lead organisation involves, next to
1 coordination team (WP1, 2, WP1, WP2, WP7 the core team that runs the project, 7 researchers,
7) of the lead organisation 4 of which are senior with 2 of them heads of
research units.
The Coordination will have a detailed mailing list
The various partners may of the partners of InfAct with various contacting
not respond timely to the possibilities e.g. email, phone, mobile phones,
2 WP1
communication of the Skype etc. The deadlines will be given in
coordination team advance and a possible delay in responses will be
anticipated.
WP1, WP10, WP2, For each of the WPs, a co-lead is identified. The
WP leader is not able to
3 WP3, WP4, WP5, WP6, co-lead is also participant in the SC so that the co-
continue the task
WP7, WP8, WP9 lead can ensure direct continuity of the task.
Two of the Affiliated Entities
are located in the United The tasks allocated to the Affiliated Entities may
Kingdom. Due to Brexit the be taken over by another Associated Partner.
4 WP9
Associated Partner may not This risk can be identified and discussed with the
be able to carry out their task partners in an early stage.
until the end of the project
Regular reports will be gathered by the
coordination team to monitor financial
Beneficiaries will not adhere WP1, WP10, WP2,
expenditure and propose redistribution of budgets
5 to planned budget and will WP3, WP4, WP5, WP6,
if necessary. Bilateral communication will be held
under- or overspend WP7, WP8, WP9
between the coordination team and individual
partners regarding expenditure.
Deliverables will be tracked by each WP Leader
and by the Coordination Team, who will discuss
Beneficiaries will not fulfill
the status of all planned deliverables in the
their planned obligations, WP1, WP10, WP2,
reporting period at SC meetings. 1 month prior to
6 will not deliver planned WP3, WP4, WP5, WP6,
the delivery of the deliverable the Coordination
outputs, or will do so with WP7, WP8, WP9
Team will be in touch with the WP about the
significant delay
status, helping to find solutions if a delay is
expected.
The questionnaires will be composed to be user-
Low response to
7 WP3, WP8 friendly and short, reminders may help to increase
questionnaires
response rates.
1. During the preparation of the JA, this was
InfAct is a very complex and
discussed and transversal links between WPs will
large consortium of people
be proposed during the kick-off meeting. Through
working in HI but different
WP1, WP10, WP2, the links, the working in clusters will ensure the
domains. This may hamper
8 WP3, WP4, WP5, WP6, coherence and strengthen the logical build-up of
the collaboration and may
WP7, WP8, WP9 the WPs. 2. The CA describes the roles and ways
have an effect on the timely
of interaction between the partners to tackle issues
delivery of milestones and
that have a negative impact on the functioning and
deliverables.
outcomes of the JA.
Lack of consensus between 1. The JA and especially its coordination team
9 MSs on the realisation of WP4, WP7 have to invest in consensus building. These
the main aim of the JA: the investments include: a) specific tasks in WP4
Page 51 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Risk
Description of risk WP Number Proposed risk-mitigation measures
number
and 7 b) the governance structure of the JA,
which specifically mentions the interaction with
the EGHI and the EGHSPA c) interaction with
EU services and international organisations 2.
preparation of a sustainable
Business cases will balance the arguments pro
structure.
and contra the ERIC, including the feasibility
of alternative options 3. The outcome and
deliverables are generic and independent of policy
options for a sustainable structure
A peer–review will be
organised in the WP on If one partner does not carry out the peer-review
evaluation. The peer-review another partner may be involved. The peer-
10 WP3
may be of low quality and reviews may be discussed during the Steering
the responses may be low or Committee to assure good quality.
delayed.
Page 52 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
1.3.6. WT6 Summary of project effort in person-months
Total Person/Months
WP1 WP2 WP3 WP4 WP5 WP6 WP7 WP8 WP9 WP10
per Participant
1 - Sciensano 36 6 5.40 7 13 2 50 2 4 3 128.40
2 - GÖG 1.46 4.50 0 2 3.50 0 0 0 3 0 14.46
3 - MCA 0.50 0 0 0 0 0 0 0 0 0 0.50
4 - CIPH 1.50 1 0 0 0.50 7 1 0 1 61 73
5 - MoHCy 0.50 0 0 0 2 0 0 1.90 0 0 4.40
6 - UZIS 0.50 0 0 0 0 0 1 4.50 2 0 8
7 - MoSA 0 0 0 0 0 0 0 0 0 0 0
· NIHD 0.50 0 0 0 2.20 0 0 0.50 0 0 3.20
8 - THL 1.50 0 0 0 1 19.03 3.10 10.50 0 0 35.13
9 - SpFrance 0.50 0 0 0.95 0 0 1.05 0 43.15 0 45.65
· INSERM 0.50 0 0 0 0 0 5.45 3.50 9.55 9 28
· IRDES 0.50 0 0 0 0 0 0 0 7.75 0 8.25
· MoH FR 0.50 0 0 6.05 0 0 1.50 0 0.95 0 9
10 - RKI 1.50 0 0 0 30.90 0 6 9.40 1 0 48.80
11 - EOPYY 0.47 0 0 0 0 1 1.50 1.50 0 0 4.47
12 - DOH 0.50 0 0 0 0 0 0 2.20 1.30 0 4
· HRB 0 0 0 0 0 1 0 0 0 0 1
13 - ISS 1.50 0 0 2 2 3.50 3 60 5 8.50 85.50
14 - CDPC 0.50 0 0 0 6 3 4 8 8 5.50 35
15 - HI 1.50 3 5 0 18.80 0 1 0 12 0 41.30
16 - MOHLUX 0.50 0 0 0 0 0 0 0 0 0 0.50
17 - MFH 1.45 0 0 0 3 0 1 0.80 1 0 7.25
18 - SMPHU 0.50 0 0 0 4 0 0 0 0 0 4.50
Page 53 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Total Person/Months
WP1 WP2 WP3 WP4 WP5 WP6 WP7 WP8 WP9 WP10
per Participant
19 - RIVM 1.50 0 0 0.40 11.20 0.80 10 11.20 2 0 37.10
20 - HD 0.50 0 0 0 5 0 0 4 4 5 18.50
21 - MZ 0 0 0 0 0 0 0 0 0 0 0
· NIPH 0.50 0 0 0 0 0 1 3.50 0 0 5
22 - MS 0.50 0 0 0 0 20 0 0 0.35 0.35 21.20
· INSA 0.50 0 0 0 0 10 0 0 1.50 0 12
· UNL 0.50 0 0 0 0 30 0 0 0 0.50 31
23 - INSP 0.50 0 2.50 0 4 8.42 0 0 2 0 17.42
24 - IPHS 0.50 0 0 0 2 4 1 1.50 0 0 9
25 - NIJZ 1.45 0 0 0 0 3 0 6 5 2.80 18.25
26 - ISCIII 1.50 2 0 72 4 3 3 1.50 6 0 93
· FCSAI 0 0 0 0 0 0 0 0 0 0 0
· IACS 1.50 0 1.50 0 0 0 3 0 0 34.50 40.50
27 - FoHM 0.50 0 0 0 0 0 0.60 0.60 1.55 0 3.25
28 - WG 0.50 0 0 0 0 0 1.40 0 0 0 1.90
· SU 0.50 0 0 2 3 0 0.60 5.20 7.50 9 27.80
· PHE 0 0 0 0 0 0 0 0 7.50 0 7.50
Total Person/Months 63.83 16.50 14.40 92.40 116.10 115.75 100.20 138.30 137.10 139.15 933.73
Page 54 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
1.3.7. WT7 Tentative schedule of project reviews
No project reviews indicated
Page 55 of 55
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
1. Project number
The project number has been assigned by the Commission as the unique identifier for your project. It cannot be
changed. The project number should appear on each page of the grant agreement preparation documents (part A
and part B) to prevent errors during its handling.
2. Project acronym
Use the project acronym as given in the submitted proposal. It can generally not be changed. The same acronym should
appear on each page of the grant agreement preparation documents (part A and part B) to prevent errors during its
handling.
3. Project title
Use the title (preferably no longer than 200 characters) as indicated in the submitted proposal. Minor corrections are
possible if agreed during the preparation of the grant agreement.
4. Starting date
Unless a specific (fixed) starting date is duly justified and agreed upon during the preparation of the Grant Agreement,
the project will start on the first day of the month following the entry into force of the Grant Agreement (NB : entry into
force = signature by the Commission). Please note that if a fixed starting date is used, you will be required to provide a
written justification.
5. Duration
Insert the duration of the project in full months.
6. Call (part) identifier
The Call (part) identifier is the reference number given in the call or part of the call you were addressing, as indicated
in the publication of the call in the Official Journal of the European Union. You have to use the identifier given by the
Commission in the letter inviting to prepare the grant agreement.
7. Abstract
8. Project Entry Month
The month at which the participant joined the consortium, month 1 marking the start date of the project, and all other start
dates being relative to this start date.
9. Work Package number
Work package number: WP1, WP2, WP3, ..., WPn
10. Lead beneficiary
This must be one of the beneficiaries in the grant (not a third party) - Number of the beneficiary leading the work in this
work package
11. Person-months per work package
The total number of person-months allocated to each work package.
12. Start month
Relative start date for the work in the specific work packages, month 1 marking the start date of the project, and all other
start dates being relative to this start date.
13. End month
Relative end date, month 1 marking the start date of the project, and all end dates being relative to this start date.
14. Deliverable number
Deliverable numbers: D1 - Dn
15. Type
Please indicate the type of the deliverable using one of the following codes:
R Document, report
DEM Demonstrator, pilot, prototype
DEC Websites, patent fillings, videos, etc.
OTHER
ETHICS Ethics requirement
ORDP Open Research Data Pilot
16. Dissemination level
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Please indicate the dissemination level using one of the following codes:
PU Public
CO Confidential, only for members of the consortium (including the Commission Services)
EU-RES Classified Information: RESTREINT UE (Commission Decision 2005/444/EC)
EU-CON Classified Information: CONFIDENTIEL UE (Commission Decision 2005/444/EC)
EU-SEC Classified Information: SECRET UE (Commission Decision 2005/444/EC)
17. Delivery date for Deliverable
Month in which the deliverables will be available, month 1 marking the start date of the project, and all delivery dates
being relative to this start date.
18. Milestone number
Milestone number:MS1, MS2, ..., MSn
19. Review number
Review number: RV1, RV2, ..., RVn
20. Installation Number
Number progressively the installations of a same infrastructure. An installation is a part of an infrastructure that could be
used independently from the rest.
21. Installation country
Code of the country where the installation is located or IO if the access provider (the beneficiary or linked third party) is
an international organization, an ERIC or a similar legal entity.
22. Type of access
VA if virtual access,
TA-uc if trans-national access with access costs declared on the basis of unit cost,
TA-ac if trans-national access with access costs declared as actual costs, and
TA-cb if trans-national access with access costs declared as a combination of actual costs and costs on the basis of
unit cost.
23. Access costs
Cost of the access provided under the project. For virtual access fill only the second column. For trans-national access
fill one of the two columns or both according to the way access costs are declared. Trans-national access costs on the
basis of unit cost will result from the unit cost by the quantity of access to be provided.
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
HISTORY OF CHANGES
05/06/2018
List of changes Text location
The detailed budget of beneficiary MCA (3) has been corrected. Section 9.2
28/05/2018
List of changes Text location
The Affiliated Entity PHI FBiH, affiliated to beneficiary MCA (3) has not yet been
validated in the Participant Portal. In order to avoid any further delay, it has been
Section 8.2, 9.2,
decided to incorporate PHI FBiH as a Collaborating Stakeholder instead of an
13
Affiliated Entity and to shift the foreseen budget to MCA. The necessary sections of
Part B were changed according to these shifts.
23/04/2018
List of changes Text location
Numbering of milestones adapted Section 7.1.
12/04/2018
List of changes Text location
The beneficiary Institut Scientifique de Sante Publique, WIV-ISP (IPH), from
Section 7.1.,
Belgium changed names. It became Sciensano. All references to the institute have
8.2., 8.4, 9.2.
been changed.
27/02/2018
List of changes Text location
As there are inconsistencies between the Consortium Agreement, the Grant
Agreement and Annex I part B of the Grant Agreement, we have chosen to limit the
Section 8.1.
details concerning the governance structure and management bodies in this
document.
Monthly costs were corrected in the detailed budget section plus correction of other
calculation errors, such as subtotals not adding up. Section 9.2.
Rounding has to be taken into account.
Person-months have been aligned between part A and part B (numbers were rounded
Section 9.2.
to one decimal in the previous version of part A).
Details added on the travel costs for partners GÖG, RKI, MFH, RIVM, NIJZ. Section 9.2.
Details added on other goods and services for partners GÖG, SMPHU. Section 9.2.
Cost of financial officer of CIPH has been eliminated. Section 9.2.
As a reply to the question for clarification by CHAFEA, we would like to confirm Section 9.2.
[801553] [InfAct] – Part B – Page 1 / 67 Document Version 3.00 dated 23/02/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
List of changes Text location
that MOHLUX will be involved for 0.5 PM, but without any budgetary means (in-
kind contribution free of charge). The same goes for affiliated entity MoH FR, who
will be involved for 9 PM.
As partner DOH does no longer participate in WP5, their budget has been corrected.
The budget has been shifted to WP1, to cover a correction in the monthly cost for Section 9.2.
the project officer.
FCSAI has been added as Affiliated Entity To ISCIII (Beneficiary 26). The original
Section 9.2.
budget of ISCIII has been redistributed between ISCIII and FCSAI.
A justification for the “total estimated eligible cost” equal to €0.00 has been added
Section 9.2.
for Beneficaries MoSA and MZ.
Collaborating stakeholder added: Platform for Better Oral Health in Europe Section 13.
21/12/2017
List of changes Text location
A timing was added for when the memorandum of understanding needs to be signed
Section 2.2.
and the number of MSs was changed.
A figure with the framework on the interaction of the WPs was added. Section 5.
Slight changes were made in the wording of the description of WP 4 and 6. WP6
Section 7.1.
focusses more on reducing health information inequalities.
More attention was given to the aspect of coherence between the different WPs.
Each WP added a sentence on how they interact with the other WPs.
Special attention was given to this in WP1 and WP4:
In WP1, teleconferences are organized between face-to-face SCMs. In these
meetings coherence between the WPs will be fostered and interlinkage between the Section 7.2.
WPs will be an agenda point for discussion. Especially during the kick-off meeting
attention will be given to this topic.
WP4 will closely work together with other WPs and fosters coherence by finding
common pathways for sustainability.
WP1: an objective was added in the description of WP1. A deliverable was added: Section 7.2, 7.3,
D1.1 Conceptual framework and vision to be delivered by month 3. 8.
WP2: In collaboration with WP7 the National Consortia will be stimulated to
disseminate the fact sheets and to provide information on InfAct on their national Section 7.2.
website. The translation of these factsheets in national languages will be promoted.
The whole WP3 was rewritten. An external and impact assessment was added. The
lead of WP3 lead was changed from NKUA (Greece) to HI (Lithuania). The
Section 7.2, 7.3,
following were added: INSP (Romania) as task leader and IACS (Spain) as task
8.
leader. EUPHA and ASPHER were involved in the external evaluation process. The
deliverables were adjusted accordingly.
WP4: The description of the WP4 was altered to be clearer. More details were given
on the meetings and workshops. The sustainability plan was altered to address Section 7.2, 7.3,
aspects beyond monitoring of sustainability. Deliverable 4.5 was adjusted 8 and 10.3.
accordingly.
WP5.1: More focus was given to address health information inequalities by trying to
Section 7.2, 7.3,
involve less advanced countries. In WP5.3 more details were given on how to
and 8
involve all MS. Deliverable 5.2 will also be done on month 22.
[801553] [InfAct] – Part B – Page 2 / 67 Document Version 3.00 dated 23/02/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
List of changes Text location
WP6: More focus was put on addressing health information inequalities and
emphasis was put on the sustainability of the task. The following aspects were added
to deliverable 6.1: Identification of the most significant and relevant health Section 7.2, 7.3,
information inequalities among MS. A detailed knowledge of existing health and 8
information systems and their capacity to respond to community requirements.
Deliverable 6.4 was also adjusted.
WP7 also contributes to the dissemination of the activities in InfAct by supporting
the National Consortia to publish the results on their national website and translate Section 7.2.
them.
WP8: RIVM was added as co-lead of the WP. Deliverable 8.2 was corrected in the
Section 7.2, 7.3,
description. The wrong description was put in the table. The month of delivery of
and 8
milestone 8.4 was changed to 22 and 32.
WP9: Detailed description of the meetings and workshops were added which will
Section 7.2, 7.3,
focus on providing support to less advanced countries. Milestone 9.2 changed to
and 8
month 6 and a milestone was added (Milestone 9.3).
WP10 description was made more extensive to include the methodology. WP10 will
Section 7.2.
liaise with eHealth JA.
The capacity of the staff was completely rewritten to explain the expertise within the
Section 9.2.
different countries participating in InfAct.
More external and internal risks were added to the analysis and contingency plan. Section 9.3.
To address the comments of CHAFEA, more support was given to less advanced
countries, the budget of evaluation was reduced and the budget for the coordination
and road map development was increased. The budget of the following countries Section 9.4,
was increased: Belgium, Latvia, Lithuania, Portugal, Romania, Serbia and Spain. 10.1, 10.2, 10.3
The budget of the following countries was decreased: Austria, Finland, France, and 13.
Germany, Greece (removed as WP3 leader), Italy, Netherlands, United Kingdom.
The person-months were changed accordingly.
[801553] [InfAct] – Part B – Page 3 / 67 Document Version 3.00 dated 23/02/2018
TABLE OF CONTENTS Associated with document Ref. Ares(2018)3121156 - 13/06/2018
HISTORY OF CHANGES ........................................................................................................................... 1
TABLE OF CONTENTS .............................................................................................................................. 4
1. PROBLEM ANALYSIS INCLUDING EVIDENCE BASE .................................................................. 5
2. AIMS AND OBJECTIVES OF THE PROJECT ................................................................................... 5
2.1. General objective of the project ............................................................................................................... 5
2.2. Specific objective(s) of the project ........................................................................................................... 6
3. TARGET GROUPS .................................................................................................................................. 8
4. POLITICAL RELEVANCE .................................................................................................................... 8
4.1. Contribution to meeting the objectives and priorities defined in the annual work programme ................ 8
4.2. Added value at EU level in the field of public health ............................................................................... 8
4.3. Pertinence of geographical coverage ........................................................................................................ 8
4.4. Consideration of the social, cultural and political context........................................................................ 8
5. METHODS AND MEANS ....................................................................................................................... 9
6. EXPECTED OUTCOMES ..................................................................................................................... 10
7. WORK PACKAGES ............................................................................................................................... 11
7.1. Timetable (in months) ............................................................................................................................ 11
8. PROJECT MANAGEMENT STRUCTURE ........................................................................................ 15
8.1. Quality of the partnership ....................................................................................................................... 15
8.2. Capacity of the staff ............................................................................................................................... 17
8.3. External and internal risk analysis and contingency planning ................................................................ 23
8.4. Financial management ............................................................................................................................ 24
9. BUDGET .................................................................................................................................................. 24
9.1. Content description and justification ...................................................................................................... 24
9.2. Detailed budget ...................................................................................................................................... 26
10. PREVIOUS AND CURRENT GRANTS RELEVANT TO THE PROGRAMME (LIMITED TO THE
LAST 3 YEARS) ................................................................................................................................ 66
11. CURRENT APPLICATIONS RELEVANT TO THE PROGRAMME........................................... 66
12. EXCEPTIONAL UTILITY .................................................................................................................. 67
13. COLLABORATING STAKEHOLDERS ........................................................................................... 67
[801553] [InfAct] – Part B – Page 4 / 67 Document Version 3.00 dated 23/02/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
1. PROBLEM ANALYSIS INCLUDING EVIDENCE BASE
For almost a quarter of a century now, there have been discussions on the need for an improved EU health
information (HI) system. Different HI programmes were organised in a vertical way and resulted in a fragmented
and project-based EU HI system. The EU HI system lacks sustainability, coherence and comprehensiveness which
leaves us without an EU-wide public health monitoring or health system performance analysis system that presents
policy-oriented evidence and advice. The ad hoc project approach hampers research continuity with loss in
knowledge, expertise, less robust data collection mechanisms, reduced, fragmented and disappearing research
capacity and frail research networks as a consequence. Strong research needs permanent and efficient data
collection. There is still a huge area in which no high-quality EU HI system exists, containing non-communicable
diseases, even though chronic diseases are the main cause of death and poor quality of life in Europe. Large
differences are found in terms of quality and, as a consequence, comparability of HI between and within Member
States (MS)1. This makes it difficult to learn from each other and challenges the equity in health as poor HI and
poor health tend to coincide. If a country or a group of countries have developed good practices, mechanisms are
lacking to disseminate these into EU-wide actions.
These observations contrast the statements that policymaking and decision-making processes should be evidence-
based and supported by adequate HI systems. The best scientific evidence derived from sound data and relevant
research is a prerequisite not only for the development of relevant public health strategies and policies and the
assurance of adequate health service but also for input for social and economic policies and developments. For EU
MS, strengthening the EU HI systems would (1) enhance coherence and sustainability; (2) allow data
harmonisation, collection, processing and reporting; (3) allow for comparison and benchmarking; (4) increase
knowledge sharing and capacity building and (5) strengthen the transferability of HI and evidence-based
policymaking.
The BRIDGE Health project concluded that the creation of a European Research Infrastructure Consortium (ERIC)
to collect, process, analyse, report and communicate HI is at this moment a feasible option to overcome a large
number of the above-mentioned obstacles and to facilitate the governance of HI activities in the EU in a way that
best supports evidence-based health policies and investments in research. The ERIC on Health Information for
Research and Evidence-based Policy (HIREP-ERIC) will:
- coordinate health data harmonisation, collection and analysis according to health policy priorities
- facilitate research on population health and health system performance and provide technical support to
MSs on indicators and inference; and
- effectively support policy- and decision-making and strengthen programme action in a sustainable way
with the overall aim of improving individual and public health.
2. AIMS AND OBJECTIVES OF THE PROJECT
2.1. General objective of the project
The overall aim of the JA on Health Information (InfAct (Information for Action)) is to create a sustainable
solid infrastructure on EU HI through improving the availability of comparable, robust and policy-relevant data for
health status, health determinants, and health system performance (HSPA). Through country collaboration, the JA
streamlines HI activities, reduces the data collection burden and works for a sustainable and robust data collection
in Europe that facilitates and supports country knowledge, health research and policymaking.
To achieve the overall aim, InfAct focuses on:
- development of the business case and road map for implementation of the HIREP-ERIC (ERIC on Health
Information for Research and Evidence-based Policy) (Work Package (WP) 7), including governance
structures and national HI consortia and domain-specific HI research networks
- a holistic HI system to better understand the dynamics of population health, the performance of the health
systems, and the interaction and impact of health on societal pillars such as the social and economic
development
- assessment of HI systems in MSs and regions through peer review by MSs (WP5)
- priority setting in HI development (WP5)
1
When referring to Member States in this document all participating countries and regions in this Joint Action are included.
[801553] [InfAct] – Part B – Page 5 / 67 Document Version 3.00 dated 23/02/2018
- development of a road map for training in HI of professionalsAssociated
workingwith in
document Ref.
HI with theAres(2018)3121156 - 13/06/2018
objective to tackle HI
inequality within Member States and throughout Europe (WP6)
- methods for implementation of high standard HI instruments, tools and methodologies (WP8)
- strengthening the efficiency of the HI system for public health policy and research through new ways of
using health and non-health data sources, and composite health indicators (WP9), and through use of new
technologies in HI (WP10)
- the introduction of the interoperability of health data instruments and sources (WP10)
- the translation of HI into public policy (WP4)
- mutual learning of MSs through exchange of best practices (WP5-10)
The JA watches over the sustainability of all actions taken by the JA (WP4). A good communication strategy,
coordination, dialogue and interaction with the European Commission (EC) Expert Group on Health Information
(EGHI) and the Expert Group on Health System Performance Analysis (EGHSPA), with Eurostat, DG Research
and other relevant DGs, and with international organisations (WHO, OECD, European Observatory on Health
Systems and Policies, IANPHI) further reinforce the sustainability of the JA’s work and outcomes (WP1, 2).
2.2. Specific objective(s) of the project
Specific Objective SO1
Number
Specific Objective To prepare MSs for the start of the HIREP-ERIC (ERIC on Health Information for
Research and Evidence-based Policy)
Process Indicator(s) Target
MSs contribute to overviews and assessments of their HI systems, of their 100% of the participating MSs
participation in international HI activities and data collecting networks provide information
and develop criteria and procedures to define common HI priorities (WP5,
7). Good practice examples are identified
The business case and road map including 5-year workplan scenarios for a The EAB and AoM analyse and
sustainable HIREP-ERIC are developed and put forward to the MSs discuss the business case and road
through the External Advisory Board (EAB) and the Assembly of map and amend it to come to a
Members (AoM) (WP4, 7) consensus
Output Indicator(s) Target
A catalogue of international HI consortia/networks that collect 100% of the documents are released
comparable health data and information with an overview of the as scheduled
participation of MSs and with relevant achievements (reports, articles,
other) (by month 22)
Memorandum of understanding (MoU) between several MSs to start up a The MoU is sent out as scheduled
HIREP-ERIC (including the submission of a proposal for the ESFRI-road
map (by month 18))
Outcome/Impact Indicator(s) Target
HI consortia/networks to support a future ERIC are set up within MS All MSs interested in participation
in an ERIC have set up HI
consortia/networks.
MoU is signed by the second Assembly of Members A necessary core set of 10 MSs
sign the MoU and proceed towards
the ERIC
[801553] [InfAct] – Part B – Page 6 / 67 Document Version 3.00 dated 23/02/2018
Specific Objective SO2 Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Number
Specific Objective To reduce the health information inequality between and within EU MS
Process Indicator(s) Target
In the framework of mutual learning, MSs initiate a peer review process At least 6 MSs participate in 2
of their HI systems to identify in a standardised way the strengths and pilots of a circle of peer reviews
limitations and suggestions for improvement (WP5)
A road map for a HI training programme is developed focusing on The EAB, AoM and all WPs
international HI aspects for professionals working in HI within MS analyse and discuss the road map
institutions. The road map is put forward to the MSs through the EAB and and amend it to come to a
the AoM (WP5, 6, 9) consensus
Learning through good practice case studies in relation to standardisation 100% of the WPs analyse the
and data quality methodologies, new methods of data gathering, analysis information and agree on
and interoperability of e-health sources (WP8, 9, 10) conclusions and recommendations
Output Indicator(s) Target
A set of documents describing the HI system peer review process, the 100% of the policy briefs and
evaluation of peer review tools, and lessons learned through the periodical documents are released as
review assessment both as assessor and as assessed (by months 28, 32) scheduled
A set of documents describing the training needs based on the current 100% of the documents and policy
capacity in MSs and supporting the framework and road map on HI briefs are released as scheduled
training (by month 12, 18, 30)
Outcome/Impact Indicator(s) Target
MSs take ownership of the review process 75% of the MSs in the JA
participate in the meeting organised
to present the peer review process
methodology and results
Pilot of training and workshops are organised in different domains (a.o. At least one third of the MSs in the
peer review of HI systems, composite health indicators and HSPA) JA participate in each of the
training pilots
Specific Objective SO3
Number
Specific Objective To develop a strategy promoting the implementation of the HIREP-ERIC strategy in
participating MS, including awareness and encouraging advocacy among stakeholders
(especially policy- and decision-makers, stakeholders in health research and public
health, and international organisations).
Process Indicator(s) Target
Identification by month 4 of key institutions at national, regional, EU and An interactive community is set up
international level (such as EHII (WHO-Europe), IANPHI, JRC, OECD) and the HIREP-ERIC is introduced
able to contribute to the promotion of the HIREP strategy and setup of an
interactive forum/e-community
Output Indicator(s) Target
The audience in the forum/e-community actively participates in the 75% of the participants give
debates and gives pertinent feedback to tailor the contents of the HIREP feedback on the consensus
network consensus documents to the needs of both research and policy document of the HIREP-ERIC
development
[801553] [InfAct] – Part B – Page 7 / 67 Document Version 3.00 dated 23/02/2018
Outcome/Impact Indicator(s) Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Target
The initial advocacy and awareness strategy promoting the HIREP-ERIC The action plan of the advocacy
in MSs is designed by month 4 and a final version fully implemented by and awareness strategy is
month 30 implemented as scheduled
3. TARGET GROUPS
InfAct targets different audiences. However, given the overall aim of InfAct, the target groups are first of all the
Ministries of Health and the Ministries of Research within the MS. They will be invited through WP4 to participate
in the AoM and support through a MoU (WP7) the initiation of the HIREP-ERIC.
More general, as InfAct contributes to better access to existing knowledge and expertise the target groups are:
- Decision-makers: qualitative information for evidence-based decisions in health and in the domains
affecting health and affected by health, health (-related) research, international comparison and learning
through exchange, priority-setting;
- National public health agencies and health statistics offices: EU-comparative data, higher data quality,
better information to support policy continuity over long periods, larger study populations and cohorts,
enhanced data access and research capacity
- Healthcare providers: data to set standards; benchmarking;
- Researchers: facilitate access to high quality EU-comparative data;
- Citizens: improved health and wellbeing, patient’s outcomes and experiences, reduction of inequality;
- Administrators and data providers: reduction of administrative burden by harmonisation and reduction of
duplication, improved training capacities;
- Financiers: better return on investment from research and routine data systems, optimised fund allocations.
4. POLITICAL RELEVANCE
4.1. Contribution to meeting the objectives and priorities defined in the annual work programme
This JA responds to thematic priority 3.7 of annex I to the 3rd Health Programme for the European Union’s actions
in the field of health 2014-2020 (“Foster a health information and knowledge system to contribute to evidence-
based decision-making”). The objectives of the JA are in accordance with the objectives of the Work Programme
2017 under point 2.2.3.2 Joint Action on Health Information towards a sustainable EU health information system
that supports country knowledge, health research and policymaking.
4.2. Added value at EU level in the field of public health
The JA will improve the availability of comparable, robust and policy-relevant health data and information by (1)
providing tools and methods for HI support through innovation in HI for public health policy development, and (2)
by assessing and piloting interoperability for public health policy. Additionally, the JA will work towards the setup
of a sustainable infrastructure on HI. It will reduce HI inequalities by strengthening countries’ capacities and
enhancing HI priority setting methodologies and practices.
4.3. Pertinence of geographical coverage
The JA ensures pertinent and meaningful geographical coverage. Bringing together 40 partners from 28 countries,
this JA involves a wide diversity of countries and regions with very different health (information) systems, diverse
health policies and different cultural, social and economic backgrounds. In addition, some MSs that are not enlisted
as applicants, participate as collaborating stakeholders as well as international agencies (see table Collaborative
Stakeholders; chapter 14).
4.4. Consideration of the social, cultural and political context
Health is a priority for EU citizens. All are expecting to reach old age in good health and to be able to use high-
quality health services. The EU citizens have the right to access correct, comparable and robust HI related to their
[801553] [InfAct] – Part B – Page 8 / 67 Document Version 3.00 dated 23/02/2018
direct environment, region, country or other countries in Europe. Associated with document
To make Ref. of
the most Ares(2018)3121156
health spending- 13/06/2018
and
investments at EU and Member State level, health policy- and decision-making must be based on robust evidence
in the form of high-quality and timely data on population health and health systems and thorough research
outcomes. The MSs participating in InfAct are working towards a sustainable HI system emphasising the need for a
sustainable structure with standardised data collection, strong analytic capacity and supporting both MS’ and EU’s
needs to bring HI into action and into policy. InfAct is an essential key to evidence-based decision-making and
contributes as such to transparency, a priority of the EC. InfAct contributes to the understanding of economic
factors relating to health and illness and the economic impact of health improvement in MS. Beyond policy, a
robust and sustainable HI and knowledge system is an important population health research tool. InfAct fits the
exceptional utility criteria, covers all European countries and actively involves MSs through peer review
evaluations of HI, through training workshops in specific HI topics and through exchange of best practices.
5. METHODS AND MEANS
To achieve the objectives of this JA, we use several means and methods. They are individually explored below, but
most often they are interlinked and developed simultaneously since the various WPs are interlinked. The Figure
below shows the framework of the various WPs and how they contribute to common goals.
Strategic means:
- The JA will seek active participation and involvement of stakeholders. WP7 seeks to organise national
consortia bringing together the stakeholders of HI within the countries participating in the JA. Criteria for
specialised nodes are set. WP4 will organise an AoM meeting creating awareness at senior level and
facilitate uptake of the outcomes of the JA. WP8 will establish a network community of HI experts.
Interaction is fostered throughout the JA with international organisations, departments or institutions;
- Maximise resources by avoiding duplication of work. Special efforts will be taken to interact with other
JAs;
- Maximise the use of previous HI projects, especially BRIDGE Health with special attention to HI
inequality (WP5, 6, 9), regional health and subgroups (WP9), HI priorities (WP5, 7, 8, 9), interoperability
and legal aspects (WP10);
- Build on consensus procedures;
- Disseminate the results and deliverables of the JA ensuring they will be available to the target groups and
key institutions and professional bodies;
- Build a policy case and road map for submission of ERIC and ESFRI.
Methods:
1. To collect and structure:
[801553] [InfAct] – Part B – Page 9 / 67 Document Version 3.00 dated 23/02/2018
- Associatedin
The governance structure enables many partners to work together with
a document Ref.
structured wayAres(2018)3121156
(more details- below)
13/06/2018
(WP1);
- To build on what has previously been achieved and learn from successful projects, especially BRIDGE
Health, the JA action will carry out best practices identification and sharing (WP4-10);
- Instead of doing widespread and costly mapping exercises, this JA will rather focus on case studies (WP6,
7, 10).
2. To discuss and consent:
- Several pilot studies will be carried out optimising current tools and programmes (WP5, 6, 7, 9);
- Conceptual development of a business plan and a road map for the ERIC and ESFRI (WP7);
- Indicator development (WP5, 8, 9);
- Training and exchange of practice sessions (WP5, 6, 9);
- Priority setting exercises and method development (WP5, 7, 8);
- Technical and legal documents for the ERIC and ESFRI (WP7).
3. To consolidate and maintain
- Network consolidation (WP5, 6, 8);
- Creation of a HI web platform to be (re)used by multiple WPs (WP5, 6, 7, 8);
- Road map for sustainability and effective implementation of the ERIC’s governance structure and potential
ERIC services (WP 4, 6, 7);
- Transferability to policy (WP4 for all WPs).
Governance of the work:
The work of InfAct is distributed over several players with a specific function for each actor.
- The coordinator is in charge of the coordination and follow-up of the implementation, administration of
resources and effective interaction amongst partners. It is responsible for analysing information, drawing
conclusions and the delivery of final documents. The coordination aims to develop a good group dynamic
and an environment where partners can best use their capacities and expertise. It coordinates the
collaboration with international organisations.
- WP leaders and co-leaders: WP leaders are in charge of a) the coordination and supervision of the work in
their respective WPs; b) the timely delivery of their WPs’ milestones and deliverables to the coordinator.
The WP leaders will be assisted by the WP co-leaders.
- Task leaders are the links between the partners contributing to a specific task. They follow up and draft
respective preliminary documents. They report to the WP leaders and co-lead.
- Partners are responsible for contributing to specific tasks in WPs. They are key to obtain local information
and to set up national HI consortia.
- The EAB consists of the members of the EGHI and EGHSPA. The EAB interacts with the JA at least 3
times during the project period in a joint meeting of the EGHI and EGHSPA.
6. EXPECTED OUTCOMES
The major expected outcome is a sustainable solid infrastructure on EU HI (i.e. HIREP-ERIC) facilitating research
and evidence-based health policymaking across MSs through improving the availability of comparable, robust and
policy-relevant health data and information. This will strengthen the basis for monitoring the health status of EU
citizens and the performance of EU health systems, such monitoring being of key importance for effective and
efficient policymaking and evaluation.
[801553] [InfAct] – Part B – Page 10 / 67 Document Version 3.00 dated 23/02/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
7. WORK PACKAGES
7.1. Timetable (in months)
WP M/D Name Deliverable and Responsible
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
# # Milestones Participant
1 D1.1 Conceptual framework and vision Sciensano x
Risk management and
1 D1.2 Sciensano x
contingency plan
1 D1.3 Interim report Sciensano x
1 D1.4 Final report Sciensano x
1 MS1 Kick-off meeting Sciensano x
Coordination meetings with the
1 MS2 WP leaders and co-leaders Sciensano x
(Steering Committee meetings)
1 MS3 Mid-term and final review Sciensano x
1 MS4 Mid-term Assembly Sciensano x
1 MS5 Final Conference Sciensano x
2 D2.1 Leaflet and Website Sciensano x
2 D2.2 Promotional video CIPH x
2 D2.3 Layman version of final report HI x
2 D2.4 Conference and workshops Sciensano x
2 MS6 Dissemination plan Sciensano x
2 MS7 Update dissemination plan Sciensano x
Scientific/policy conference EPH Sciensano
2 MS8 x
2018-2019-2020
2 MS9 European Health Forum 2019 GÖG x
Interim & final report of
3 D3.1 IACS x
“External Evaluation Committee”
3 MS10 Agreement with subcontracts IACS x
First interim internal and external
3 MS11 HI x
evaluation report
Second interim internal and
3 MS12 HI x
external evaluation report
3 MS13 Final interim internal and HI x
[801553] [InfAct] – Part B – Page 11 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
WP M/D Name Deliverable and Responsible
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
# # Milestones Participant
external evaluation report
Terms of Reference and
4 D4.1 ISCIII x
Operating Procedure of the AoM
4 D4.2 Reports on AoM assessments ISCIII x
4 D4.3 Fact sheets ISCIII x x
Reports on key holders and
4 D4.4 relevant EU-international ISCIII x
partners meeting
Sustainability Plan: follow-up of
4 D4.5 integrated proposals and long- ISCIII x x
term reporting scenarios
4 MS14 Assembly of Members ISCIII x
Review and analysis on
4 MS15 implementation from other WPs ISCIII x
by AoM
Policy dialogues with key
4 MS16 stakeholders at the national and ISCIII x
international level
4 MS17 Sustainability Plan ISCIII x
Pilot HI system peer assessment
5 D5.1 MFH x
and review of experience
Cataloguing health information
5 D5.2 networks, projects and indicator RIVM x x
sets
Prioritisation in HI development
5 D5.3 RKI x
and recommendations
HI system peer assessment
5 MS18 MFH x
country reports
Review of pilot HI system peer
assessment experience including
5 MS19 MFH x
scientific publication and manual
for peer assessment
Method development for
5 MS20 RKI x
prioritisation
Mapping needs, capacities and
6 D6.1 training programmes in health MS x
information
A flagship training programme to
6 D6.2 improve MS capacities in MS x
population health and health
[801553] [InfAct] – Part B – Page 12 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
WP M/D Name Deliverable and Responsible
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
# # Milestones Participant
system performance analysis and
monitoring
Training Piloting and Flagship
6 D6.3 MS x
Training Programme Evaluation
Road map for capacity building
6 D6.4 MS x
programme
Mapping of Health Information
6 MS21 education/training programmes MS x
and needs
Flagship capacity build
6 MS22 MS x
programme
A sustainable network of
7 D7.1 Sciensano x
networks
HIREP- ERIC: Business case and
7 D7.2 RIVM x
Road map for implementation
Governance structures of a
7 D7.3 sustainable health information Sciensano x
system
7 D7.4 Health Information web platform Sciensano x
Guidelines national consortia and Sciensano
7 MS23 x
domain specific notes
5-year operational plan HIREP- Sciensano
7 MS24 x
ERIC
Memorandum of understanding Sciensano
7 MS25 x
HIREP-ERIC
7 MS26 Business structure web platform Sciensano x
Health Information System
development: data collection and
8 D8.1 ISS x
quality assurance for a common
health information system
Sustainable ECHI process from
8 D8.2 technical, content and user RIVM x
perspective
Guidelines for accessibility and
8 D8.3 ISS x
availability of health information
Guidelines for MS and regions
8 D8.4 RKI x x
for health report
Questionnaires for MS regarding
8 MS27 ISS x
data collection methods and
[801553] [InfAct] – Part B – Page 13 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
WP M/D Name Deliverable and Responsible
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
# # Milestones Participant
procedures
Research/desk work on review of
8 MS28 data collection methods and ISS x
procedures
Research / desk work on health
8 MS29 RKI x
reporting in MS
ECHI documentation, format,
8 MS30 RIVM x x
technical and content update
9 D9.1 Road map and case studies report SpFrance x
Guidelines, case study and best
9 D9.2 SpFrance x
practices
Report series on the application
9 D9.3 SpFrance x
of the best practices
Tool kit to produce better health
9 D9.4 WG x
indicators
Road map for uptake of
9 D9.5 indicators – opportunities and SpFrance x
obstacles
9 MS31 3 workshops on BoD WG x
9 MS32 EuroPeristat Meeting SpFrance x
Health system performance
9 MS33 SpFrance x
expert workshop
9 MS34 EHLEIS meeting Sciensano x
Report: Interoperability
10 D10.1 CIPH x
landscape in Europe
Technical report: interoperability
10 D10.2 ISCIII x
implementation
Report on mapping exercise:
10 MS35 identification of inspirational CIPH x
experiences
Report on mapping exercise:
10 MS36 legal and organizational CIPH x
interoperability
Report on mapping exercise:
10 MS37 semantic and technical CIPH x
interoperability
10 MS38 Empirical case studies ISCIII x
[801553] [InfAct] – Part B – Page 14 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
8. PROJECT MANAGEMENT STRUCTURE
8.1. Quality of the partnership
Partnership overview
The partners in the InfAct consortium (competent authorities and their affiliates) represent 29 European countries
and build on the expertise they have in several domains of HI, including indicator development, health status
monitoring, HSPA, data analysis, reporting and transferability to policy. Many of them have responsibilities in
coordination of HI at regional and national level and have been active in successful HI-related projects such as
ECHI, HES, EHLEIS, ECHO and BRIDGE Health. The consortium is also strengthened through the strong links of
some of the partners with international organisations such as WHO-Europe (European Health Information
Initiative) and OECD.
Governance structure
InfAct integrates a significant number of partners. This represents a challenge, since it is necessary to establish
structures and processes that enable the consortium to benefit from all the knowledge and expertise that each
partner can provide, and produce a clear impact on the MSs’ policies. At the same time, the structure must allow a
flexible but strong decision-making process and a quick response capacity against any unforeseen contingency.
The management structure of InfAct has been defined to ensure the success of and a maximum impact on policy to
be adopted by the MSs. The management structure of InfAct is described in detail in a Consortium Agreement
(CA) that all partners sign. The CA stipulates the tasks and responsibilities of each managing body, as well as the
liability towards each other and the decision-making process.
Below, essential elements of the governance structure are summarised:
1. The strategic, executive and operational management levels are based on three main decision-making
bodies within the consortium: The General Assembly (GA), the Steering Committee (SC), and the JA
Coordinator (Coordinator), as well as on the active involvement of the EAB. The figure below displays the
main interactions and flows between these bodies.
a. The main decision making body is the GA in which all partners are represented and strategic
decisions concerning the entire project and the general course of the work are taken. The
Coordinator acts as the intermediary between the project partners and CHAFEA.
b. The Coordinator is assisted by a SC.
c. The EAB supports, advises and guides the SC.
2. The GA will hold one meeting per year. These will serve as a platform for discussions, knowledge transfer
and decision-making.
3. The SC decides on high-level management and technical issues, including exploitation, financial,
legislative, planning and monitoring matters.
4. The Coordinator is the single point of contact between the EC and the consortium. The coordinator shall
sign the Grant Agreement with the EC. The Coordinator regularly informs the SC about the overall project
status, reviews and all relevant control matters and will consolidate all technical and financial information
and report to the EC. Individual tasks may be delegated to individual members of the SC.
5. The WP leaders, co-leads and Task Leaders are defined for the execution of the WP. The Task Leader is
responsible for the detailed planning and coordination of the respective technical work as well as for the
monitoring and reporting of results to respective WP leaders. Working groups will meet according to the
specific needs of the tasks under the chairmanship of the respective WP Leader. The results of each task
are summarised when respective milestones and deliverables are reported and communicated directly by
the WP Leader, assisted by the WP Co-leader, to all members of the SC to ensure full information to all
partners as soon as possible. WP Leaders will be responsible for the coordination of their WPs and will be
assisted in this task by the WP Co-leader.
6. The EAB is composed of members of the joined meeting of the EGHI and EGHSPA. These members are
appointed by the MSs and are active experts in the respective HI domains.
[801553] [InfAct] – Part B – Page 15 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Management structure InfAct
CHAFEA
coordinator
consortium
steering
committee
general
assembly
EGHI EGHSPA
Management procedures
The management strategy of InfAct is based on the coordinator’s and partners’ extensive proven experience in
organising, managing and participating in international collaborative research activities. A good management
methodology provides the framework, processes, guidelines and techniques to manage people and the workload. It
should rely on proven and repeatable processes and techniques to achieve this action success. This management
methodology will be integrated in a three-dimensional global management structure composed of three work areas
– Administration, Coordination and Quality – which are considered essential to manage complete interrelation and
collaborative actions.
For the first area, an appropriate administrative management system is indispensable for the maintenance of a high-
quality project and an effective communication system between partners and with the EC. Secondly, coordination
assures the procurement of high-quality deliverables according to the expected results and a good communication
system. The last management area, quality management, focuses on the analysis of the progress and results of the
project to assure the achievement of the expected results.
If we translate this theoretical concept to the Joint Action at hand, we get the following results:
- Administration: as part of project management, administration takes a considerable amount of effort and
responsibility. Its aim is to be the administrative enabler of the objectives of the project, minimising the
administrative burden on the performers. This purpose will be met by means of an administration plan that
will detail all the administrative procedures, strategies and agreements in order to create a common
administrative and communication methodology. One of the most important administrative issues in a
support action is the financial control (see also WP1 task 1.2). The JA puts in place several tools to support
the administration including a JA web platform, a JA email account, a web survey tool, proactive
communication and well-defined meeting agendas. Besides that, project events will be continuously
monitored and analysed in order to minimise the project risks. Appropriate response parameters and actions
will be defined and established to overcome unexpected risk situations for the project objectives (see WP1
task 1.3).
- Coordination: a standardised and global coordination is fundamental to assure an optimal collaborative
work environment between the consortium partners. This activity will be supervised by the SC. The
Coordinator will supervise and mediate meetings so that possible disagreements can be solved. The main
objective will be to coordinate the achievement of the aimed collaborative developments and to accomplish
coordination of the know-how and its sharing within the project.
[801553] [InfAct] – Part B – Page 16 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
- Quality management: the Quality Manager is WP Leader of WP3. The quality management approach
includes the processes as describes under WP3 task1.
Conflict resolution procedures
In addition to the risks inherent in the management of any consortium, InfAct has additional risks related to the
significant number of participants. The size of the consortium has been taken into careful consideration. Therefore,
a management structure and procedures for day-to-day management have been designed based on fair
representation within the framework of WPs. The GA is composed of a large number of partners. There is also an
EAB that supports the consortium with additional expertise and knowledge. The CA describes and ensures an
appropriate approach to the management of any potential conflict by means of the executive bodies: the SC and the
Coordinator have the ability to quickly resolve any dispute that may block the work of the consortium with sound
conflict resolution procedures, as outlined below:
- The InfAct partnership members sign a CA. The CA specifies the formal structures and procedures for
governance of the action and contains detailed provisions concerning conflict resolution procedures. Effective
preventive and remedial measures will avoid any potential conflict among partners.
- All partners are responsible for making every reasonable effort to carry out the tasks agreed upon as outlined in
the respective WPs, and to ensure the accuracy of any information or materials submitted. Each partner agrees
to make every reasonable effort to report any unforeseen delay. They will also inform other partners of relevant
communication received from third parties related to the Project.
- In case of conflicts arising among partners they will be settled amicably and, when needed, with the
collaboration of the Coordinator. Failing such a resolution, the CA stipulates further steps to resolve the
conflict.
Meetings scheme and schedule
As far as possible, the InfAct partnership will promote the communication among partners and stakeholders by
using virtual means, such as conference calls and videoconference, information notes in order to optimise time and
resources. However, a number of face-to-face meetings will be needed. The table below shows the regular face-to-
face meetings scheduled. In addition, some extraordinary meetings could be scheduled. In this case, the organising
entity (normally the coordinator, or WP leader) will comply with the notice period for extraordinary meetings laid
down in the CA.
Meetings When
Kick-off meeting Month 1
Meetings of coordinator with WP leaders Every 6 months
Annual plenary meeting involving all partners, EAB and Every year
stakeholders
Final meeting Month 35 or 36
8.2. Capacity of the staff
Austria: The Public Health Institute (Gesundheit Österreich GmbH, GÖG) is the national healthcare planning
and research Institute, established in its current form in 2006. Since 1973 our task is to support health policy and
improve the efficiency and quality of the healthcare system through innovative research, analyses, monitoring
activities and expert advice. Key staff: Claudia Habl, MBA, almost 25 years of experience in healthcare systems
and project management; head of international affairs and consultancy. Florian Bachner, Health Economist, Head
of Dept. Health Economics and System Analysis, almost 10 years of experience; Stefan Mathis-Edenhofer, PhD,
healthcare planning and data specialist; Andrea E. Schmidt, MSc PhD in Social Sciences and Economics with a
focus on social policy analysis. She completed an MSc at Maastricht University and looks back on academic stays
at London School of Economics and University of Stockholm.
Belgium: Sciensano is the scientific reference in the field of public health in Belgium. For 112 years, they have
supported health policy and policymaking through innovative research, analyses, monitoring activities and expert
advice. Key staff: Prof. Herman Van Oyen, Medical doctor, PhD, over 25 years of experience in Public health.
Petronille Bogaert, Biomedical scientist and degree in Public Health, PhD candidate, experience coordinating
BRIDGE Health project. Brecht Devleesschauwer, senior epidemiologist, PhD in veterinary sciences and public
health, extensive experience in policy-driven public health research.
[801553] [InfAct] – Part B – Page 17 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Bosnia and Herzegovina: Ministry of Civil Affairs of Bosnia and Herzegovina –Department for Health is the
ministry on the National level with responsibilities coordinating activities between entities ministries of health and
public health institutions, to harmonise plans and define strategies and to report to international institutions. Key
staff: Sabina Šahman Salihbegović, MSc, health information system expert, experience coordinating IPA
projects.
Croatia: Croatian Institute of Public Health (CIPH) is a central public health institute in the Republic of
Croatia. It was founded in 1893 and its main tasks are to plan, promote and implement measures for the
enhancement of population health and reduction of health problems. Key staff: Ivan Pristaš, MD, PhD, Public
Health Specialist, head of the Division for Health Informatics and Biostatistics with more than 10 years of
experience in the fields of Public Health, Medical Informatics and eHealth. Mario Trošelj, MD, Epidemiologist at
the Division for Public Health and head of the Department for Human and Material Resources in Health with more
than 10 years of experience in Epidemiology, Public Health and Registries. Damir Ivanković, MD, MBA, Public
Health Resident at the Division for Health Informatics and Biostatistics with experience in Public Health, Health
Policy and Medical Informatics.
Cyprus: The Health Monitoring Unit (HMU) is under the Cyprus Ministry of Health (MoHCY). It is responsible
for the development, medical data collection and analysis of (a) national registries on Births, Deaths, Cancer,
AIDS/HIV; and (b) regional registries (from public sector only) on medical Discharge summaries coding (diagnosis
& procedures) and the Disease Related Groups (DRG’s). Key staff: Dr. Vasos Scoutellas, Rheumatologist,
Coordinator of the HMU
Czech Republic: Institute of Health Information and Statistics of the Czech Republic / Ústav zdravotnických
informací a statistiky České republiky UZIS is a Czech government organisation responsible for the
management and coordination of the National Health Information System (NHIS), including its further
development and improvement. Key staff: Ondřej Májek, Degree in mathematical biology, PhD in oncology, 11
years of experience in public health activities, especially in cancer epidemiology and evaluation of cancer screening
programmes. Sarka Dankova, Degree in demography, 13 years of experience in health information activities,
especially in health interview surveys
Estonia: Ministry of Social Affairs is the Government authority. Objectives of the Ministry of Social Affairs
emerge through compiling development plans for the fields being under our control, as well as organization-based
development plans. We operate in the field of social security, where we have set for ourselves five strategic
objectives: to ensure people's long and high-quality life; to ensure people's economic prosperity and their good
work; to ensure people's social coping and development; to support the well-being of children and families; to
promote people's mutual care, equal opportunities, and gender equality. Key staff: Eleri Lapp, epidemiologist,
Master of Science (MSc) in Health Sciences (Public Health), four years of work experience in healthcare system
policy development. The National Institute for Health Development is a government established research and
development body collecting, connecting and providing reliable national information from a multitude of sources,
related to the health of the Estonian population. Our mission is to establish and share health related knowledge as
well as to influence health behaviour and determinants of health so as to increase the wellbeing of the people in
Estonia and help them live longer and healthier lives. We engage in public health related research and health
promotion as well as development and implementation of disease prevention programmes and activities. Our
further responsibilities include the administration of Estonian national health statistics and five population based
registers and databases. Key staff: Natalja Eigo, MSc in Public Economy, MSc in Mathematical Statistics, 14
years of experience in healthcare statistics and health information systems.
Finland: The National Institute for Health and Welfare (THL) studies and monitors - and develops measures to
promote - the well-being and health of the population in Finland, and it gathers and produces information based on
research and statistics. Key staff: Research Professor Mika Gissler (THL), Dr.Phil, M.Soc.Sc has worked more
than 25 years with health information system, health statistics and registers, and he is responsible for international
health statistics at THL. Research Manager Hanna Tolonen (THL), PhD, Adjunct Professor has worked more
than 20 years with health monitoring and health examination surveys, especially on standardized methods.
France: Agence Nationale de Santé Publique, Santé publique France (SpFrance) is the Competent authority
for the JA. The Ministry of Solidarities and Health, INSERM U 1153, INSERM U 1138 and IRDES have
been designated as Affiliated Entities. Santé publique France, The national public health agency was created on
1st May 2016. Its missions are: to analyze up-to-date knowledge and data on the determinants of health and risk
factors, to provide decision makers at all levels with independent evidence-based guidance and recommendations,
to propose public health measures to health authorities to protect the population from health threats, to develop
[801553] [InfAct] – Part B – Page 18 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
evidence-based interventions for prevention and health promotion, to contribute to preparedness and management
of health crisis, and support the implementation of response plans. SpFrance contributes to the development of
robust methodologies to define appropriate morbidity indicators from healthcare utilization (HCU) data bases and
to validate their performance for the purpose of health status monitoring. SpFrance has been involved in several
projects dedicated to identify new indicators based on HCU data, or new administrative data sources. It coordinates
with the MoH the French Heath Profile report. SpFrance is responsible for the User Committee of the National
Health Data System within the National Health Data Institute. SpFrance has an extensive experience in setting up
and contributing to infrastructures and surveys (Health examination surveys, national biomonitoring, surveys…)
related to health monitoring and surveillance (use of large healthcare databases, organisation, technical, legal and
ethical issues, relations with stakeholders and users…). SpFrance will work with two INSERM research units, with
IRDES and with the Strategy and Research Office of the Directorate General for Health at the Ministry of
Solidarities and Health. Key staff: SpFrance: Dr Emmanuelle Bauchet – Deputy Head of the Chronic Diseases
and Trauma Division (in-kind) – Public Health Medical Doctor; Dr Michel Vernay – epidemiologist – Head of a
regional office (East region), Dr Anne Catherine Viso, Deputy Head of the Science and International Office, a
coordinator and scientific contributor of WP9 to be hired. Ministère des solidarités et de la santé (Ministry of
Solidarities and Health): Dr Alain Fontaine Head of Strategy and Research Office at the General Directorate for
Health, member of the Expert Group for Health Information (EGHI) of DG SANTE. INSERM: INSERM U1153:
Dr Jennifer Zeitlin, Senior Research Scientist, Principal Investigator of EuroPeristat since 2000 and INSERM
U1138 Prof. Anita Burgun, (F) MD, PhD, is professor of medical informatics at Paris Descartes University and has
expertise in biomedical ontologies, and data integration. She has developed knowledge driven and data driven
methods tailored to secondary use of health data. She is member of the scientific advisory board of the
INSERM/Aviesan Public Health Institute IRDES, Institut de Recherches et de documentation en Economie de
la Santé: Dr Zeynep Or, (F), HDR (tenure) in economics, Research Director at IRDES. She has vast experience in
empirical evaluation of health system performance from an international comparative perspective, including the
determinants of health outcomes, analysis of efficiency, equity and healthcare quality.
Germany: The Robert Koch-Institute (RKI), founded in 1891, is the national public health institute for
Germany. Its two major areas of responsibility lie in combatting infectious diseases and in analysing health trends
in the population. Key staff: Dr. Thomas Ziese, Medical doctor and epidemiologist, head of the Unit Health
Reporting at the RKI, over 25 years of experience in Public Health. Angela Fehr, Doctor of Public Health,
researcher at RKI, over 15 years of experience in health research and international relations. Dominika Urbanski,
MSc Socio-Economics, MSc Global Health, researcher at RKI, extensive experience in health services research.
Greece: Ethnikos Organismos Parochis Ypiresion Ygias - EOPYY is a National Organization of Greece, whose
main purpose is the purchase of health services for its insured, pensioners and their dependent members. EOPYY’s
main objectives include: The establishment of rules for design, quality, development, evaluation, safety and
efficiency of the health services market, managing and controlling funding. The establishment of criteria and
contract terms for the purchase of health services with institutions of public and private sector as well as affiliated
doctors. The negotiation with all affiliated providers of their remuneration, their contract terms with EOPYY. Key
staff: Christina Georgakapoulou, Spyridon Goulas.
Ireland: The Department of Health's role is to provide leadership and policy direction for the health sector in
Ireland to improve health outcomes. Key staff: Alan Cahill, Senior Statistician has over 10 years of experience
working in the Department on health statistics and analytics. Patrick Black is senior health analyst with the
Department of Health working on health analytics and data visualisation.
Italy: The Istituto Superiore di Sanità (ISS) is a national research and development institute under the Italian
Ministry of Health (MoH); it is the scientific reference in the field of Public Health in Italy. For more than 80 years
the ISS has been supporting MoH in health policy and policymaking through studying, analyzing, monitoring and
promoting health, healthcare and welfare, preventing diseases, and cutting-edge research. ISS will conduct
activities in consortium with the University of Milano-Bicocca, Università Politecnica delle Marche, University of
Naples Federico II, and the Ministry of Health as third parties. Key staff: Dr. Luigi Palmieri, Biostatistician, PhD,
senior researcher, over 20 years of experience in CVD epidemiology and surveillance, national CVD registries
coordination, participation to several European Projects (e.g. EUROCISS, EHES-JA, BRIDGE Health). Dr
Simona Giampaoli, Medical Doctor, research manager, over 30 years of experience in CVD and NCD
epidemiology and Public Health, experience in coordinating EUROCISS project and BRIDGE Health WP.
Latvia: The Centre for Disease Prevention and Control (CDPC) of Latvia was established on 1st April 2012 by
Cabinet of Ministers of Latvia and is supervised by Ministry of Health. CDPC of Latvia goals are to strengthen
[801553] [InfAct] – Part B – Page 19 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Latvia’s public health system, prevent diseases, including infectious and rare diseases. Key staff: Senior
Researcher/ Competent Authority: Assistant professor Janis Misins MD., PhD, Head of Health Statistics Unit,
Centre for Disease Prevention and Control; in the healthcare sector since 1995. Senior Researcher: Irisa Zile PhD,
Healthcare Statistician, Centre for Disease Prevention and Control; in the healthcare sector since 2001. Researcher:
Zane Pavlovska, Master of Healthcare, Healthcare Statistician, Centre for Disease Prevention and Control; in the
healthcare sector since 2005. In some of the tasks could be involved experts from the University of Latvia and Riga
Stradins University.
Lithuania: Institute of Hygiene is s a budgetary institution of the Ministry of Health, which carries out state
functions in the areas of monitoring Lithuanian residents’ health state and healthcare institution activities, assessing
public health inconsistencies and public healthcare technologies, investigating the effects of the working
environment on health and assessing occupational healthcare technologies. Key staff: Ausra Zelviene, Public
Health PhD, over 10 years of experience in public health monitoring and analysis of public health information.
Sandra Meksriunaite, public health specialist, experience in analyzing avoidable mortality, avoidable
hospitalizations, GIS (geographical information systems). Rita Gaidelyte, over 25 years of experience in health
statistics. Head of Health Statistics Division, responsible for official health statistics in Lithuania, health statistics
data presentation for international organizations. Milda Garbuvienė, statistician, responsible for health
information systems and databases, data processing and preparation of health statistics, data calculation
methodologies, linking of health information systems/registries, improvement of data quality.
Luxembourg: Directorate of Health of Luxembourg falls under the authority of the Ministry of Health which is
in charge of the health policy in Luxembourg. The missions of the Directorate of Health are to protect and promote
health, to study, monitor and evaluate the health status of the population, to set up prevention programmes, and to
contribute to the practical application of the health policy. Key staff: Dr. Nathalie de Rekeneire, Medical doctor,
MS in Epidemiology, over 20 years of experience in Epidemiology and Public health. Anne-Charlotte Lorcy-
Thomas, MS in Economy and management of healthcare services, experience coordinating studies in the
healthcare sector and healthcare system
Malta: The Directorate for Health Information & Research is part of the Department of Health Policy within
the Ministry for Health under the guidance of the Chief Medical Officer for Malta. It has been responsible for most
of the national health registers, some of which date back more than 20 years, and is also responsible for
epidemiological surveys such as the European Health Interview Survey. The DHIR is the national and international
focal point for health statistics and evidence for health policymaking. Key staff: Dr Neville Calleja, Public health
specialist & medical statistician, PhD in medical statistics, 15 years of experience in health information. Dr
Kathleen England, Public health specialist, 15 years of experience in public health registers, epidemiological
surveys and health policy. Dr Miriam Gatt, Public health specialist, 25 years of experience in perinatal health
registers. Dr Alexandra Distefano, Public health specialist, 25 years of experience in hospital activity registers. Dr
Domenic Agius, Primary care specialist, 10 years of experience in cancer registration.
Republic of Moldova: School of Public Health Management (SPHM) is the scientific reference in the field of
public health in the country. For 15 years, the activity of SPHM is focused on the triad - education, research and
consultancy services, being an important academic and scientific resource in the field of public health and health
policy in the Republic of Moldova. Key staff: Prof. Oleg Lozan, Medical Doctor, PhD, over 25 years of
experience in public health. Rodica Gramma, Medical Doctor with master degree in Health Law and
Management, PhD in Philosophy of Science, experience in research in public health. Ana Niculita, master degree
in economic sciences PhD candidate, extensive experience in policy-driven public health research.
Netherlands: The National Institute for Public Health and the Enviroment (RIVM) is the leading knowledge
institute for public health in the Netherlands with several decades of experience in (inter)national public health
research, monitoring, implementing preventive actions and policy advice and support. Key staff: Dr Peter
Achterberg, PhD, senior advisor; over 25 years of experience in public health information research and projects.
Ms Dr Mariken Tijhuis, PhD, health scientist, epidemiologist; over 10 years of experience in international public
health research. Ms Dr Marieke Verschuuren, PhD, senior researcher with over 15 years of experience in
international health research and project coordination
Norway: The Norwegian Directorate of Health – Hdir is an executive agency and professional authority under
the Ministry of Health and Care Services. Our public mandate is to improve the health of the citizens and the
community as a whole through targeted activities across services, sectors and administrative levels. Key Staff:
Sissel Husøy, Division Director for Health Economcis; Håkon Haaheim, Senior Advisor for Health Information at
[801553] [InfAct] – Part B – Page 20 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
the Norwegian Patient Registries (Key personnel to EU JA Health information); Janicke Fischer, Senior Advisor
for International Health Hanne Narbuvold, Department Director for Statistics and Indicators; Trond Ødegaard
Christensen, Senior Advisor for International Indicators; Knut Ivar Johansen, Section Director for National and
International Data Delivery; Håvard Wahl Kongsgaard, Senior Adviser for Data Science and Big Data
Applications; Julia Nemeth, Senior Advisor for Governmental Indicators and Decision Data; Steinar Olsen,
Department Director for Emergency Medical Services and Liaison to NATO and WHO. The Norwegian Institute
of Public Health - NIPH acts as a national competence institution placed under the Ministry of Health and Care
Services. The NIPH is responsible for knowledge production and systematic reviews for the health sector and
provides knowledge about the health status of the population, influencing factors and how it can be improved.
Heidi Lyshol, Senior Adviser, Department of Health and Inequality, Norwegian Institute of Public Health
Poland: Ministry of Health in Poland (MZ) is responsible for healthcare. It is a regulatory body for the
organization of healthcare in Poland. It is also responsible for supervising the health statistics matters.. National
Institute of Public Health – National Institute of Hygiene (NIZP-PZH) for 100 years has been a main Polish
public health institution, conducting scientific research in the area of epidemiology of communicable as well non-
communicable diseases, and health promotion. The Institute is responsible for monitoring health status of Polish
population with focus on causes of death, hospitalised morbidity, incidence of infectious diseases, vaccinations,
biological, chemical and physical risk factors in food and water. Key staff: dr Paweł Goryński, ScD, Public
Health expert, dr Anna Poznańska, Biostatistician, MSc in medical physics, PhD in medical biology.
Portugal: The Directorate-General of Health (MS) is a central department of the Ministry of Health, integrated
in the direct administration of the State, with administrative autonomy. It is a reference body for all those who think
and act in the health field, its main areas of intervention focus to Protect and improve the health and well-being of
citizens, ensuring that, through the quality, safety and inequities reduction in health, all reach their health potential.
Key staff: Prof. Paulo Jorge Nogueira, Director of the Directorate of Analysis and Information and Member of
the Statistical Council, PhD, over 23 years of experience. The Portuguese Institute of Hygiene and Tropical
Medicine (IHMT) is an Organic Unit of the Universidade Nova de Lisboa (UNL). It functions in the dependence
of the Ministry of Education and Science, and it aims at developing the scientific knowledge of health problems
related with the tropical and intertropical world. IHMT is also WHO Collaborating Center for Health Workforce
Policy and Planning. Key Staff: Prof. Paulo Ferrinho (IHMT Diretor and a member of the International
Association of Public Health) Prof. Luís Lapão (Population Health, Policies and Services Group Leader of the
Global Health and Tropical Medicine Research Laboratory – Evalated as Excellent by the Portuguese Foundation
of Science and Technology) Prof.ª Zulmira Harzt (Expert in Evaluation). The National Health Institute Dr.
Ricardo Jorge (INSA) is a public body within the indirect administration of the State, under the Ministry of
Health, endowed with scientific autonomy, technical, administrative, financial and own assets. Founded as a
laboratory arm of the Portuguese health system, the Ricardo Jorge Institute develops a threefold mission as State
laboratory in the health sector, the national reference laboratory and national health observatory. Key staff: Prof.
Carlos Dias.
Romania: National Institute of Public Health is the main public institution in the field of public health in
Romania. For 90 years, it is the main methodological coordinator for public health activities related to health status
monitoring, analysis and reporting. Key staff: Dr. Alexandra Cucu, MD, PHD, Associate Professor for public
health, Faculty of Midwives and nursing, “Carol Davila” University of Medicine Bucharest, Director of the
National Centre for Health Status Evaluation and Health Promotion; Math. Cristian Calomfirescu, Director
National Centre for Health Statistics and Informatics for Public Health, Senior specialist in health reporting with
more than 20 years of practice in public health. Adriana Galan, Public health senior expert, Head of non-
communicable diseases monitoring Department, with over 20 years of professional experience in Public Health
Surveillance and Control.
Serbia: The Institute of Public Health of Serbia (IPHS) represents an expert institution which conducts
independent researches related to public health in order to provide advice, support and guidance for the Serbian
government. Informatics and Biostatistics Department is organizational part at IPHS with following tasks:
collecting data on health and healthcare within the jurisdiction of national statistics, maintenance of databases on
the resources of healthcare system, providing data from population studies, and providing health information for
the effective coverage of healthcare intended for government agencies and the public. Key staff: Maja Krstic,
MD, MPH, specialist in Social Medicine, head of Database Development and Administration Unit, 20 years of
experience in Public Health. Ivan Ivanovic MD, specialist in Social Medicine, head of Informatics and
Biostatistics Department, 20 years of experience in Public Health.
[801553] [InfAct] – Part B – Page 21 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Slovenia: The National institute of Public Health Slovenia (NIJZ) is the central Slovenian institution for public
health practice, research and education, covering the areas of epidemiology of communicable and non-
communicable diseases, health promotion, health system research, eHealth and it serves as a central national hub
for health information. Metka Zaletel, MA, Head of Health Data Centre at NIJZ. She's got over 20 years of
experience in statistics and various statistical methods, last eight years with the emphasis on health information and
patient registries. She served as work package leader in JA Parent, responsible for the Guidelines on Patient
Registries. Tatjana Kofol Bric, Medical Doctor, specialist in public health, senior researcher, over 25 years of
experience in epidemiology and public health, leading researcher in national project of health indicator system at
local level and member of several EU working groups and committees.
Spain: The Instituto de Salud Carlos III (Institute of Health Carlos III, ISCIII) is the main Public Research
Entity funding, managing and carrying out biomedical research in Spain. The Institute has been conducting
research and providing key services in the life and health sciences for over 20 years. Key staff: Dr. Isabel Noguer
Zambrano MD, PhD, MPH Epidemiologist and Director of the National Centre for Epidemiology with more than
30 years of experience in public Health and international organizations. Dr. Beatriz Pérez-Gómez MD, PhD,
MPH tenured senior researcher and Head of Unit in the Department of Chronic Diseases. More than 17 years of
experience in chronic diseases. Dr. Pablo Fernandez, PhD, tenured senior researcher in the National Centre for
Epidemiology of Spain with more than 15 years of experience. Alicia Padrón Monedero MD, PhD, OMS tenured
Program Director, and researcher in Chronic Diseases with more than 10 years of experience. Adela Castelló
Pastor. PhD. MPH Epidemiologist with more than 10 years of experience. Institute for Health Sciences in
Aragon (IACS). The IACS mission is to promote research, innovation and knowledge brokering in biomedicine
and health sciences for the Aragon Health System. The IACS Health Services and Policy Research Group
(ARiHSP) leads the cutting-edge "project Atlas VPM", initiative on Variations in Medical Practice in the Spanish
National Health System. Key staff: ARiHSP: Enrique Bernal Delgado. Medical Doctor, Senior Health Services
and Policy Researcher, Specialist in Preventive Medicine and Public Health; Large experience in management of
large scale multi-national projects. Francisco Ramon Estupiñan. Medical Doctor, Manager data analysis and
reporting, Specialist in Statistics, Health Economics, Medical Technology. Ramon Launa Garces, Lawyer, Project
Officer, has experience in management of large scale multi-national projects, legal, financial, administrative issues.
Spanish foundation for international cooperation, health and social policy (FCSAI) founded in 2000, by the
Spanish Government, is a Public Sector Foundation of Public Interest. Mrs. Berta María Iradier Sanchiz,
permanent staff. General Coordinator with more than 20 years of experience. Mrs. Agueda Besnard Ruiz,
permanent staff. Deputy General Coordinator with more than 20 years of experience.
Sweden: The Public Health Agency of Sweden (FOHM) is a government agency accountable to the Ministry of
Health and Social Affairs. The agency has a national responsibility for public health issues and works to ensure
good public health. It also works to ensure that the population is protected against communicable diseases and other
health threats. Key staff: Anders Tegnell Head of Dept. of Monitoring and Evaluation. Katarina Paulsson,
Analyst. Richard Bränström, Analyst.
United Kingdom: The Welsh Government is the devolved government for Wales, responsible for key areas of
public life such as health, social care, education, housing, economy and the environment. The Welsh Government
is responsible for proposing and implementing policy and laws which would apply in Wales and which aim to
improve the lives of everyone in Wales. Key Staff: Professor Jon Bisson, Director of Health & Care Research
Wales and Professor in Psychiatry. Nick Batey, 25 years of experience in healthcare policy and 15 years of
international programme management. Public Health England exists to protect and improve the nation's health
and wellbeing, and reduce health inequalities through world-leading science, knowledge and intelligence,
advocacy, partnerships and providing specialist public health services. Key Staff: Prof John Newton senior public
health doctor and epidemiologist, responsible for national public health information assets. Swansea University:
Operates the Secure Anonymised Information Linkage (SAIL) databank on behalf of Welsh Government and hosts
2 UK data linkage research centre addressing multiple policy domains. Key staff: Prof. Ronan Lyons, Medical
Doctor, MD, over 30 years’ experience in medicine, epidemiology, public health and informatics, Directs two
RCUK funded centres of excellence in informatics and has participated in multiple Join Actions.
[801553] [InfAct] – Part B – Page 22 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
8.3. External and internal risk analysis and contingency planning
A risk management plan and a contingency plan will be proposed in the first Kick-off meeting of the JA and will be
finalised by WP1 as deliverable by month 3. Identification of any issue with negative impact on JA will be on the
agenda of the foreseen meetings. Furthermore, the project’s risks are followed up at regular intervals in the internal
and external evaluations (WP3).
The risks below have already been identified for InfAct.
Identified Risk Likelihood Impact Contingency planning
Departure of key staff in the Low High The lead organisation has to provide qualified
coordination team (WP1, 2, 7) substitutes. The lead organisation involves, next to
of the lead organisation the core team that runs the project, 7 researchers, 4
of which are senior with 2 of them heads of
research units.
The various partners may not Medium High The Coordination will have a detailed mailing list
respond timely to the of the partners of InfAct with various contacting
communication of the possibilities e.g. email, phone, mobile phones,
coordination team Skype etc. The deadlines will be given in advance
and a possible delay in responses will be
anticipated.
WP leader is not able to Low High For each of the WPs, a co-lead is identified. The co-
continue the task lead is also participant in the SC so that the co-lead
can ensure direct continuity of the task.
Two of the Affiliated Entities Medium Medium The tasks allocated to the Affiliated Entities may be
are located in the United taken over by another Associated Partner. This risk
Kingdom. Due to Brexit the can be identified and discussed with the partners in
Associated Partner may not be an early stage.
able to carry out their task
until the end of the project
Beneficiaries will not adhere Medium Medium Regular reports will be gathered by the coordination
to planned budget and will team to monitor financial expenditure and propose
under- or overspend redistribution of budgets if necessary. Bilateral
communication will be held between the
coordination team and individual partners regarding
expenditure.
Beneficiaries will not fulfill Low High Deliverables will be tracked by each WP Leader
their planned obligations, will and by the Coordination Team, who will discuss the
not deliver planned outputs, or status of all planned deliverables in the reporting
will do so with significant period at SC meetings. 1 month prior to the delivery
delay of the deliverable the Coordination Team will be in
touch with the WP about the status, helping to find
solutions if a delay is expected.
Low response to Medium High The questionnaires will be composed to be user-
questionnaires friendly and short, reminders may help to increase
response rates.
[801553] [InfAct] – Part B – Page 23 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
InfAct is a very complex and Intermediate High 1. During the preparation of the JA, this was
large consortium of people discussed and transversal links between WPs
working in HI but different will be proposed during the kick-off meeting.
domains. This may hamper the
Through the links, the working in clusters will
collaboration and may have an
effect on the timely delivery ensure the coherence and strengthen the logical
of milestones and deliverables. build-up of the WPs.
2. The CA describes the roles and ways of
interaction between the partners to tackle issues
that have a negative impact on the functioning
and outcomes of the JA.
Lack of consensus between High High 1. The JA and especially its coordination team have
MSs on the realisation of the to invest in consensus building. These
main aim of the JA: the investments include:
preparation of a sustainable
a) specific tasks in WP4 and 7
structure.
b) the governance structure of the JA, which
specifically mentions the interaction with the
EGHI and the EGHSPA
c) interaction with EU services and
international organisations
2. Business cases will balance the arguments pro
and contra the ERIC, including the feasibility of
alternative options
3. The outcome and deliverables are generic and
independent of policy options for a sustainable
structure
A peer–review will be Medium Medium If one partner does not carry out the peer-review
organised in the WP on another partner may be involved. The peer-reviews
evaluation. The peer-review may be discussed during the Steering Committee to
may be of low quality and the assure good quality.
responses may be low or
delayed.
8.4. Financial management
A dedicated financial officer, as well as an administrative officer of the coordinating institute will tackle budgetary
issues and oversee financial reports. The financial management will be on the agenda of every Steering Committee
Meeting. The financial and administrative officers will prepare this point together with the project coordinator. The
required interim and final financial reports will be completed on time in order to ensure that the coordinator has an
overview of the budget and expenditure at regular intervals. Prior to the interim and final reports, the financial and
administrative officers will contact the financial officers of the different partners. A financial audit has been
foreseen in the budget of the coordinator (Sciensano).
9. BUDGET
9.1. Content description and justification
The budget is spread over the different WPs and within WPs over different tasks. The budget distribution is in
function of set priorities and the estimated cost in person-time and travel needed to execute the task. The budget
was discussed with the WP leaders and co-leaders and agreed upon during a preparatory meeting in Rome on 15
September 2017. 9.2% of the budget is for the coordination, dissemination and evaluation of the project. 10.3% is
[801553] [InfAct] – Part B – Page 24 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
dedicated to the proof of concept of a sustainable structure on HI in order to ensure the acceptance of a sustainable
HI structure by a maximum number of MSs. The remaining 80.5% is divided over the other WPs.
The personnel cost is 79,1% of the total budget. Personnel mainly consists of researchers and staff involved in HI.
The coordinator also includes IT staff to ensure the development of the web platform and data platform for WP5, 6,
7, 8 and 10, next to administrative personnel, including a financial officer. Travel cost and subsistence allowances
are mainly related to the participation in the SC and GA, to the participation in 3 dissemination events in
accordance with the JA dissemination plan and to network meetings. Other costs are also related to travel for
invited networks, training, but also to data acquisition. Equipment is very limited and mostly in function of IT
needs. Subcontracts are limited to 1.4% of the total budget (including financial audit, communication and expert
consultation on the HIS development in one MS).
[801553] [InfAct] – Part B – Page 25 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
9.2. Detailed budget
Applicant Number/ 1
Short Name Sciensano
(A) Direct personnel costs
Staff function Monthly Cost (€) Estimated Sum Cost (€)
Person-month
Senior researcher 6,800.00 13.3 90,440.00
Junior researcher 5,734.02 78.8 451,840.78
ICT developer 8,227.27 6.6 54,299.98
Project officer 6,069.01 29.7 180,249.60
Total person months Total Costs (€) for (A)
128.4 776,830.36
Justification
Sciensano coordinates the Joint Action, leads WP 2 on dissemination. The
follow-up of all deliverables and milestones, interim and final reporting and the
organisation of different meetings with the partners asks for extended
administrative support, as well as scientific input of several researchers to guide
the partners in their work. Sciensano contributes to all 3 tasks of WP3 on
evaluation.
Sciensano leads WP7 (Proof of concept of sustainable structure on health
information). The researchers will further be involved in WP5 as co-lead of the
task 5.1 on mapping and assessment of health information systems. Further
participation in WPs 4, 6, 8, 9 and 10.
The IT department will develop a new website, a file sharing platform for the
partners and an information platform that can be used for different WPs.
Updates of the website will be performed by the project officers
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
28,192.00 As partner in charge of the coordination and dissemination,
Sciensano will take part in the following meetings and
conferences: EPH 2018, 2019 and 2020; Gastein European
Health Forum 2019 and 2020; WHO training course (WP5);
2 SC meetings, 2 GA meetings, 3 WP5 meetings; evaluation
meetings, country visits and visit with international
organisation and with CHAFEA
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
42,650.00 Production of logo and leaflets (layout, printing and
distribution), publication of scientific articles, an abstract
book and workshop proceedings, organisation of Kick-off
meeting (Luxembourg), Healthy Life Years conference and
final meeting in Brussels, open to stakeholders
Total Costs (€) of (C) 70,842.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 59,337.07
Total estimated eligible costs 907,009.43
[801553] [InfAct] – Part B – Page 26 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ 2
Short Name GÖG
(A) Direct personnel costs
Staff function Monthly Cost (€) Estimated Sum Cost (€)
Person-month
Deputy head of department 7,938.14 0.97 7,700.00
Senior Expert 8,989.69 3.88 34,880.00
Senior Expert 11,370.79 2.67 30,360.00
Data Analyst 7,854.74 4.22 33,147.00
Expert 7,720.59 2.72 21,000.00
Total person months Total Costs (€) for (A)
14.46 127,087.00
Justification
Expertise in the fields of action, co-lead of WP 2, Austria is partner of many
health information activities in WP 4,5,9.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
20,270.00 A total of 20 travels are covered including 26 meetings (as
some are organised back to back to limit travel cost): 7
Steering Committees, 3 General Assemblies, 6 in WP2, 3 in
WP4, 4 in WP5, and 3 in WP9
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
18,000.00 Conference Fees of 8,000 € for WP 2 (3 European Public
Health Conferences and European Health Forum Gastein)
and fees of 10,000 € for hosting of a session at European
Health Forum Gastein
Total Costs (€) of (C) 38,270.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 11,574.99
Total estimated eligible costs 176,931.99
[801553] [InfAct] – Part B – Page 27 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ 3
Short Name MCA
(A) Direct personnel costs
Staff function Monthly Cost (€) Estimated Sum Cost (€)
Person-month
Researcher 1,834.00 0.5 917.00
Total person months Total Costs (€) for (A)
0.5 917.00
Justification
MCA will participate in WP 1 of the Joint Action.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
C1b 3,200.00 MCA will take part in the three General Assemblies
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
0.00
Total Costs (€) of (C) 3,200.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 288.19
Total estimated eligible costs 4,405.19
[801553] [InfAct] – Part B – Page 28 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ 4
Short Name CIPH
(A) Direct personnel costs
Staff function Monthly Cost (€) Estimated Sum Cost (€)
Person-month
Senior Researcher 3,233.95 8 25,871.63
Junior Researcher 1,482.94 27 40,039.50
ICT Support 1,921.50 3 5,764.50
Researcher and coordinator 1,824.77 35 63,867.00
Total person month Total Costs (€) for (A)
73 135,542.63
Justification
CIPH will lead WP10 (Health information interoperability in the EU) and
participate in WP1 (Coordination; as the WP lead), WP2 (Promotional video),
WP5 (Expert group members), WP6 (Piloting HIS capacity building
programmes), WP7 (Cooperation with WP10) and WP9 (Cooperation with
WP10).
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
3,500.00 Promotional Video
Total Costs (€) of (B) 3,500.00
Justification
Joint Action promotional video as part of the WP2 Dissemination work
(C) Other direct costs
(C.1) Travel Costs (€) Justification
11,790.00 As WP10 lead, CIPH will participate in GA and SC
meetings as well as all the WP10 meetings
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
12,000.00 Organisation of the WP10 Kick-off meeting in Zagreb,
Croatia as well as costs associated with publication of
WP10 findings and results in scientific journals.
Total Costs (€) of (C) 23,790.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 11,398.28
Total estimated eligible costs 174,230.91
[801553] [InfAct] – Part B – Page 29 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ 5
Short Name MoHCy
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Senior Medical Officer 7,070.43 0.86 6,080.57
Statistical officer 4,134.66 3.54 14,636.70
Total person month Total Costs (€) for (A)
4.40 20,717.27
Justification
Participation for WP1, WP5 (Task 5.2.3) and WP8 (Task 8.1).
Total person months (PM) include 0.5 PM for General Assembly (3 times)
meetings (as directed by Project leader)
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
4,284.00 Participation in the GA meetings
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
700.00 Paper, toner, library use fees, publication of scientific article
Total Costs (€) of (C) 4,984.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 1,799.09
Total estimated eligible costs 27,500.36
[801553] [InfAct] – Part B – Page 30 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ 6
Short Name UZIS
(A) Direct personnel costs
Staff function Monthly Cost (€) Estimated Sum Cost (€)
Person-month
Senior researcher 2,596.00 4 10,384.00
Junior researcher 2,200.00 4 8,800.00
Total person months Total Costs (€) for (A)
8 19,184.00
Justification
UZIS will participate in WP1, WP 7 (this is mandatory collaboration for all
partners), in WP8, where researchers will cooperate on continuation of existing
projects (ECHI, EHES methodology, EHLEIS) and revising methods of existing
data collections, WP9, where researchers will perform activities related to
innovations in data production and linkages.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
8,730.00 Participation in relevant WP meetings, workshops and
conferences (kick-off meeting, mid-term meeting, closing
meeting, meetings and workshops organised within WP8,
country visits in WP9).
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
0.00
Total Costs (€) of (C) 8,730.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 1,953.98
Total estimated eligible costs 29,867.98
[801553] [InfAct] – Part B – Page 31 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ 7
Short Name MoSA
(A) Direct personnel costs
Staff function Monthly Cost (€) Estimated Sum Cost (€)
Person-month
0.00 0 0.00
Total person months Total Costs (€) for (A)
0 0
Justification
MoSA only acts as Competent Authority, but will not participate in any tasks.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
0.00
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
0.00
Total Costs (€) of (C) 0.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 0.00
Total estimated eligible costs 0 .00
[801553] [InfAct] – Part B – Page 32 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/
Short Name NIHD
(If affiliated entity: Affiliated to which 7. MoSA
Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost (€) Estimated Sum Cost (€)
Person-month
Head of the department 2,959.35 1.23 3,640.00
Senior analyst 2,185.75 1.97 4305.92
Total person months Total Costs (€) for (A)
3.20 7,945.92
Justification
NIHD will participate in WP 5 and 8 assessing of our HIS using the WHO tool;
as well as 2 other counties HIS assessments. Also NIHD plan to deal with
contribution in form of providing information about availability, accessibility,
national data collection methods from different sources and reporting of health
information including quality of data of e-health, registers and some surveys
what has been done in Estonia. Describing legislation support and challenges for
accessibility of data in the health information system.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
12,600.00 NIHD will take part in the following meetings: The kick-off
meeting, Midterm general assembly, Closing general
assembly, WHO training course (WP5); two country visits
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
0.00
Total Costs (€) of (C) 12,600.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 1,438.21
Total estimated eligible costs 21,984.13
[801553] [InfAct] – Part B – Page 33 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ 8
Short Name THL
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Senior researcher 7,000.00 6.00 42,000.00
Research manager 8,200.00 14.75 120,950.00
Research professor 10,500.00 1.00 10,500.00
Junior researcher 5,497.94 13.38 73,562.50
Total person month Total Costs (€) for (A)
35.13 247,012.50
Justification
THL is a co-leader of WP6 and involved additionally in WPs 5, 7 and 8.
Research manager will be a WP6 co-leader and contributes to WP7 and WP8.
Senior researchers, and junior researchers will contribute to tasks under WPs 6-
8. Research professor will contribute to tasks 5 and 8, for questions related to
ECHI work.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
22,000.00 As a member of the Steering Group (WP6 co-leader), THL
will participate to 6 SG meetings, kick-off meeting, general
assembly and final meeting, and 2 WP6, 4 WP7, 3 WP8
working meetings and 3 EPH conferences.
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
4,080.00 Registration fees for 3 EPH conferences and
meeting/workshop organization costs.
Total Costs (€) of (C) 26,080.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 19,116.48
Total estimated eligible costs 292,208.98
[801553] [InfAct] – Part B – Page 34 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ 9
Short Name SpFRANCE
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Senior Public Health specialist(WP 4) 10,200.00 0.95 9,690.00
Epidemiologist ( WP 7) 6,500.00 1.05 6,825.00
Epidemiologist (WP9) 10,200.00 0.65 6,630.00
Epidemiologists/data scientists(WP9) 5,200.00 11.00 57,200.00
Epidemiologist WP 9 + Coordination 5,200.00 32.00 166,400.00
WP1
Total person month Total Costs (€) for (A)
45.65 246,745.00
Justification
SpFrance will lead WP9 and co-lead WP4. SpFrance will also be involved in
WP1 and WP7.
SpFrance will bring its specific expertise on the use of health-administrative
data base for health monitoring purposes through several examples in WP9.
Given its experience with the governance and organisation of national and
European health information systems and governance of international
organisations, SpFrance will bring its knowledge to co-lead WP4 and to support
WP7.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
7,400.00 SpFrance will host the mid-term meeting (WP1) in Paris.
WP9 meetings will be organised back to back to the kick off
meeting, mid-term meeting and final conference.
SpFrance will participate to the 3 above mentioned
meetings and to the Steering committee meetings planned in
WP1
(C.2) Equipment Costs (€) Justification
(C.3) Other goods and services Costs (€) Justification
42,180.00 In order to allow the development of national BoD studies,
three workshops will be organised in WP9.4: in Berlin
(workshop 1) and in Paris (workshops 2 and 3 organised
back to back).
Total Costs (€) of (C) 49,580.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 20,742.75
Total estimated eligible costs 317,067.75
[801553] [InfAct] – Part B – Page 35 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/
Short Name IRDES
(If affiliated entity: Affiliated to which 9. SpFRANCE
Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Senior researcher, Director 10,629.00 1.25 13,286.25
Research fellow 5,349.80 7.00 37,448.60
Total person month Total Costs (€) for (A)
8.25 50,734.85
Justification
IRDES will review emerging and data and information sources to develop new
measures for HSPA and propose methods to construct a platform and
disseminate new information & indicators (WP9). Liaise with other HSPA
partners (MSs and international (OECD, etc.) (WP9). IRDES will interact with
WP6 (capacity). IRDES will brings its expertise to WP5 (prioritization of health
information development)
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
750.00
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
5,000.00 HSPA experts meeting to develop and validate the
framework and methods and set priorities for improving
HSPA
Total Costs (€) of (C) 5,750.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 3,953.94
Total estimated eligible costs 60,438.79
[801553] [InfAct] – Part B – Page 36 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
gApplicant Number/
Short Name Inserm (U1153 Team & U1138 Team)
(If affiliated entity: Affiliated to which 9. SpFRANCE
Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Senior Research Director 8,122.00 1.50 12,183.00
Project Manager 5,254.00 0.75 3,940.50
Coordinator data/statistician 4,167.00 11.02 45,920.34
Researcher 4,775.00 5.18 24,734.50
Professor 12,000.00 1.25 15,000.00
Assistant professor 3,927.00 1.00 3,927.00
Post Doctorant 3,740.00 1.00 3,740.00
Post Doctorant 3,710.32 6.30 23,375.00
Total person month Total Costs (€) for (A)
28.00 132,820.34
Justification
INSERM U1153 is specialized in perinatal health, and more specifically on
research on the impact of the organization and quality of care on the health of
pregnant women and newborns. INSERM U1153 will contribute to WP7, WP8
and WP9 in three ways 1) expert knowledge in the development of maternal and
infant health indicators for monitoring health on the national and European level
(thanks to the Europeristat network coordinated by J. Zeitlin) in WP8 and WP9
2) define the functioning of domain specific networks within a sustainable
structure in W7.1 and 3) Contribute to the transition of results and achievements
of domain specific networks with respect to HI into the EU Statistical System
(perinatal health)
Prof. Anita Burgun her team will bring its experience in data integration, data
mining and artificial intelligence methods applied to learning health systems and
will bring expertise in medical informatics and interoperability in WP10. Her
team will contribute to the WP10 task on interoperability and security issues.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
1,450.00
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
20,000.00 Europeristat network Project Meeting
Total Costs (€) of (C) 21,450.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 10,798.92
Total estimated eligible costs 165,069.26
[801553] [InfAct] – Part B – Page 37 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/
Short Name Ministry of Solidarities and Health
(If affiliated entity: Affiliated to which 9. SpFRANCE
Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Senior Consultant 0.00 9 0.00
Total person month Total Costs (€) for (A)
9 0.00
Justification
The Ministry of Health, team of Alain Fontaine, will contribute (in kind
contribution as indicated above) mainly to WP1, WP4 and WP7. In addition, the
Ministry will contribute to WP5, WP8 and WP9 to provide its insights with
regards to policy needs and practices in France. Person-months have been
foreseen for WP1, 4, 7, and 9, but no financial means are requested.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
1,800.00 The MoH will participate to the GA meetings and when
relevant to the WP 4,5,7,8,9 meetings
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
0.00
Total Costs (€) of (C) 1,800.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 126.00
Total estimated eligible costs 1,926.00
[801553] [InfAct] – Part B – Page 38 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ 10
Short Name RKI
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Scientific Officer 7,583.40 15.60 118,301.04
Senior researcher 7,575.10 33.20 251,493.12
Total person month Total Costs (€) for (A)
48.80 369,794.16
Justification
RKI is in charge of WP5 that performs reviews and analyses related to health
information systems and health information prioritization. It is further involved
in WP 7 (Proof of Concept), 8 (Tools and Methods) and 9 (Innovation). Costs
incur for staff performing scientific research (lit. review, survey development
and implementation, preparation of reports, presentations, publications). This
will be done by the senior researcher and the scientific officers. Next the WP5
lead will take part in WP5 and WP8 expert groups and attend SC and GA
meetings. If necessary, he may be represented by the senior research and/or the
scientific officer. All positions require a specific expertise in health indicators,
comparative health information and international cooperation.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
25,752.00 Costs cover 23 travel and subsistence expenses related to 26
meetings: 7 SC and 3 GA meetings; 2 meetings in the
context of task 5.1; 1 meeting in WP4, 1 meeting in WP7, 3
meetings in WP8 and 3 meetings in WP9 ; participation, as
part of the dissemination strategy, at 3 European Public
Health (EPH) conference for 2 people. At EPH, workshops
are planned.
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
0.00
Total Costs (€) of (C) 25,752.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 27.688,23
Total estimated eligible costs 423,234.39
[801553] [InfAct] – Part B – Page 39 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ 11
Short Name EOPYY
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Head Manager of Strategic Planning
2,336.84 2.47 5,772.00
Department
Employee of Strategic Planning
2,190.00 2.00 4,380.00
Department
Total person month Total Costs (€) for (A)
4.47 10,152.00
Justification
Work as contributor at preparing questionnaire and collecting information on
availability and accessibility of health data, national health data collection
methods, and related quality assurance procedures. EOPYY is involved in WP
1, 6, 7 and 8.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
3,151.75 Will participate in GA meetings
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
0.00
Total Costs (€) of (C) 3,151.75
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 931.26
Total estimated eligible costs 14,235.01
[801553] [InfAct] – Part B – Page 40 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ 12
Short Name DOH
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Senior Statistician 8,531.72 1.00 8,531.72
Senior Data Analyst 6,640.93 1.50 9,961.40
Data Analyst 4,211.53 1.50 6,317.30
Total person month Total Costs (€) for (A)
4.00 24,810.42
Justification
DOH will participate directly in 2 work packages, WP8 and WP9. We will also
coordinate the involvement of an Affiliated entity, the Health Research Board,
in WP6.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
5,259.90 Participation in the GA meetings, workshops for WP8 and
workshops and an advanced training for WP9
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
0.00 30,069.92
Total Costs (€) of (C) 5,259.90
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 2,104.92
Total estimated eligible costs 32,175.24
[801553] [InfAct] – Part B – Page 41 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/
Short Name HRB
(If affiliated entity: Affiliated to which 12. DOH
Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Head of National Health Information 8,531.80 0.50 4,265.90
Systems
Programme Manager 6,641.00 0.50 3,320.50
Total person month Total Costs (€) for (A)
1.00 7,586.40
Justification
The HRB will contribute to WP 6.1 and WP6.4
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
Contribution to WP6: Task 6.1. and Task 6.4.
(C) Other direct costs
(C.1) Travel Costs (€) Justification
413.50
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
0.00
Total Costs (€) of (C) 413.50
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 559.99
Total estimated eligible costs 8,559.89
[801553] [InfAct] – Part B – Page 42 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ 13
Short Name ISS
(A) Direct personnel costs
Estimated Person-
Staff function Monthly Cost Sum Cost (€)
month
Researcher/Senior researcher 4,949.82 28.50 141,069.86
Junior researcher 2,549.78 55.00 140,238.00
Technician/Administrator 3,420.00 2.00 6,840.00
Total person month Total Costs (€) for (A)
85.50 288,147.86
Justification
ISS will lead the WP 8 of the Joint Action on 'Tools and methods for Health
Information Support'. The follow-up of WP8 deliverables and milestones, interim
and final reporting and the organisation of several meetings with the participating
partners asks for technical/administrative support, as well as scientific input of
several researchers to work on topics of the WP8 and guide the partners in their
work. The researchers will further be involved in WP6 as contributor to the task
on designing a training program to improve MS capacities in population health
and HSPA; in WP9 as lead of the Deliverable on 'Guidelines for development
and testing specific new indicators to assess both degree of integration and
performance of integrated care systems'; in WP10 as contributor to the task on
'Empirical case studies'. Further participation in WPs 4, 5, 7.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
As lead of WP8, ISS will take part in the following meetings
and conferences: EPH 2018, 2019 and 2020, 3 General
19,430.00 Assembly, 3 Steering Committee; as co-lead and partner in
WPs 4, 5, 6, 7, 9, 10, ISS will take part in WP's specific
meetings.
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
Publication of scientific articles, organisation of 1 WP8
annual meeting (3 meeting in total) in Rome:
- 1st WP8 (face to face); aim of the meeting is to seek
feedback and inputs from participants at an early stage, to
facilitate effective planning and subsequent implementation
of WP8 activities; (target audience: WP8/other WPs
participants, 25/30 expected attendees);
- 2nd WP8 (face to face/teleconference); aim of the meeting
5,050.00 is to monitor WP8 planned activities, to facilitate exchange
of updated result, evaluate possible raised issues identifying
agreed solution; (target audience: WP8/other WPs
participants, 25/30 expected attendees);
- 3rd WP8 (face to face); aim of the meeting is to summarise
and present planned results and deliverables of WP8;
proposing dissemination and harmonization of WP8
outcomes within overall JA results; (target audience:
WP8/other WPs participants, 25/30 expected attendees).
Total Costs (€) of (C) 24,480.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 21,883.95
Total estimated eligible costs 334,511.81
[801553] [InfAct] – Part B – Page 43 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ Short Name 14
CDPC
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Senior researcher/ competent authority 1,538.70 10 15,386.96
Senior Researcher 1,473.82 5 7,369.12
Researcher 1,342.17 20 26,843.44
Total person month Total Costs (€) for (A)
35 49,599.52
Justification
CDPC will coordinate the Joint Action in Latvia as competent authority and will
participate in WP’s 1, 5 (including the evaluation of the HIS), 6, 7, 8, 9 and 10 as
participant.
(B) Direct costs of sub-contracting Costs (€) Task(s)/ Justification
25,000.00 Expert consultations about Health status monitoring (including
biomonitoring) and Monitoring system of health care quality and
efficiency
Total Costs (€) of (B) 25,000.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
15,085.00 Travel to WP’s meetings – airline ticket, insurance, hotel,
subsistence allowances for travel (for 3 days). Staff will
take part in the WHO training course (WP5); 2 country
visits for evaluation of health information systems and 1
final evaluation of the tool meeting
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
0.00
Total Costs (€) of (C) 15,085.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 6,277.92
Total estimated eligible costs 95,962.44
[801553] [InfAct] – Part B – Page 44 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ 15
Short Name HI
(A) Direct personnel costs
Staff function Monthly Cost (€) Estimated Sum Cost (€)
Person-month
Head of division 1,670.91 26.50 44,279.09
Specialist 1,202.11 14.80 17,791.25
Total person months Total Costs (€) for (A)
41.30 62,070.34
Justification
2 public health specialists and 2 statisticians from HI will participate in 6
working packages: WP1, WP2, WP3, WP5, WP7, WP9.
As a participant of WP1, HI will participate in the management of InfAct. In the
activities of dissemination (WP2), HI staff will deliver a layman version of the
final technical report. HI is the WP-leader of WP3.
The staff will be actively participating in the activities of WP5 in mapping and
assessment of health information systems, cataloguing international health
information collecting networks, projects and indicator/data- sets and
prioritisation in health information developments.
The heads of divisions will be part of WP7 supporting the presentation of the
ERIC through country visit with bilateral meetings with MoH and Research
representatives.
As participants and co-leaders of WP9, HI staff will make a case study and share
an inspiring example in the topic of innovation in public Health information for
public Health Policy development.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
14,753.00 HI will participate in SC and GA meetings.
Hi staff will take part in the WHO training course (WP5); 2
country visits for evaluation of health information systems
and 1 final WP5 meeting.
Participation in 2 WP9 meetings are planned.
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
0,00
Total Costs (€) of (C) 14,753.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 5,377.63
Total estimated eligible costs 82,200.97
[801553] [InfAct] – Part B – Page 45 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ 16
Short Name MOHLUX
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Researcher 0 0.50 0.00
Total person month Total Costs (€) for (A)
0.50 0.00
Justification
Person-months have been foreseen, but no financial means are requested (in-kind
contribution free of charge).
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
24,215.00 Subcontracting to Luxembourg Institute of Health for participation
in WP7 and WP8. Selection and definition of health and health
determinant related domains and identification of sources of
information.
Summarizing the availability of health data , adopted data
collection methods, adopted quality assurance procedures, and data
collection methods alternative to standardised ones Collecting
information on available stratification of health data Provide
material on health data availability, standardized data collection
methods and related quality assurance methods to the established
Health Information platform
Total Costs (€) of (B) 24,215.00
Justification
Salary costs and travel costs
(C) Other direct costs
(C.1) Travel Costs (€) Justification
780.00 Participation in midterm GA and closing GA
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
0.00
Total Costs (€) of (C) 780.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 1,749.65
Total estimated eligible costs 26,744.65
[801553] [InfAct] – Part B – Page 46 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ 17
Short Name MFH
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Director 7,620.00 5.50 41,910.00
Consultant Public Health 7,620.00 1.00 7,620.00
Research Officer 1,903.20 0.75 1,427.40
Total person month Total Costs (€) for (A)
7.25 50,957.40
Justification
MFH will be contributing to the coordination of the Joint Action in WP1.
MFH is co-lead WP5 and will be leading one of the tasks in WP5 – the piloting of
peer health information system assessment methodology among participating
countries, together with training of all involved and a concluding event at the end
which would lead to recommendations on the conduct of such assessments.
MFH will also be contributing to WP7, WP8, WP9.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
31,200.00 22 travels including 25 meeting. The lead partner at MFH
will be supervising the in-country peer health information
system assessments (10 travels), and also participating in 7
Steering Committees and 3 General Assemblies. In addition,
MFH will take part in meetings related to WP7 (1 meeting),
and WP9 (1 meeting), and contributing to the dissemination
of project findings in EPH2018, EPH2019, and EPH2020.
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
5,000.00 Organisation of concluding event in Malta to draw up
conclusions on the peer health information system
assessment methodology, plus registration fees for the
abovementioned EPH conferences
Total Costs (€) of (C) 36,200.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 6,101.02
Total estimated eligible costs 93,258.42
[801553] [InfAct] – Part B – Page 47 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ 18
Short Name SMPHU
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Country coordinator 1,000.00 4.50 4,500.00
Total person month Total Costs (€) for (A)
4.50 4,500.00
Justification
PHM (SMPHU) will be involved in WP1, WP5: peer review of HI, training
course organisation in collaboration with WHO-Europe
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
3,300.00 PHM (SMPHU) will take part in the WP5 final meeting and
all 3 GA meetings
(C.2) Equipment Costs (€) Justification
1,000.00 Training materials and equipment (2 computers) for the
trainings and workshops
(C.3) Other goods and services Costs (€) Justification
2,300.00 2 days training in Chisinau, Moldova. This includes the rent
of the venue and catering.
Total Costs (€) of (C) 6,600.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 777.00
Total estimated eligible costs 11,877.00
[801553] [InfAct] – Part B – Page 48 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ 19
Short Name RIVM
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Expert researcher 8,642.87 5.00 43,214.33
Senior researcher 5,697.33 22.60 128,759.63
Junior researcher 4,714.21 9.50 44,785.04
Total person month Total Costs (€) for (A)
37.10 216,759.00
Justification
RIVM will be involved in WP 1, 4, 5, 6, 7, 8 and 9.
RIVM will co-lead WP 7 and 8 and lead tasks in WP 5, 7 and 8.
RIVM will focus on mapping the international health information landscape and
promoting efficient use of data and networks, on developing a sustainable ECHI
set and on preparing the business case for a future health information research
infrastructure.
Within its activities, RIVM will have special attention for dissemination of
information via a web-based platform to support the JA and the future
infrastructure.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
17,977.00 3 travels for European Public Health conferences, 4 travels
for Steering Committee meetings, 4 travels for WP5, 4
travels for WP7, 6 travels for WP8, 2 travels WP9, 5 travels
for the GAas. This covers a total of 28 meetings (some
meetings are back to back and for some meetings 2 people
are attending).
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
0.00
Total Costs (€) of (C) 17,977.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 16,431.52
Total estimated eligible costs 251,167.52
[801553] [InfAct] – Part B – Page 49 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ 20
Short Name HD
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Senior staff 8,915.40 10.00 89,154.00
Senior research 7,444.60 8.50 63.279.10
Total person month Total Costs (€) for (A)
18.50 152,433,10
Justification
Co-lead for task 5.2. Participant in tasks 1.1, 5.1, 8.1, 8.2, 8.3, 9.2, 9.3. 9.5, 10.2,
and 10.4.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
8,400.00 Participation in the GA meetings and in 3 training events.
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
0.00
Total Costs (€) of (C) 8,400.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 10,158.65 6.32 %
Total estimated eligible costs 170,991.75
[801553] [InfAct] – Part B – Page 50 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ 21
Short Name MZ
(A) Direct personnel costs
Staff function Monthly Cost (€) Estimated Sum Cost (€)
Person-month
0.00 0 0.00
Total person months Total Costs (€) for (A)
0 0.00
Justification
MZ only acts as Competent Authority, but will not participate in any tasks.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
0.00
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
0.00
Total Costs (€) of (C) 0.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 0.00
Total estimated eligible costs 0.00
[801553] [InfAct] – Part B – Page 51 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/
Short Name NIPH
(If affiliated entity: Affiliated to which 21. MZ
Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost (€) Estimated Sum Cost (€)
Person-month
Senior researcher 1,920.00 2.50 4,800.00
Junior researcher 1,920.00 2.50 4,800.00
Total person months Total Costs (€) for (A)
5.00 9,600.00
Justification
NIPH will contribute with its expertise to WP7 (working towards a national HI
network) and WP8 related to guidelines in data standardisation processes.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
0.00
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
0.00
Total Costs (€) of (C) 0.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 672.00
Total estimated eligible costs 10,272.00
[801553] [InfAct] – Part B – Page 52 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ 22
Short Name MS
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Senior Researcher/coordinator 1,981.18 3.80 7,528.50
Researcher 1,841.00 11.95 21,999.95
Junior researcher 1,841.83 5.45 10,038.00
Total person month Total Costs (€) for (A)
21.20 39,566.45
Justification
Directorate-General of Health (DGS), the Competent Authority, is a central
agency of the Ministério da Saúde – República Portuguese [Ministry of Health
of the Portuguese Republic]. DGS coordinates the Portuguese participation in
this Joint action, which includes lead WP 6 on Strengthen EU countries health
information capacity and interact with WP 9 and WP 10.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
36,150.00 WP 6 proposes a piloting on key issues for training on
health information capacities that will bring together
several (5-7) member state representatives along with
others via web to participate, the 12 meetings associated
with this are herein included. Also proposed is a
workshop to evaluate the capacity build program
generated from Task 6.2. the respective team traveling is
also in this budget (either if they are done back-to-back
with pilot or independently).
DGS will participate in all 10 JA face-to-face SC and GA
meetings. 2 persons will attend the 3 GA meetings.
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
2,500.00 Workshop on capacity building programme proposal
evaluation logistics
Total Costs (€) of (C) 38,650.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 5,475.15
Total estimated eligible costs 83,691.60
[801553] [InfAct] – Part B – Page 53 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/
Short Name UNL
(If affiliated entity: Affiliated to which 22. MS
Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Senior Researcher/Coordinator 1,840.22 21.91 40,319.30
Researcher 1,840.48 9.09 16,730.00
Total person month Total Costs (€) for (A)
31.00 57,049.30
Justification
The Institute of Hygiene and Tropical Medicine (IHMT) of UNL will be involved
in WP1 and in all stages of WP 6 development with main tasks on Task 6.2. in
which a proposal for a Capacity build on health information in Europe will be
made. Will also be fully involved in piloting key-issues of training defined within
tasks 6.1 and 6.2. Will also be involved in the Portuguese participation in WP10.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
4,150.00 IHMT will Participate in the thee plenary meetings. Will
participate in the piloting of training key-issues week and in
the Capacity Building program proposal workshop.
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
0.00
Total Costs (€) of (C) 4,150.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 4,283.95
Total estimated eligible costs 65,483.25
[801553] [InfAct] – Part B – Page 54 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/
Short Name INSA
(If affiliated entity: Affiliated to which 22. MS
Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Senior Researcher/Coordinator 1,839.24 4.73 8,699.60
Researcher 1,840.99 7.27 13,384.00
Total person month Total Costs (€) for (A)
12.00 22,083.60
Justification
INSA will be involved inWP1 and in all stages of WP 6, being the Portuguese
institution responsible for the evaluation of the national health plans, will be
leading the evaluation of the proposal for a Capacity build on health information
in Europe will be done in task 6.2. Will also be involved in the Portuguese
participation in WP9.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
4,150.00 INSA will Participate in the GA meetings. Will participate
in the piloting of training key-issues week and in the
Capacity Building program proposal workshop.
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
0.00
Total Costs (€) of (C) 4,150.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 1,836.35
Total estimated eligible costs 28,069.95
[801553] [InfAct] – Part B – Page 55 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ 23
Short Name INSP
(A) Direct personnel costs
Staff function Monthly Cost (€) Estimated Sum Cost (€)
Person-month
Senior researcher 1,062.5 8.00 8,500.00
Junior researcher 849.26 4.71 4,000.00
Project consultants 849.26 4.71 4,000.00
Total person months Total Costs (€) for (A)
17.42 16,500.00
Justification
NIPH will participate in WP1, WP3, WP5, WP6 and WP 9. It will contribute to
all deliverables and ensure financial and technical reporting. It will contribute to
the HIS assessment and will participate in the training course and study visits
organized for the assessment. Will actively contribute in mapping capacities and
education/training programmes in health information across MSs as member in
WP 5 and WP 6. Also will actively support the WG dedicated to project
evaluation. The IT department will develop a project presentation file within the
NIPH website.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
27,738.32 As partner in WP 3, WP5, WP6 and WP9 NIPH will take
part in the following meetings and conferences: EPH 2018,
2019 and 2020; Gastein European Health Forum 2019 and
2020; WHO training course (WP5); 3 WP meetings;
evaluation meetings, country visits, WP 5 training course.
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
4,300.00 Production of project leaflets in Romanian and distribution
in national events and the HIS stakeholders assessment
workshop organization
Total Costs (€) of (C) 32,038.32
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 3,397.68
Total estimated eligible costs 51,936.00
[801553] [InfAct] – Part B – Page 56 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ 24
Short Name IPHS
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Senior researcher, Coordinator 1,650.00 3 4,950.00
Senior researcher 1,650.00 3 4,950.00
Junior researcher 1,320.00 3 3,960.00
Total person month Total Costs (€) for (A)
9 13,860.00
Justification
Researchers from IPHS will be involved in WP5, WP6, WP7 and WP8. In WP5,
two researchers will go through WHO peer review training as well through peer
review country visits.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
14,800.00 IPHS representatives will take part in the meetings as
planned for WP1, WP5, WP6, WP7, and WP8.
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
280.00 Costs for two stakeholders meeting
Total Costs (€) of (C) 15,080.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 2,025.80
Total estimated eligible costs 30,965.80
[801553] [InfAct] – Part B – Page 57 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ 25
Short Name NIJZ
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Senior researcher 5,102.97 4.37 22,300.00
Junior researcher 2,379.78 3.66 8,710.00
Researcher 3,477.12 9.18 31,920.00
Coordinator 2,740.38 1.04 2,850.00
Total person month Total Costs (€) for (A)
18.25 65,780.00
Justification
Experts will provide input in WP6, WP8 and WP9; namely participation in health
information web platform, identifying criteria for networks of experts involved in
all WPs activities within the entire JA and identifying and sharing inspiring
examples from MS with regards to emerging indicators and promising data
sources for public health and healthcare strategies and participating in empirical
case studies in WP10.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
17,723.00 9 travels are foreseen for the 7 Steering Committees and 3
General Assemblies. 2 travels for WP8 meetings, 4 travels
for WP10 meetings
(C.2) Equipment Costs (€) Justification
1,054.00 1 laptop
(C.3) Other goods and services Costs (€) Justification
500.00 Organisation of meetings with health information
stakeholders in Slovenia
Total Costs (€) of (C) 19,277.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 5,953.99
Total estimated eligible costs 91,010.99
[801553] [InfAct] – Part B – Page 58 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ 26
Short Name ISCIII
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Staff Senior Researchers (POs) 4,400.00 18 79,200.00
Junior Researchers (non POs) 3,000.00 75 225,000.00
Total person month Total Costs (€) for (A)
93 304,200.00
Justification
ISCIII will lead WP4 on sustainability.
In WP 2, ISCIII will developing Fact-Sheets translating main outcomes of JA
(collaboration with WP 2, 5-10).
In WP7 ISCIII will participate developing the governance structures for
sustainability.
In WP9 ISCIII will participate developing an innovative case-study and will lead
task 9.4 and also participate provide scientific input of several researchers to
guide the partners in their work.
In WP 5, 6 and 8 ISCIII will provide counselling about sustainability and discuss
different options.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
0.00 Travels for ISCIII will be arranged by FSCAI (its Affiliated
Entity)
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
0.00 Other goods and services for ISCIII will be arranged by
FSCAI (its Affiliated Entity)
Total Costs (€) of (C) 0.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 21,294.00
Total estimated eligible costs 325,494.00
[801553] [InfAct] – Part B – Page 59 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/
Short Name IACS
(If affiliated entity: Affiliated to which 26. ISCIII
Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost (€) Estimated Sum Cost (€)
Person-month
Senior Researcher 5,690.17 5.00 28,450.83
Researcher 3,160.23 7.00 22,121.60
Data Manager 2,978.59 2.00 5,957.17
Data Scientist 4,337.25 7.00 30,360.75
Junior Data Scientist 3,276.00 13.00 42,587.94
Project Officer 3,303.52 6.50 21,472.91
Total person months Total Costs (€) for (A)
40.50 150,951.20
Justification
IACS will co-lead WP10 on Assessing and Piloting interoperability for Public
Health Policy and will lead Task 10.4 on Empirical case studies. Within this Task,
IACS will develop a case study on Comparative effectiveness in acute treatment
of Ischemic Stroke (Stroke Code), combining HER and administrative data from
at least three countries. IACS will participate in WP3 on Evaluation, in particular
in Task 3.1 by handling the subcontracting and in leading Task 3.3 on impact
assessment. IACS will participate in WP7 on Proof of concept of sustainable
structure on health information, in particular in Task 7.1 (Define the desired
structure and content areas of a functional network of networks) and Task 7.2
(Business case and roadmap for implementation). Finally, IACS will participate in
WP1 on Management of the Joint Action specifically in the coordination activities
and meetings.
For the above activities the following staff is needed: Senior Researcher,
Researcher, Data Manager, Data Scientist, Junior Data Scientist and Project
Officer.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
15,000.00 Subcontracting: external evaluation (WP3): 6000 subcontract 1;
9000€ subcontract 2.
Total Costs (€) of (B) 15,000.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
12,410.31 WP 1, WP 7 and WP 10 meetings. Additionally, IACS will
participate in 3 conferences such as EPH or Gastein
European Health Forum.
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
4,000.00 Registration fee (3 events); Venue and catering for 2
Workshops on case studies (WP 10)
Total Costs (€) of (C) 16,410.31
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 12,765.31
Total estimated eligible costs 195,126.82
[801553] [InfAct] – Part B – Page 60 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ FCSAI
Short Name
(If affiliated entity: Affiliated to which 26. ISCIII
Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
0.00 0 0.00
Total person month Total Costs (€) for (A)
0 0.00
Justification
Personnel costs only include those of administrative officers, which are covered in
the Indirect Costs. No person-months are therefore required.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
13,800.00 FCSAI will make all necessary travel arrangements for
beneficiary ISCIII personnel’s participation in meetings:
these travels include participation in 10 WP1 meetings, 1
WP7 meeting, 2 WP8 meetings and 4 WP9 meetings
These expenses will be reimbursed at 100%; the own
contribution is being covered by ISCIII.
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
FCSAI will be responsible of the organisation of all
meetings related to the tasks of beneficiary ISCIII. These
meetings are: 4 meetings and 3 workshops (M18 and M30)
with national consortia and with WP 5, 6,7,8,9,10 leaders or
67,500.00 in collaboration with WHO Europe (in one of these
workshops).
Organisation and funding of 2 AoM meetings (M18 and 32)
with high governmental representatives (Ministries of
Health (MH) and Ministries of Research (MR)) of all
MS/EEA participating in JA
(see WP4 descriptions for details)
These expenses will be reimbursed at 100%; the own
contribution is being covered by ISCIII.
Total Costs (€) of (C) 81,300.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 5.691.00
Total estimated eligible costs 86,991.00
[801553] [InfAct] – Part B – Page 61 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ 27
Short Name FoHM
(A) Direct personnel costs
Staff function Monthly Cost (€) Estimated Sum Cost (€)
Person-month
Coordinator 9,200.00 1.25 11,500.00
Researcher 9,200.00 2.00 18,400.00
Total person month Total Costs (€) for (A)
3.25 29,900.00
Justification
FoHM will contribute by sharing knowledge (WP7, 8, 9) and/or information and
participate in the GA meetings
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
8,541.00 FoHM will participate in WP and GA meetings and
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
0.00
Total Costs (€) of (C) 8,541.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 2,690.87
Total estimated eligible costs 41,131.87
[801553] [InfAct] – Part B – Page 62 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/ 28
Short Name WG
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Director 14,000.00 0.80 11,200.00
Researcher / co-ordinator 8,545.45 1.10 9,400.00
Total person month Total Costs (€) for (A)
1.90 20,600.00
Justification
WG contribute to WP7 development of the roadmap for a future ERIC. The
Director will attend the GA and SC meetings. The Researcher/co-ordinator will
work to him on the preparation of necessary documents to complete these tasks.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
3,576.00 WG will take part in the GA meetings.
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
0.00
Total Costs (€) of (C) 3,576.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 1,692.32
Total estimated eligible costs 25,868.32
[801553] [InfAct] – Part B – Page 63 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/
Short Name PHE
(If affiliated entity: Affiliated to which 28.WG
Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Scientist 7,226.67 7.50 54,200.00
Total person month Total Costs (€) for (A)
7.50 54,200.00
Justification
In WP 9 Public Health England will lead the work on Development of composite
indicators to monitor the burden of disease at population level (Task 9.4a).
Senior leadership will be provided by PHE at no cost. A junior scientist working
part time on the project will collate experience and contributions from member
states using the existing WHO network and other mechanisms to identify good
practice and experience. The scientist will prepare and support the workshops on
Burden of Diseases metrics (workshop expenses are not included in this budget).
Working in collaboration with IHME and WHO EURO BoD network the scientist
will help prepare a report using available metrics on EC countries with an
emphasis on data gaps. The scientist will also support work on an educational
resource to share skills and experience and on a report of examples of use of these
metrics with a view to promoting good practice in use of burden of disease
metrics.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
3,600.00 Costs for travel and subsistence have been included to
attend international meetings with members of WHO
network including initial meeting set up and quarterly
steering groups (4 per year x 3 years).
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
0.00
Total Costs (€) of (C) 3,600.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 4,046.00
Total estimated eligible costs 61,846.00
[801553] [InfAct] – Part B – Page 64 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Applicant Number/
Short Name SU
(If affiliated entity: Affiliated to which 28. WG
Applicant number/Short name)
(A) Direct personnel costs
Staff function Monthly Cost Estimated Sum Cost (€)
Person-month
Director 14,526.32 3.80 55,200.00
Researcher 4,400.00 24.00 105,600.00
Total person month Total Costs (€) for (A)
27.80 160,800.00
Justification
Swansea University will participate in WP1 and contribute to WPs 4, 5, 8, 9 and
10. The work involves desk research on health informatics, mapping and
assessment of health information systems and networks in UK, contribution to the
development of the ERIC and the provision of inspiring examples using analyses
of multi-sourced linked data for WPs 8, 9 and 10. Professor Lyons will direct and
lead all activities, attend the GA meetings and 5 meetings of individual WPs. The
research analyst will identify existing inspirational activities from literature
searches, administer surveys to UK networks and conduct new and complex
analyses using linked individual and household population data from multiple
health and non-health sources held within the SAIL databank. The final content of
the inspiring examples will be agreed with other country partners to ensure
maximise comparability and potential impact.
(B) Direct costs of sub-contracting Costs (€) Task(s)/Justification
0.00
Total Costs (€) of (B) 0.00
Justification
(C) Other direct costs
(C.1) Travel Costs (€) Justification
5,727.00 SU will take part in the GA meetings, plus up to 5 meetings
of WPs (5,8,9,10).
(C.2) Equipment Costs (€) Justification
0.00
(C.3) Other goods and services Costs (€) Justification
0.00
Total Costs (€) of (C) 5,727.00
(D) Indirect Costs Total Costs (€)
(Max. 7% on A, B and C) 11,656.89
Total estimated eligible costs 178,183.89
[801553] [InfAct] – Part B – Page 65 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
10. PREVIOUS AND CURRENT GRANTS RELEVANT TO THE PROGRAMME (LIMITED TO THE LAST 3 YEARS)
- ADVANTAGE - HP-ADHOC-2014-2020-JA-2015 - Managing Frailty. A comprehensive approach to
promote a disability-free advanced age in Europe: the ADVANTAGE initiative
- BRIDGE Health - HP-JA-2014 - BRidging Information and Data Generation for Evidence-based Health
Policy and Research
- CARE - HP-HA-2015 - Common Approach for REfugees and other migrants' health
- CHRODIS-PLUS - HP-JA-2016 - CHRODIS-PLUS: Implementing good practices for chronic diseases
- DEM 2 - HP-JA-2014 - Joint Action on Dementia 2015-2018
- eHN-JA - HP-JA-2014 - Joint Action to support the eHealth Network
- EMERGE - HP-JA-2014 - Efficient response to highly dangerous and emerging pathogens at EU level
- EUHWforce - 2HP-PRG-THEM - European Health Workforce Planning and Forecasting
- EUCERD - 2HP-PRG-THEM - EUCERD Joint Action: working for rare diseases
- EU – JAMRAI - HP-JA-2016 - Joint Action Joint Action on Antimicrobial Resistance and Healthcare-
Associated Infections
- EUnetHTA JA3 - HP-ADHOC-2014-2020-JA-2015 - European Network for Health Technology
Assessment (EUnetHTA) - Joint Action 3
- EUROCAT - 2HP-PRG-THEM - European Surveillance of Congenital Anomalies
- Euro-GTP II - HP-PJ-2015 - Good Practices for demonstrating safety and quality through recipient follow-
up
- F.Y.F.A. - HP-PJ-2016 - Focus on Youth, Football and Alcohol
- GAPP - HP-JA-2016-2 - GAbapentin in Paediatric Pain
- GET READY - HP-PJ-2015 - Gathering and Exchanging Tools to REduce Alcohol Dangerous use in
Youngsters
- HA-REACT - HP-JA-2014 - Joint Action on HIV and Co-infection Prevention and Harm Reduction
- JA INTEGRATE - HP-JA-2016 – Joint Action on integrating prevention, testing and linkage to care
strategies across HIV, viral hepatitis, TB and STIs in Europe (INTEGRATE)
- JAMIE – 2HP-PRG-THEM - Joint Action on Monitoring Injuries in Europe
- JAMS - HP-ADHOC-2014-2020-JA-2015 - Market surveillance of medical devices
- JANPA - HP-JA-2014 - Joint Action on Nutrition and Physical Activity
- JARC - HP-ADHOC-2014-2020-JA-2015 - JA on Rare Cancers
- JAseHN - HP-JA-2014 - Joint Action to support the eHealth Network
- MH-WB Joint Action - 2HP-PRG-THEM - Mental health and well-being
- NEXT-LEVEL - HP-PJ-2014 - Innovative Approaches to Prevention and Developing the NEXT-LEVEL
of Prevention Management in Europe
- JA-Orphanet Europe - 2HP-PRG-THEM- Development of the European portal of rare diseases and orphan
drugs
- RARHA - 2HP-PRG-THEM - Joint Action on reducing alcohol-related harm
- RD-ACTION - HP-JA-2014 – Promoting Implementation of Recommendations on Policy, Information and
Data for Rare Diseases
- TRANSPOSE - HP-PJ-2016 - TRANSfusion and transplantation: PrOtection and SElection of donors
- UNDER PRESSURE - HP-PJ-2016 - UNDERstanding and PRomoting Evaluated succeSSful practices
aimed at Underage and youth problem drinking REduction
- VICTOR-E - HP-PJ-2014 - VIrtual Coaching TOol for Risk reduction in Europe
- VISTART - HP-JA-2014 - Vigilance and Inspection for the Safety of Transfusion, Assisted Reproduction
and Transplantation
11. CURRENT APPLICATIONS RELEVANT TO THE PROGRAMME
- JA-01-2017 Joint Action on Health inequalities
- JA-02-2017 Joint Action – Innovative Partnership on Action against Cancer
- JA-03-2017 Joint Action on Vaccination
- JA-04-2017 Joint Action on preparedness and action at points of entry (air, maritime and ground crossing)
- JA-05-2017 Joint Action supporting the eHealth Network
[801553] [InfAct] – Part B – Page 66 / 67 Document Version 5.00 dated 28/05/2018
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
12. EXCEPTIONAL UTILITY
The proposal fulfils the criteria for exceptional utility. Sixteen countries with a Gross National Income below 90%
of the EU average participate (Bosnia and Herzegovina, Croatia, Cyprus, Czech Republic, Estonia, Greece, Latvia,
Lithuania, Malta, Moldova, Poland, Portugal, Romania, Serbia, Slovenia and Spain). A total of 30.49% of the
budget is allocated to these countries.
13. COLLABORATING STAKEHOLDERS
City & Country Institution Contact person
(First name and last name)
Albania Ministry of Health Romeo Zegali
Belgium Belgian Consortium on Health Information (IBRI) Lieven De Raedt
Bulgaria Ministerstvo Na Zdraveopazvaneto (Ministry of Nayden Chivarov
Health)
Bosnia- Public Health Institute of the Federation Bosnia and Šeila Cilović-Lagarija
Herzegovina Herzegovina
Tanja Mičić
Denmark Direktør, Statens Institut for Folkesundhed Morten Grønbæk
Germany Federal Environment Agency Marike Kolossa-Gehring
Iceland Directorate of Health Gudrún Gudfinnsdóttir
Slovakia National Health Information Centre Jan Cap
Switzerland Swiss Tropical and Public Health Institute Nicole Probst,
Michael Käser
United Kingdom Analytical Section Head Population, Geography & Robyn Wilson
International Statistics NHS Digital
International OECD Ian Brownwood
Gaetan Lafortune
International WHO Europe Claudia Stein
International European Observatory on Health Systems and Josep Figueras
Policies
International IANPHI Jean-Claude Desenclos
International Platform for Better Oral Health in Europe Mathilde Bouvier
[801553] [InfAct] – Part B – Page 67 / 67 Document Version 5.00 dated 28/05/2018
Grant Agreement number: 801553 — InfAct — HP-JA-2017
ESTIMATED BUDGET FOR THE ACTION (page 1 of 7) Associated with document Ref. Ares(2018)3121156 - 13/06/2018
1
Estimated eligible costs (per budget category) EU contribution Action's estimated receipts
A. Direct B. Direct C. Other direct D. Indirect Total costs Financial
personnel costs costs of costs costs2 Income contributions
Reimbursement Maximum EU Maximum Action’s
subcontracting generated by given by third
rate %3 contribution4 grant amount5 total receipts
the action parties to the
beneficiaries
A.1 C.1 Travel
Employees (or C.2
equivalent) Equipment
A.2 Natural C.3 Other
persons under goods and
direct contract services
and seconded
persons
Cost form6 Actual Actual Actual Flat-rate7
7%
d = 0.07×(a
a b c e = a+b+c+d f g=e×f h i j k=i+j
+b+c)
1. Sciensano 776830.36 0.00 70842.00 59337.07 907009.43 n\a n\a 725607.54 0.00 0.00 0.00
2. GÖG 127087.00 0.00 38270.00 11574.99 176931.99 n\a n\a 141545.59 0.00 0.00 0.00
3. MCA 917.00 0.00 3200.00 288.19 4405.19 n\a n\a 3010.55 0.00 0.00 0.00
4. CIPH 135542.63 3500.00 23790.00 11398.28 174230.91 n\a n\a 139384.73 0.00 0.00 0.00
5. MoHCy 20717.27 0.00 4984.00 1799.09 27500.36 n\a n\a 22000.29 0.00 0.00 0.00
6. UZIS 19184.00 0.00 8730.00 1953.98 29867.98 n\a n\a 23894.38 0.00 0.00 0.00
7. MoSA 0.00 0.00 0.00 0.00 0.00 n\a n\a 0.00 0.00 0.00 0.00
- NIHD 7945.92 0.00 12600.00 1438.21 21984.13 n\a n\a 17587.30 0.00 0.00 0.00
Total beneficiary 7945.92 0.00 12600.00 1438.21 21984.13 n\a n\a 17587.30 0.00 0.00 0.00
1
Grant Agreement number: 801553 — InfAct — HP-JA-2017
ESTIMATED BUDGET FOR THE ACTION (page 2 of 7) Associated with document Ref. Ares(2018)3121156 - 13/06/2018
1
Estimated eligible costs (per budget category) EU contribution Action's estimated receipts
A. Direct B. Direct C. Other direct D. Indirect Total costs Financial
personnel costs costs of costs costs2 Income contributions
Reimbursement Maximum EU Maximum Action’s
subcontracting generated by given by third
rate %3 contribution4 grant amount5 total receipts
the action parties to the
beneficiaries
A.1 C.1 Travel
Employees (or C.2
equivalent) Equipment
A.2 Natural C.3 Other
persons under goods and
direct contract services
and seconded
persons
Cost form6 Actual Actual Actual Flat-rate7
7%
d = 0.07×(a
a b c e = a+b+c+d f g=e×f h i j k=i+j
+b+c)
8. THL 247012.50 0.00 26080.00 19116.48 292208.98 n\a n\a 233767.18 0.00 0.00 0.00
9. SpFrance 246745.00 0.00 49580.00 20742.75 317067.75 n\a n\a 253654.20 0.00 0.00 0.00
- INSERM 132820.34 0.00 21450.00 10798.92 165069.26 n\a n\a 132055.41 0.00 0.00 0.00
- IRDES 50734.85 0.00 5750.00 3953.94 60438.79 n\a n\a 48351.03 0.00 0.00 0.00
- MoH FR 0.00 0.00 1800.00 126.00 1926.00 n\a n\a 1540.80 0.00 0.00 0.00
Total beneficiary 430300.19 0.00 78580.00 35621.61 544501.80 n\a n\a 435601.44 0.00 0.00 0.00
10. RKI 369794.16 0.00 25752.00 27688.23 423234.39 n\a n\a 338587.51 0.00 0.00 0.00
11. EOPYY 10152.00 0.00 3151.75 931.26 14235.01 n\a n\a 11388.01 0.00 0.00 0.00
12. DOH 24810.42 0.00 5259.90 2104.92 32175.24 n\a n\a 25740.19 0.00 0.00 0.00
2
Grant Agreement number: 801553 — InfAct — HP-JA-2017
ESTIMATED BUDGET FOR THE ACTION (page 3 of 7) Associated with document Ref. Ares(2018)3121156 - 13/06/2018
1
Estimated eligible costs (per budget category) EU contribution Action's estimated receipts
A. Direct B. Direct C. Other direct D. Indirect Total costs Financial
personnel costs costs of costs costs2 Income contributions
Reimbursement Maximum EU Maximum Action’s
subcontracting generated by given by third
rate %3 contribution4 grant amount5 total receipts
the action parties to the
beneficiaries
A.1 C.1 Travel
Employees (or C.2
equivalent) Equipment
A.2 Natural C.3 Other
persons under goods and
direct contract services
and seconded
persons
Cost form6 Actual Actual Actual Flat-rate7
7%
d = 0.07×(a
a b c e = a+b+c+d f g=e×f h i j k=i+j
+b+c)
- HRB 7586.40 0.00 413.50 559.99 8559.89 n\a n\a 6847.91 0.00 0.00 0.00
Total beneficiary 32396.82 0.00 5673.40 2664.91 40735.13 n\a n\a 32588.10 0.00 0.00 0.00
13. ISS 288147.86 0.00 24480.00 21883.95 334511.81 n\a n\a 267609.45 0.00 0.00 0.00
14. CDPC 49599.52 25000.00 15085.00 6277.92 95962.44 n\a n\a 76769.95 0.00 0.00 0.00
15. HI 62070.34 0.00 14753.00 5377.63 82200.97 n\a n\a 65760.78 0.00 0.00 0.00
16. MOHLUX 0.00 24215.00 780.00 1749.65 26744.65 n\a n\a 21395.72 0.00 0.00 0.00
17. MFH 50957.40 0.00 36200.00 6101.02 93258.42 n\a n\a 74606.74 0.00 0.00 0.00
18. SMPHU 4500.00 0.00 6600.00 777.00 11877.00 n\a n\a 9501.60 0.00 0.00 0.00
19. RIVM 216759.00 0.00 17977.00 16431.52 251167.52 n\a n\a 200934.02 0.00 0.00 0.00
3
Grant Agreement number: 801553 — InfAct — HP-JA-2017
ESTIMATED BUDGET FOR THE ACTION (page 4 of 7) Associated with document Ref. Ares(2018)3121156 - 13/06/2018
1
Estimated eligible costs (per budget category) EU contribution Action's estimated receipts
A. Direct B. Direct C. Other direct D. Indirect Total costs Financial
personnel costs costs of costs costs2 Income contributions
Reimbursement Maximum EU Maximum Action’s
subcontracting generated by given by third
rate %3 contribution4 grant amount5 total receipts
the action parties to the
beneficiaries
A.1 C.1 Travel
Employees (or C.2
equivalent) Equipment
A.2 Natural C.3 Other
persons under goods and
direct contract services
and seconded
persons
Cost form6 Actual Actual Actual Flat-rate7
7%
d = 0.07×(a
a b c e = a+b+c+d f g=e×f h i j k=i+j
+b+c)
20. HD 152433.10 0.00 8400.00 10158.65 170991.75 n\a n\a 136793.40 0.00 0.00 0.00
21. MZ 0.00 0.00 0.00 0.00 0.00 n\a n\a 0.00 0.00 0.00 0.00
- NIPH 9600.00 0.00 0.00 672.00 10272.00 n\a n\a 8217.60 0.00 0.00 0.00
Total beneficiary 9600.00 0.00 0.00 672.00 10272.00 n\a n\a 8217.60 0.00 0.00 0.00
22. MS 39566.45 0.00 38650.00 5475.15 83691.60 n\a n\a 66953.28 0.00 0.00 0.00
- INSA 22083.60 0.00 4150.00 1836.35 28069.95 n\a n\a 22455.96 0.00 0.00 0.00
- UNL 57049.30 0.00 4150.00 4283.95 65483.25 n\a n\a 52386.60 0.00 0.00 0.00
Total beneficiary 118699.35 0.00 46950.00 11595.45 177244.80 n\a n\a 141795.84 0.00 0.00 0.00
23. INSP 16500.00 0.00 32038.32 3397.68 51936.00 n\a n\a 41548.80 0.00 0.00 0.00
4
Grant Agreement number: 801553 — InfAct — HP-JA-2017
ESTIMATED BUDGET FOR THE ACTION (page 5 of 7) Associated with document Ref. Ares(2018)3121156 - 13/06/2018
1
Estimated eligible costs (per budget category) EU contribution Action's estimated receipts
A. Direct B. Direct C. Other direct D. Indirect Total costs Financial
personnel costs costs of costs costs2 Income contributions
Reimbursement Maximum EU Maximum Action’s
subcontracting generated by given by third
rate %3 contribution4 grant amount5 total receipts
the action parties to the
beneficiaries
A.1 C.1 Travel
Employees (or C.2
equivalent) Equipment
A.2 Natural C.3 Other
persons under goods and
direct contract services
and seconded
persons
Cost form6 Actual Actual Actual Flat-rate7
7%
d = 0.07×(a
a b c e = a+b+c+d f g=e×f h i j k=i+j
+b+c)
24. IPHS 13860.00 0.00 15080.00 2025.80 30965.80 n\a n\a 24772.64 0.00 0.00 0.00
25. NIJZ 65780.00 0.00 19277.00 5953.99 91010.99 n\a n\a 72808.79 0.00 0.00 0.00
26. ISCIII 304200.00 0.00 0.00 21294.00 325494.00 n\a n\a 260395.20 0.00 0.00 0.00
- FCSAI 0.00 0.00 81300.00 5691.00 86991.00 n\a n\a 69592.80 0.00 0.00 0.00
- IACS 150951.20 15000.00 16410.31 12765.31 195126.82 n\a n\a 156101.46 0.00 0.00 0.00
Total beneficiary 455151.20 15000.00 97710.31 39750.31 607611.82 n\a n\a 486089.46 0.00 0.00 0.00
27. FoHM 29900.00 0.00 8541.00 2690.87 41131.87 n\a n\a 32905.50 0.00 0.00 0.00
28. WG 20600.00 0.00 3576.00 1692.32 25868.32 n\a n\a 20694.66 0.00 0.00 0.00
- SU 160800.00 0.00 5727.00 11656.89 178183.89 n\a n\a 142547.11 0.00 0.00 0.00
5
Grant Agreement number: 801553 — InfAct — HP-JA-2017
ESTIMATED BUDGET FOR THE ACTION (page 6 of 7) Associated with document Ref. Ares(2018)3121156 - 13/06/2018
1
Estimated eligible costs (per budget category) EU contribution Action's estimated receipts
A. Direct B. Direct C. Other direct D. Indirect Total costs Financial
personnel costs costs of costs costs2 Income contributions
Reimbursement Maximum EU Maximum Action’s
subcontracting generated by given by third
rate %3 contribution4 grant amount5 total receipts
the action parties to the
beneficiaries
A.1 C.1 Travel
Employees (or C.2
equivalent) Equipment
A.2 Natural C.3 Other
persons under goods and
direct contract services
and seconded
persons
Cost form6 Actual Actual Actual Flat-rate7
7%
d = 0.07×(a
a b c e = a+b+c+d f g=e×f h i j k=i+j
+b+c)
- PHE 54200.00 0.00 3600.00 4046.00 61846.00 n\a n\a 49476.80 0.00 0.00 0.00
Total beneficiary 235600.00 0.00 12903.00 17395.21 265898.21 n\a n\a 212718.57 0.00 0.00 0.00
7
Total consortium 3947437.62 67715.00 658427.78 326050.95 4999631.35 80 3999705.08 3999191.48 0.00 0.00 0.00
6
Grant Agreement number: 801553 — InfAct — HP-JA-2017
ESTIMATED BUDGET FOR THE ACTION (page 7 of 7) Associated with document Ref. Ares(2018)3121156 - 13/06/2018
(1) See Article 6 for the eligibility conditions
(2) The indirect costs claimed must be free of any amounts covered by an operating grant (received under any EU or Euratom funding programme). A beneficiary that receives an operating grant during the action's duration
cannot claim any indirect costs for the year(s)/reporting period(s) covered by the operating grant (see Article 6.2.D).
(3) See Article 5.2 for the reimbursement rate.
(4) This is the theoretical amount of the EU contribution, if the reimbursement rate is applied to all the budgeted costs. This theoretical amount is capped by the 'maximum grant amount'.
(5) The 'maximum grant amount' is the maximum grant amount decided by the Agency. It normally corresponds to the requested grant, but may be lower.
(6) See Article 5 for the cost forms.
(7) Flat rate : 7% of eligible direct costs.
7
Grant Agreement number: 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
GESUNDHEIT ÖSTERREICH GMBH (GÖG), established in STUBENRING 6, WIEN 1010,
Austria, VAT number: ATU62777178, (‘the beneficiary’), represented for the purpose of signing this
Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘2’)
in Grant Agreement No 801553 (‘the Grant Agreement’)
between SCIENSANO and the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) ('the Agency'), under the powers delegated by the European Commission ('the
Commission'),
for the action entitled Information for Action (InfAct).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-928836208_75_210--]
1
Grant Agreement number: 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
MINISTRY OF CIVIL AFFAIRS (MCA), established in Trg Bosne i Hercegovine 1, SARAJEVO
71000, Bosnia and Herzegovina, (‘the beneficiary’), represented for the purpose of signing this
Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘3’)
in Grant Agreement No 801553 (‘the Grant Agreement’)
between SCIENSANO and the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) ('the Agency'), under the powers delegated by the European Commission ('the
Commission'),
for the action entitled Information for Action (InfAct).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-998728588_75_210--]
2
Grant Agreement number: 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO (CIPH), established in ROCKEFELLEROVA 7,
ZAGREB 10000, Croatia, VAT number: HR75297532041, (‘the beneficiary’), represented for the
purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘4’)
in Grant Agreement No 801553 (‘the Grant Agreement’)
between SCIENSANO and the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) ('the Agency'), under the powers delegated by the European Commission ('the
Commission'),
for the action entitled Information for Action (InfAct).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-998128255_75_210--]
3
Grant Agreement number: 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
Ministry of Health of the Republic of Cyprus (MoHCy), established in 1 Prodromou Street & 17
Chilonos Street 1 & 17, Nicosia 1448, Cyprus, (‘the beneficiary’), represented for the purpose of
signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘5’)
in Grant Agreement No 801553 (‘the Grant Agreement’)
between SCIENSANO and the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) ('the Agency'), under the powers delegated by the European Commission ('the
Commission'),
for the action entitled Information for Action (InfAct).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-994267946_75_210--]
4
Grant Agreement number: 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
USTAV ZDRAVOTNICKYCH INFORMACI A STATISTIKY CESKE REPUBLIKY (UZIS),
established in PALACKEHO NAMESTI 4, PRAHA 12801, Czech Republic, (‘the beneficiary’),
represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘6’)
in Grant Agreement No 801553 (‘the Grant Agreement’)
between SCIENSANO and the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) ('the Agency'), under the powers delegated by the European Commission ('the
Commission'),
for the action entitled Information for Action (InfAct).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-920415929_75_210--]
5
Grant Agreement number: 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
SOTSIAALMINISTEERIUM (MoSA), established in Suur-Ameerika 1, TALLINN 10122, Estonia,
(‘the beneficiary’), represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘7’)
in Grant Agreement No 801553 (‘the Grant Agreement’)
between SCIENSANO and the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) ('the Agency'), under the powers delegated by the European Commission ('the
Commission'),
for the action entitled Information for Action (InfAct).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-998429731_75_210--]
6
Grant Agreement number: 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
TERVEYDEN JA HYVINVOINNIN LAITOS (THL), established in MANNERHEIMINTIE 166,
HELSINKI 00271, Finland, VAT number: FI22295006, (‘the beneficiary’), represented for the
purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘8’)
in Grant Agreement No 801553 (‘the Grant Agreement’)
between SCIENSANO and the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) ('the Agency'), under the powers delegated by the European Commission ('the
Commission'),
for the action entitled Information for Action (InfAct).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-996697893_75_210--]
7
Grant Agreement number: 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
AGENCE NATIONALE DE SANTE PUBLIQUE (SpFrance), established in 12 RUE DU VAL
D'OSNE, SAINT MAURICE 94415, France, VAT number: FR53130022338, (‘the beneficiary’),
represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘9’)
in Grant Agreement No 801553 (‘the Grant Agreement’)
between SCIENSANO and the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) ('the Agency'), under the powers delegated by the European Commission ('the
Commission'),
for the action entitled Information for Action (InfAct).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-917843489_75_210--]
8
Grant Agreement number: 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
ROBERT KOCH-INSTITUT (RKI), established in Nordufer 20, Berlin 13353, Germany, VAT
number: DE165893430, (‘the beneficiary’), represented for the purpose of signing this Accession
Form by the undersigned,
hereby agrees
to become beneficiary No (‘10’)
in Grant Agreement No 801553 (‘the Grant Agreement’)
between SCIENSANO and the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) ('the Agency'), under the powers delegated by the European Commission ('the
Commission'),
for the action entitled Information for Action (InfAct).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-999515549_75_210--]
9
Grant Agreement number: 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
ETHNIKOS ORGANISMOS PAROCHIS YPIRESION YGIAS (EOPYY), established in
APOSTOLOU PAVLOY 12, ATHENS 15123, Greece, VAT number: EL997478553, (‘the
beneficiary’), represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘11’)
in Grant Agreement No 801553 (‘the Grant Agreement’)
between SCIENSANO and the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) ('the Agency'), under the powers delegated by the European Commission ('the
Commission'),
for the action entitled Information for Action (InfAct).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-924325805_75_210--]
10
Grant Agreement number: 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
DEPARTMENT OF HEALTH (DOH), established in poolbeg St, Hawkins House, Dublin dn
6, Ireland, (‘the beneficiary’), represented for the purpose of signing this Accession Form by the
undersigned,
hereby agrees
to become beneficiary No (‘12’)
in Grant Agreement No 801553 (‘the Grant Agreement’)
between SCIENSANO and the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) ('the Agency'), under the powers delegated by the European Commission ('the
Commission'),
for the action entitled Information for Action (InfAct).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-972459824_75_210--]
11
Grant Agreement number: 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
ISTITUTO SUPERIORE DI SANITA (ISS), established in Viale Regina Elena 299, ROMA 00161,
Italy, VAT number: IT03657731000, (‘the beneficiary’), represented for the purpose of signing this
Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘13’)
in Grant Agreement No 801553 (‘the Grant Agreement’)
between SCIENSANO and the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) ('the Agency'), under the powers delegated by the European Commission ('the
Commission'),
for the action entitled Information for Action (InfAct).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-999978821_75_210--]
12
Grant Agreement number: 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
SLIMIBU PROFILAKSES UN KONTROLES CENTRS (CDPC), established in Duntes 22, Riga
LV1005, Latvia, VAT number: 90009756700, (‘the beneficiary’), represented for the purpose of
signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘14’)
in Grant Agreement No 801553 (‘the Grant Agreement’)
between SCIENSANO and the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) ('the Agency'), under the powers delegated by the European Commission ('the
Commission'),
for the action entitled Information for Action (InfAct).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-952714019_75_210--]
13
Grant Agreement number: 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
HIGIENOS INSTITUTAS (HI), established in DIDZIOJI STREET 22, VILNIUS LT-01128,
Lithuania, (‘the beneficiary’), represented for the purpose of signing this Accession Form by the
undersigned,
hereby agrees
to become beneficiary No (‘15’)
in Grant Agreement No 801553 (‘the Grant Agreement’)
between SCIENSANO and the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) ('the Agency'), under the powers delegated by the European Commission ('the
Commission'),
for the action entitled Information for Action (InfAct).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-941996780_75_210--]
14
Grant Agreement number: 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
MINISTERE DE LA SANTE (MOHLUX), established in VILLA LOUVIGNY, ALLEE
MARCONI, LUXEMBOURG 2120, Luxembourg, (‘the beneficiary’), represented for the purpose of
signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘16’)
in Grant Agreement No 801553 (‘the Grant Agreement’)
between SCIENSANO and the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) ('the Agency'), under the powers delegated by the European Commission ('the
Commission'),
for the action entitled Information for Action (InfAct).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-998888153_75_210--]
15
Grant Agreement number: 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
Ministry for Health - Government of Malta (MFH), established in Palazzo Castellania, Merchants
Street 15, Valletta VLT 200, Malta, VAT number: MT12979127, (‘the beneficiary’), represented for
the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘17’)
in Grant Agreement No 801553 (‘the Grant Agreement’)
between SCIENSANO and the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) ('the Agency'), under the powers delegated by the European Commission ('the
Commission'),
for the action entitled Information for Action (InfAct).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-974144423_75_210--]
16
Grant Agreement number: 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
UNIVERSITATEA DE STAT DE MEDICINA SI FARMACIE NICOLAE TESTEMITANU
DIN REPUBLICA MOLDOVA (SMPHU), established in Stefan cel Mare Avenue 165, Chisinau
MD2004, Moldova (Republic of), (‘the beneficiary’), represented for the purpose of signing this
Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘18’)
in Grant Agreement No 801553 (‘the Grant Agreement’)
between SCIENSANO and the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) ('the Agency'), under the powers delegated by the European Commission ('the
Commission'),
for the action entitled Information for Action (InfAct).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-997321506_75_210--]
17
Grant Agreement number: 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU (RIVM), established in
Antonie Van Leeuwenhoeklaan 9, BILTHOVEN 3721 MA, Netherlands, VAT number:
NL821772302B01, (‘the beneficiary’), represented for the purpose of signing this Accession Form
by the undersigned,
hereby agrees
to become beneficiary No (‘19’)
in Grant Agreement No 801553 (‘the Grant Agreement’)
between SCIENSANO and the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) ('the Agency'), under the powers delegated by the European Commission ('the
Commission'),
for the action entitled Information for Action (InfAct).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-999991431_75_210--]
18
Grant Agreement number: 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
HELSEDIREKTORATE (HD), established in UNIVERSITETSGATA 2, OSLO 0164, Norway,
VAT number: NO983544622, (‘the beneficiary’), represented for the purpose of signing this Accession
Form by the undersigned,
hereby agrees
to become beneficiary No (‘20’)
in Grant Agreement No 801553 (‘the Grant Agreement’)
between SCIENSANO and the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) ('the Agency'), under the powers delegated by the European Commission ('the
Commission'),
for the action entitled Information for Action (InfAct).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-974772304_75_210--]
19
Grant Agreement number: 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
THE MINISTRY OF HEALTH OF THE REPUBLIC OF POLAND (MZ), established in
Miodowa 15, Warsaw 00-952, Poland, VAT number: not applicable, (‘the beneficiary’), represented
for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘21’)
in Grant Agreement No 801553 (‘the Grant Agreement’)
between SCIENSANO and the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) ('the Agency'), under the powers delegated by the European Commission ('the
Commission'),
for the action entitled Information for Action (InfAct).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-973658453_75_210--]
20
Grant Agreement number: 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
MINISTERIO DA SAUDE - REPUBLICA PORTUGUESA (MS), established in Av. João
Crisóstomo, 9, LISBOA 1049-062, Portugal, (‘the beneficiary’), represented for the purpose of
signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘22’)
in Grant Agreement No 801553 (‘the Grant Agreement’)
between SCIENSANO and the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) ('the Agency'), under the powers delegated by the European Commission ('the
Commission'),
for the action entitled Information for Action (InfAct).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-986364095_75_210--]
21
Grant Agreement number: 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
INSTITUTUL NATIONAL DE SANATATE PUBLICA (INSP), established in STR DR LEONTE
1-3 SECTOR 5, BUCURESTI 050463, Romania, (‘the beneficiary’), represented for the purpose of
signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘23’)
in Grant Agreement No 801553 (‘the Grant Agreement’)
between SCIENSANO and the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) ('the Agency'), under the powers delegated by the European Commission ('the
Commission'),
for the action entitled Information for Action (InfAct).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-985926237_75_210--]
22
Grant Agreement number: 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
INSTITUT ZA ZASTITU ZDRAVLJA SRBIJEDR MILAN JOVANOVIC BATUT (IPHS),
established in DR SUBOTICA STREET 5, BEOGRAD 11000, Serbia, VAT number: RS102000930,
(‘the beneficiary’), represented for the purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘24’)
in Grant Agreement No 801553 (‘the Grant Agreement’)
between SCIENSANO and the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) ('the Agency'), under the powers delegated by the European Commission ('the
Commission'),
for the action entitled Information for Action (InfAct).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-941063349_75_210--]
23
Grant Agreement number: 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
NACIONALNI INSTITUT ZA JAVNO ZDRAVJE (NIJZ), established in TRUBARJEVA CESTA
2, LJUBLJANA 1000, Slovenia, VAT number: SI44724535, (‘the beneficiary’), represented for the
purpose of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘25’)
in Grant Agreement No 801553 (‘the Grant Agreement’)
between SCIENSANO and the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) ('the Agency'), under the powers delegated by the European Commission ('the
Commission'),
for the action entitled Information for Action (InfAct).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-948891346_75_210--]
24
Grant Agreement number: 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
INSTITUTO DE SALUD CARLOS III (ISCIII), established in MONFORTE DE LEMOS 5,
MADRID 28029, Spain, VAT number: ESQ2827015E, (‘the beneficiary’), represented for the purpose
of signing this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘26’)
in Grant Agreement No 801553 (‘the Grant Agreement’)
between SCIENSANO and the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) ('the Agency'), under the powers delegated by the European Commission ('the
Commission'),
for the action entitled Information for Action (InfAct).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-999507886_75_210--]
25
Grant Agreement number: 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
FOLKHALSOMYNDIGHETEN (FoHM), established in NOBELS VAG 18, SOLNA 171 82,
Sweden, VAT number: SE202100654501, (‘the beneficiary’), represented for the purpose of signing
this Accession Form by the undersigned,
hereby agrees
to become beneficiary No (‘27’)
in Grant Agreement No 801553 (‘the Grant Agreement’)
between SCIENSANO and the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) ('the Agency'), under the powers delegated by the European Commission ('the
Commission'),
for the action entitled Information for Action (InfAct).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-949789954_75_210--]
26
Grant Agreement number: 801553 — InfAct
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 3
ACCESSION FORM FOR BENEFICIARIES
WELSH ASSEMBLY GOVERNMENT (WG), established in CATHAYS PARK WELSH
ASSEMBLY GOVERNMENT, CARDIFF CF10 3NQ, United Kingdom, VAT number:
GB888835056, (‘the beneficiary’), represented for the purpose of signing this Accession Form by the
undersigned,
hereby agrees
to become beneficiary No (‘28’)
in Grant Agreement No 801553 (‘the Grant Agreement’)
between SCIENSANO and the Consumers, Health, Agriculture and Food Executive Agency
(CHAFEA) ('the Agency'), under the powers delegated by the European Commission ('the
Commission'),
for the action entitled Information for Action (InfAct).
and mandates
the coordinator to submit and sign in its name and on its behalf any amendments to the Agreement,
in accordance with Article 39.
By signing this Accession Form, the beneficiary accepts the grant and agrees to implement it in
accordance with the Agreement, with all the obligations and conditions it sets out.
SIGNATURE
For the beneficiary/new beneficiary/new coordinator
[--TGSMark#signature-998043380_75_210--]
27
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
i print format A4
MODEL ANNEX 4 CHAFEA MGA — MULTI
landscape
FINANCIAL STATEMENT FOR [BENEFICIARY [name]/AFFILIATED ENTITY [name]] FOR REPORTING PERIOD [reporting period]
1 Receipts EU contribution
Eligible costs (per budget category)
Financial
contributions Reimburseme Maximum EU
A. Direct personnel B. Direct costs of C. Other direct 2 Income generated Requested EU
D. Indirect costs Total costs given by third Total receipts 3 4
costs subcontracting costs by the action nt rate % constribution contribution
parties to the
beneficiaries
A.1 Employees (or
C.1 Travel
equivalent)
A.2 Natural persons
C.2 Equipment
under direct contract
and seconded persons
C.3 Other goods and
services
6
5 Actual Actual Actual Flat-rate
Cost form
7%
d= e=
a b c f g h= f + g i j k
0,07 * (a + b + c) a+ b + c + d
[short name beneficiary
/ affiliated entity]
The beneficiary/affiliated entity hereby confirms that:
The information provided is complete, reliable and true.
The costs declared are eligible (see Article 6).
The costs can be substantiated by adequate records and supporting documentation that will be produced upon request or in the context of checks, reviews, audits and investigations (see Articles 12, 13 and 17).
For the last reporting period: that all the receipts have been declared (see Article 5.3.3).
i Please declare all eligible costs, even if they exceed the amounts indicated in the estimated budget (see Annex 2). Only amounts that were declared in your individual financial
statements can be taken into account lateron, in order to replace other costs that are found to be ineligible.
1
See Article 6 for the eligibility conditions.
2
The indirect costs claimed must be free of any amounts covered by an operating grant (received under any EU or Euratom funding programme). A beneficiary that receives an operating grant during the duration of the action cannot
claim any indirect costs for the year(s) covered by the operating grant (see Article 6.2.D).
3
See Article 5.2 for the reimbursement rate
4
This is the theoretical amount of EU contribution that the system calculates automatically (by multiplying the reimbursement rate by the total costs declared). The amount you request (in the column 'requested EU contribution') may
have to be less.
5
See Article 5 for the cost forms.
6
Flat rate : 7% of eligible direct costs.
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
ANNEX 5
MODEL FOR THE CERTIFICATE ON THE FINANCIAL STATEMENT (CFS)
This document sets out:
- the objectives and scope of the independent report of factual findings on costs declared
under a EU grant agreement financed under the Health Programme (2014-2020) or
Consumer Programme (2014-2020) and
- a model for the certificate on the financial statement (CFS).
1. Background and subject matter
[OPTION 1 for actions with one RP and NO interim payments: Within 60 days of the end of
the reporting period, the coordinator must submit to the Commission a final report, which
should include (among other documents and unless otherwise specified in Article 15 of the
Grant Agreement) a certified financial statement (CFS; see proposed model below) for each
beneficiary and (if applicable) each affiliated entity, if:
- it requests an EU contribution of EUR 325 000 or more as reimbursement of actual
costs and
- the maximum EU contribution indicated for that beneficiary/affiliated entity in the
estimated budget (see Annex 2) as reimbursement of actual costs is EUR 750 000 or
more.]
[OPTION 2 for actions with several RPs and interim payments: Within 60 days of the end
of each reporting period, the coordinator must submit to the Commission a periodic report,
which should include (among other documents and unless otherwise specified in Article 15 of
the Grant Agreement) a certified financial statement (CFS; see proposed model below) for
each beneficiary and (if applicable) each affiliated entity, if:
- the cumulative amount of EU contribution the beneficiary/affiliated entity requests as
reimbursement of actual costs is EUR 325 000 or more and
- the maximum EU contribution indicated for that beneficiary/affiliated entity in the
estimated budget (see Annex 2) as reimbursement of actual costs is EUR 750 000 or
more.
The CFS must be submitted every time the cumulative amount of payments requested (i.e.
including in previous financial statements) reaches the threshold (i.e. a first certificate once
the cumulative amount reaches 325 000, a second certificate once it reaches 650 000, a third
certificate once it reaches 975 000, etc.).
Once the threshold is reached, the CFS must cover all reporting periods for which no
certificate has yet been submitted.]
1
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
The beneficiary must provide the CFS for itself and, if applicable, for its affiliated entity(ies).
The purpose of the audit on which the CFS is based is to give the Agency ‘reasonable
assurance’1 that costs declared as eligible costs under the grant (and, if relevant, receipts
generated in the course of the action) are being claimed by the beneficiary in accordance with
the relevant legal and financial provisions of the Grant Agreement.
The scope of the audit is limited to the verification of eligible costs included in the CFS. The
audit must be conducted in line with point 3 below.
Certifying auditors must carry out the audits in compliance with generally accepted audit
standards and indicate which standards they have applied. They must bear in mind that, to
establish a CFS, they must carry out a compliance audit and not a normal statutory audit. The
eligibility criteria in the Grant Agreement always override normal accounting practices.
The beneficiary and the auditor are expected to address any questions on factual data or
detailed calculations before the financial statement and the accompanying certificate are
submitted. It is also recommended that the beneficiary take into account the auditor’s
preliminary comments and suggestions in order to avoid a qualified opinion or reduce the
scope of the qualifications.
Since the certificate is the main source of assurance for cost claims and payments, it will be
easier to consider amounts as eligible if a non-qualified certificate is provided.
The submission of a certificate does not affect the Agency’s right to carry out its own
assessment or audits. Neither does the reimbursement of costs covered by a certificate
preclude the Agency or the Commission, the European Anti-Fraud Office or the European
Court of Auditors from carrying out checks, reviews, audits and investigations in accordance
with Article 17 of the Grant Agreement.
The Agency expects the certificates to be issued by auditors according to the highest
professional standards.
2. Auditors who may deliver a certificate
The beneficiary is free to choose a qualified external auditor, including its usual external
auditor, provided that:
- the external auditor is independent from the beneficiary and
- the provisions of Directive 2006/43/EC2 are complied with.
Independence is one of the qualities that permit the auditor to apply unbiased judgement and
objective consideration to established facts to arrive at an opinion or a decision. It also means
that the auditor works without direction or interference of any kind from the beneficiary.
1
This means a high degree of confidence.
2
Directive 2006/43/EC of the European Parliament and of the Council of 17 May 2006 on statutory audits of
annual accounts and consolidated accounts or similar national regulations (OJ L 157, 9.6.2006, p. 87).
2
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Auditors are considered as providing services to the beneficiary/affiliated entity under a
purchase contract within the meaning of Article 9 of the Grant Agreement. This means that
the costs of the CFS may normally be declared as costs incurred for the action, if the cost
eligibility rules set out in Articles 6 and 9.1.1 of the Grant Agreement are fulfilled (especially:
best value for money and no conflict of interests; see also below eligibility of costs of other
goods and services). Where the beneficiary/affiliated entity uses its usual external auditor, it is
presumed that they already have an agreement that complies with these provisions and there is
no obligation to find new bids. Where the beneficiary/affiliated entity uses an external auditor
who is not their usual external auditor, it must select an auditor following the rules set out in
Article 9.1.1.
Public bodies can choose an external auditor or a competent public officer. In the latter case,
the auditor’s independence is usually defined as independence from the audited beneficiary
‘in fact and in appearance’. A preliminary condition is that this officer was not involved in
any way in drawing up the financial statements. Relevant national authorities establish the
legal capacity of the officer to carry out audits of that specific public body. The certificate
should refer to this appointment.
3. Audit methodology and expected results
3.1 Verification of eligibility of the costs declared
The auditor must conduct its verification on the basis of inquiry and analysis,
(re)computation, comparison, other accuracy checks, observation, inspection of records and
documents and by interviewing the beneficiary (and the persons working for it).
The auditor must examine the following documentation:
the Grant Agreement and any amendments to it;
the periodical and/or final report(s);
for personnel costs
o salary slips;
o time sheets;
o contracts of employment;
o other documents (e.g. personnel accounts, social security legislation, invoices,
receipts, etc.);
o proofs of payment;
for subcontracting
o the call for tender;
o tenders (if applicable);
o justification for the choice of subcontractor;
o contracts with subcontractors;
o invoices;
o declarations by the beneficiary;
o proofs of payment;
o other documents: e.g. national rules on public tendering if applicable, EU
Directives, etc.;
for travel and subsistence costs
o the beneficiary’s internal rules on travel;
3
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
o transport invoices and tickets (if applicable);
o declarations by the beneficiary;
o other documents (proofs of attendance such as minutes of meetings, reports,
etc.);
o proofs of payment;
for equipment costs
o invoices;
o delivery slips / certificates of first use;
o proofs of payment;
o depreciation method of calculation;
for costs of other goods and services
o invoices;
o proofs of payment; and
o other relevant accounting documents.
General eligibility rules
The auditor must verify that the costs declared comply with the general eligibility rules set out
in Article 6.1 of the Grant Agreement.
In particular, the costs must:
be actually incurred;
be linked to the subject of the Grant Agreement and indicated in the beneficiary's
estimated budget (i.e. the latest version of Annex 2);
be necessary to implement the action which is the subject of the grant;
be reasonable and justified, and comply with the requirements of sound financial
management, in particular as regards economy and efficiency;3
have been incurred during the action, as defined in Article 3 of the Grant Agreement
(with the exception of the invoice for the audit certificate and costs relating to the
submission of the final report);
not be covered by another EU or Euratom grant (see below ineligible costs);
be identifiable, verifiable and, in particular, recorded in the beneficiary's accounting
records and determined according to the applicable accounting standards of the
country where it is established and its usual cost-accounting practices;
comply with the requirements of applicable national laws on taxes, labour and social
security;
be in accordance with the provisions of the Grant Agreement (see, in particular,
Articles 6 and 9-11a) and
have been converted to euro at the rate laid down in Article 15.6 of the Grant
Agreement:
o for beneficiaries with accounts established in a currency other than the euro:
Costs incurred in another currency must be converted into euros at the average
of the daily exchange rates published in the C series of the EU Official Journal
determined over the corresponding reporting period.
3
To be assessed in particular on the basis of the procurement and selection procedures for service providers.
4
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
If no daily euro exchange rate is published in the EU Official Journal for the
currency in question, the rate used must be the average of the monthly
accounting rate established by the Commission and published on its website;
o for beneficiaries with accounts established in euro:
Costs incurred in another currency should be converted into euros applying the
beneficiary’s usual accounting practice.
The auditor must verify whether expenditure includes VAT and, if so, verify that the
beneficiary:
- cannot recover the VAT (this must be supported by a statement from the competent
body) and
- is not a public body acting as a public authority.
The auditor should base his/her audit approach on the confidence level following a review of
the beneficiary's internal control system. When using sampling, the auditor should indicate
and justify the sampling size.
Specific eligibility rules
In addition, the auditor must verify that the costs declared comply with the specific cost
eligibility rules set out in Article 6.2 and Articles 9.1.1, 10.1.1, 11.1.1, 11a.1.1 and 11a.2.1 of
the Grant Agreement.
Personnel costs
The auditor must verify that:
personnel costs have been charged and paid in respect of the actual time devoted by
the beneficiary’s personnel to implementing the action (justified on the basis of time
sheets or other relevant time-recording system);
personnel costs were calculated on the basis of annual gross salary, wages or fees (plus
obligatory social charges, but excluding any other costs) specified in an employment
or other type of contract, not exceeding the average rates corresponding to the
beneficiary’s usual policy on remuneration;
the work was carried out during the period of implementation of the action, as defined
in Article 3 the Grant Agreement and
the personnel costs are not covered by another EU or Euratom grant (see below
ineligible costs);
for additional remunerations: the 2 conditions set out in Article 6.2.A.1 are met (i.e.
that it is part of the beneficiary’s usual remuneration practices and is paid in a
consistent manner whenever the same kind of work or expertise is required and that
the criteria used to calculate the supplementary payments are objective and generally
applied by the beneficiary, regardless of the source of funding used);
for in-house consultants: the 3 conditions set out in Article 6.2.A.2 of the Grant
Agreement are met (i.e. that the in-house consultant works under the beneficiary’s
instructions, that the result of the work carried out belongs to the beneficiary, and that
the costs are not significantly different from those for personnel performing similar
tasks under an employment contract).
5
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
The auditor should have assurance that the management and accounting system ensures
proper allocation of the personnel costs to various activities carried out by the beneficiary and
funded by various donors.
Subcontracting costs
The auditor must verify that:
the subcontracting complies with best value for money (or lowest price) and that there
was no conflict of interests;
the subcontracting was necessary to implement the action for which the grant is
requested;
the subcontracting was provided for in Annex 1 and Annex 2 or agreed to by the
Agency at a later stage;
the subcontracting is supported by accounting documents in accordance with national
accounting law
public bodies have complied with the national rules on public procurement.
Travel and subsistence costs
The auditor must verify that travel and subsistence costs:
have been charged and paid in accordance with the beneficiary's internal rules or usual
practices;
are not covered by another EU or Euratom grant (see below ineligible costs);
were incurred for travels linked to action tasks set out in Annex 1 of the Grant
Agreement.
Equipment costs
The auditor must verify that:
the equipment is purchased, rented or leased at normal market prices;
public bodies have complied with the national rules on public procurement;
the equipment is written off, depreciation has been calculated according to the tax and
accounting rules applicable to the beneficiary and only the portion of the depreciation
corresponding to the duration of the action has been declared and
the costs are not covered by another EU or Euratom grant (see below ineligible costs).
Costs of other goods and services
The auditor must verify that:
the purchase complies with best value for money (or lowest price) and that there was
no conflict of interests;
public bodies have complied with the national rules on public procurement;
the costs are not covered by another EU or Euratom grant (see below ineligible costs).
Ineligible costs
The auditor must verify that the beneficiary has not declared any costs that are ineligible
under Article 6.4 of the Grant Agreement:
6
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
costs relating to return on capital;
debt and debt service charges;
provisions for future losses or debts;
interest owed;
doubtful debts;
currency exchange losses;
bank costs charged by the beneficiary’s bank for transfers from the Agency;
excessive or reckless expenditure;
deductible VAT;
VAT incurred by a public body acting as a public authority;
costs incurred during suspension of the implementation of the action;
in-kind contributions from third parties;
costs declared under other EU or Euratom grants (including those awarded by a
Member State and financed by the EU or Euratom budget or awarded by bodies other
than the Agency for the purpose of implementing the EU or Euratom budget); in
particular, indirect costs if the beneficiary is already receiving an operating grant
financed by the EU or Euratom budget in the same period;
costs incurred for permanent staff of a national administration for activities that are
part of its normal activities (i.e. not undertaken only because of the grant);
costs incurred for staff or representatives of EU institutions, bodies or agencies.
3.2 Verification of receipts
The auditor must verify that the beneficiary has declared receipts within the meaning of
Article 5.3.3 of the Grant Agreement, i.e.:
income generated by the action (e.g. from the sale of products, services and
publications, conference fees) and
financial contributions given by third parties, specifically to be used for costs that are
eligible under the action.
3.3 Verification of the beneficiary’s accounting system
The auditor must verify that:
the accounting system (analytical or other suitable internal system) makes it possible
to identify sources of financing for the action and related expenses incurred during
the contractual period and
expenses/income under the grant have been recorded systematically using a
numbering system that distinguishes them from expenses/income for other projects.
7
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
Certificate on the financial statement (CFS)
To
[Beneficiary/affiliated entity’s full name
address]
We, [full name of the audit firm/organisation], established in [full address/city/country],
represented for signature of this audit certificate by [name and function of an authorised
representative],
hereby certify
that:
1. We have conducted an audit relating to the costs declared in the financial statement of
[name of beneficiary/affiliated entity] (the [‘beneficiary’][‘affiliated entity’]), to which
this audit certificate is attached and which is to be presented to the Consumers, Health,
Agriculture and Food Executive Agency under Grant Agreement No [insert number] —
[insert acronym], covering costs for the following reporting period(s): [insert reporting
period(s)].
2. We confirm that our audit was carried out in accordance with generally accepted
auditing standards in compliance with ethical rules and on the basis of the provisions of
the Grant Agreement and its Annexes (and in particular the audit methodology
described in Annex 5).
3. The financial statement was examined and all necessary tests of [all][[X]%] of the
supporting documentation and accounting records were carried out in order to obtain
reasonable assurance that, in our opinion and on the basis of our audit
total costs of EUR [insert number] ([insert amount in words]) are eligible, i.e.:
actual;
determined in accordance with the [beneficiary’s][affiliated entity’s]
accounting principles;
incurred during the period referred to in Article 3 of the Grant Agreement;
recorded in the [beneficiary’s][affiliated entity’s] accounts (at the date of this
audit certificate);
comply with the specific eligibility rules in Article 6.2 of the Grant Agreement;
do not contain costs that are ineligible under Article 6.4 of the Grant
Agreement, in particular:
costs relating to return on capital;
debt and debt service charges;
provisions for future losses or debts;
interest owed;
doubtful debts;
currency exchange losses;
8
Associated with document Ref. Ares(2018)3121156 - 13/06/2018
bank costs charged by the [beneficiary’s][affiliated entity’s] bank for
transfers from the Agency;
excessive or reckless expenditure;
deductible VAT;
VAT incurred by a public body acting as a public authority;
costs incurred during suspension of the implementation of the action;
in-kind contributions provided by third parties;
costs declared under other EU or Euratom grants (including those
awarded by a Member State and financed by the EU or Euratom budget
or awarded by bodies other than the Agency for the purpose of
implementing the EU or Euratom budget); in particular, indirect costs if
the [beneficiary][affiliated entity] is already receiving an operating
grant financed by the EU or Euratom budget in the same period;
costs incurred for permanent staff of a national administration, for
activities that are part of its normal activities (i.e. not undertaken only
because of the grant);
costs incurred for staff or representatives of EU institutions, bodies or
agencies;
[are claimed according to the euro conversion rate referred to in Article 15.6 of
the Grant Agreement;]
total receipts of EUR [insert number] ([insert amount in words]) have been declared
under Article 5.3.3 of the Grant Agreement and
the [beneficiary’s][affiliated entity’s] accounting procedures are in compliance with
the accounting rules of the state in which it is established and permit direct
reconciliation of the costs incurred for the implementation of the action covered by the
EU grant with the overall statement of accounts relating to its overall activity.
[However, our audit opinion is qualified for:
costs of EUR [insert number]
receipts of EUR [insert number]
which in our opinion do not comply with the applicable rules.]
4. We are qualified/authorised to deliver this audit certificate [(for additional information,
see appendix to this certificate)].
5. The [beneficiary][affiliated entity] paid a price of EUR [insert number]) (including VAT
of EUR [insert number]) for this audit certificate. [OPTION 1: These costs are eligible
(i.e. incurred within 60 days of the end of the action referred to in Article 3 of the Grant
Agreement) and included in the financial statement.][OPTION 2: These costs were not
included in the financial statement.]
Date, signature and stamp
9
Digitally sealed by the European Commission
Date: 2018.06.13 16:55:16 CEST
This document is digitally sealed. The digital sealing mechanism uniquely binds the
document to the modules of the Participant Portal of the European Commission, to the
transaction for which it was generated and ensures its integrity and authenticity.
Any attempt to modify the content will lead to a breach of the electronic seal, which can
be verified at any time by clicking on the digital seal validation symbol.
Commission européenne/Europese Commissie, 1049 Bruxelles/Brussel, BELGIQUE/BELGIË - Tel. +32 22991111
Saatja: Marek Jaansoo <
[email protected]>
Saaja: Ülle Näksi
Teema: Sildfinantseeringu taotlemine 9T90-INFACT
Tere Ülle!
Taotlus sildfinantseerimise avamiseks
Palun avada Tervise Arengu Instituudile välisprojekti (tunnus 9T90-INFACT) sildfinantseering 2019 aastaks, seoses projekti tegevuste koondumisega valdavalt 2019 aastasse. Projektile on osaliselt laekunud ettemaks, aga see ei kata jooksva aasta vajadusi.
Projekt: Information for Action - InfAct
Akronüüm: InfAct
Tunnus SAP-is: 9T90-INFACT
Nimetus SAP-is: 801553-Information for Action-HP-JA-2017,SCIENCANO
Projekti periood: 01.03.2018-28.02.2021 ja eelarve 21 984,13 EUR
Eelarve avamise taotlus (manus Sildfinantseeringu suurendamine 2019 aastaks 9T90-INFACT.xlsx)
Lugupidamisega,
Marek Jaansoo
finantsjuht
Tervise Arengu Instituut
tel +372 659 3913
[email protected] <mailto:
[email protected]>
www.tai.ee <http://www.tai.ee>
From: Ülle Näksi <
[email protected] <mailto:
[email protected]> >
Sent: Thursday, February 28, 2019 3:31 PM
To: Marek Jaansoo <
[email protected] <mailto:
[email protected]> >
Subject: RE: Uute välistoetuste sisestamine REIS-i
Tere!
Kas on tegemist uute projektidega, mis ei ole 2019 REIS planeeritud? Kui soovite silda, siis uute projektide puhul tuleb silla taotlused mulle saata. Nii nagu eelmisel nädalal taotluse esitasite. REIS sisestamise info edastan Liinale ja Mairile.
Tervitades
Ülle Näksi
finantspeaspetsialist
Finantsosakond
Sotsiaalministeerium
________________________________
[email protected]
6269710
Suur-Ameerika 1, 10122 Tallinn
www.sm.ee <http://www.sm.ee/>
From: Marek Jaansoo <
[email protected] <mailto:
[email protected]> >
Sent: Thursday, February 28, 2019 3:13 PM
To: Ülle Näksi <
[email protected] <mailto:
[email protected]> >
Cc: Andres Paris <
[email protected] <mailto:
[email protected]> >
Subject: Uute välistoetuste sisestamine REIS-i
Tere Ülle!
Kas selline taotlus tuleb teile esitada? Või äkki oskate selle õigele inimesele edasi suunata?
Palun lisada REIS-i järgmised välistoetuste koodid (lepingud lisatud):
Kood
Nimetus
Asutus
Algus
Lõpp
Välistoetuse %
OFi %
RKF % projekti abikõlblikest kogukuludest
9T90-ASAP-Training
Building effective drug prevention results across Europe, based on prevention systems analysis and widespread professional training. — ASAPTraining
T90
01.01.2019
31.12.2020
80%
20%
9T90-STOP
Science and Technology in childhood Obesity Policy
T90
01.06.2018
30.05.2022
100%
0%
9T90-JAHEE
Joint Action Health Equity Europe
T90
01.06.2018
31.05.2021
80%
20%
9T90-INTEGRATE
EU Joint Action on Quality of HIV/AIDS/STI, viral Hepatitis and tuberculosis prevention
and linkage to care
T90
01.09.2017
31.08.2020
80%
20%
Tänades,
Marek Jaansoo
finantsjuht
Tervise Arengu Instituut
tel +372 659 3913
[email protected] <mailto:
[email protected]>
www.tai.ee <http://www.tai.ee>
/
Virve-Hella Haavam
Rahandusministeerium
[email protected] Meie 11.03.2019 nr 1.8-1/731-1
Tervise Arengu Instituudi taotlus
sildfinantseerimise avamiseks
Lugupeetud Virve-Hella Haavam
Palun avada Tervise Arengu Instituudile välisprojekti (9T90-INFACT) sildfinantseering 2019.
aastaks summas 16 707,94 eurot seoses projekti tegevuste koondumisega valdavalt 2019
aastasse. Projektile on osaliselt laekunud ettemaks, aga see ei kata jooksva aasta vajadusi.
Projekt: Information for Action - InfAct
Akronüüm: InfAct
Tunnus SAP-is: 9T90-INFACT
Nimetus SAP-is: 801553-Information for Action-HP-JA-2017,SCIENCANO
Projekti periood: 01.03.2018-28.02.2021
Eelarve 21 984,13 eurot
Lugupidamisega
(allkirjastatud digitaalselt)
Ester Timmas
toetuste juht
Lisa: 1. Sildfinantseeringu taotlemine 9T90-INFACT
2. Grant Agreement-801553-InfAct
3. Sildfinantseeringu suurendamine 2019 aastaks 9T90-INFACT
Ülle Näksi 6269710
[email protected]
Suur-Ameerika 1 / 10122 Tallinn / 626 9301 /
[email protected] / www.sm.ee / registrikood 70001952